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Foreword
Drug and alcohol use is commonplace in our society. As health care professionals, nursing staff are often confronted with 
the complexities of caring for individuals who are affected by the use of drugs and alcohol. In 1998, the NSW Nursing 
Project–Alcohol and Other Drugs convened a clinical policy working group to develop supporting documentation for the 
document, Alcohol and Other Drugs Policy for Nursing Practice in NSW: A Framework for Progress 2000–2003, which was 
launched in 2000. The Clinical Guidelines provided a clear, consistent and detailed policy for implementation in public health 
services throughout NSW. These have proved to be a valuable resource for nurses and midwives across the health system.
Given the passage of time and changes in clinical management, it is timely that the Guidelines have now been reviewed and 
updated. The challenges of managing patients with drug and alcohol issues have not diminished since the first Guidelines 
were released. The necessity for all nurses and midwives to be able to recognise issues of drug and alcohol use continues 
to be relevant and important across all settings. Guidelines such as these facilitate and support nurses and midwives.
Once again these Clinical Guidelines have been developed through extensive input from nursing and medical experts in the 
clinical management of drug and alcohol issues in NSW and elsewhere. They are based on research evidence, day-to-day 
clinical experience and feedback from consultation with a broad range of stakeholders. I commend the Guidelines to all 
nurses and midwives.
Adjunct Professor Debra Thoms
Chief Nursing Officer
NSW Department of Health
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These guidelines provide nurses and midwives with support and a benchmark for quality drug and alcohol use assessment 
and care in daily practice. Each clinician needs to use these guidelines within the context of their role and scope of 
practice, and update their knowledge by accessing new research and clinical guidelines as they emerge.
Chapters 1 to 8 outline general principles and guidelines for drug and alcohol assessment, intervention, communication 
with patients, and managing intoxication, overdose and withdrawal.
Chapter 9 provides specific information on commonly used substances, with details of symptoms, signs, management 
and risks.
Chapter 10 provides additional information on pharmacotherapies for dependence on alcohol and on opioids.
The Appendices provide withdrawal assessment scales and other useful information.
The Handouts section contains handouts on selected drugs that you can photocopy and give to your patients.
The Glossary describes terms used in these guidelines related to drug and alcohol issues.
Resources contains a list of tools, literature, organisations, emergency numbers and useful websites.
These Guidelines will be accompanied by a supporting Policy Directive: Nursing Management of Drug and Alcohol issues 
in the delivery of health care. 
About these guidelines
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This revised version of the Clinical Guidelines for Nursing and Midwifery Practice in NSW: Identifying and Responding to 
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publication, Alcohol, Tobacco & Other Drugs Guidelines for Nurses and Midwives produced by Flinders University and the 
Drug and Alcohol Services Council, SA, 2003.
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Coast Area Health Service
■ Nick Miles – Current Chairperson, Clinical Nurse Consultant, Drug and Alcohol Services, Northern Sydney and Central 
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■ Christine Stephens, D&A Nurses of Australasia (DANA) and Editorial Reference Group
■ Gail Legg, Acting Area Director/Editorial Reference Group
■ Kim Bofinger, Rural Clinical Nurse Consultant / Editorial Reference Group
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■ Michelle Daly, Rural Clinical Nurse Consultant/Editorial Reference Group
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These Clinical Guidelines for Nursing and Midwifery 
Practice in NSW: Identifying and Responding to Drug and 
Alcohol Issues, rest on the following principles:
■ The focus of nursing and midwifery practice aims to 
give equal regard to the physical, psychosocial and 
cultural wellbeing of all patients receiving care. 
All practice should therefore include a comprehensive 
substance use assessment and offer suitable interventions 
and harm reduction strategies to all clients identified 
as being at risk of, or experiencing, problems associated 
with substance use. These problems may include 
intoxication, regular/harmful use, withdrawal and/or 
dependence, and related health and social issues.
■ All episodes of care provide an important opportunity 
or a critical moment for a person to be offered 
appropriate and easy-to-understand health 
information and education related to drug and 
alcohol use, and assessment and evidence-based 
interventions if a problem is identified.
■ Access to comprehensive health care is every 
individual’s right. All health professionals need to 
ensure that their own attitudes, value judgments and 
personal experiences do not interfere with a person’s 
right to quality care.
■ A client-centered approach is needed to care 
effectively for a person with drug and alcohol 
problems, and where appropriate, such care needs to 
include the person’s family and/or significant others.
■ Health Professionals and Health Services have a 
responsibility to effectively manage and support each 
person presenting with substance related problems.
CHAPTER 1
Principles of practice
Principles of practice
PAGE 8  NSW HEALTH  Clinical guidelines for nursing and midwifery practice in NSW 
Drug and alcohol problems affect individuals in all 
sections of society regardless of their race, cultural 
background, education, religion, gender and age. It is 
important to recognise that alcohol and/or other drugs 
use is common and those who use these substances may 
be affected because of ignorance and the prejudice of 
other people.
Assumptions about people who use alcohol and/or other 
drugs are often founded on myths, stereotypes, media 
images or another’s experience. Within the role and 
scope of nursing and midwifery practice it is common to 
come across people who have used substances for a 
variety of reasons. Substances used may be legal (such as 
tobacco, alcohol, prescribed and over the counter 
medications) or illegal (such as amphetamines or opioids). 
In each case, however, the nurse or midwife must 
consider the clinical implications associated with any 
substance use that has occurred.
It is within the role and scope of practice of all nurses and 
midwives to minimise the harm associated with 
hazardous substance use resulting from intoxication, 
withdrawal and dependence. All registered and enrolled 
nurses, midwives, and assistants in nursing in NSW are 
responsible for adhering to the principles herein, and for 
clinical expertise according to these Guidelines.
This section examines briefly the trends in polydrug use, 
myths about drug and alcohol use, the concept of harm 
minimisation, the importance of non-judgmental care, 
and why people don’t seek help.
2.1 Polydrug use
Over the last two decades, people have increasingly used 
more than one drug at a time. In fact, a person who 
presents with a single type of drug use is becoming 
increasingly rare. Medications, over-the-counter drugs, 
naturopathic, homoeopathic, legal and illicit drugs all 
have the potential to interact with each other.
Polydrug use and its risk factors should be considered 
during assessment of a person’s substance use.
Drug interactions can occur in two major ways:
■ pharmacokinetic—when changes take place in the 
absorption, distribution, metabolism or excretion of 
the drugs 
■ pharmacodynamic—when changes occur in the 
effects of drugs.
The dangers of polydrug use include increased risk of:
■ overdose
■ adverse drug reactions
■ medical conditions not responding to prescribed 
medications
■ intoxication and subsequent effect on performance 
being greater than anticipated
■ the amount of drugs used being increased to attain 
the desired effect
■ increased or decreased duration of effects due to 
altered metabolism
■ false sense of competence, e.g. when caffeine and 
alcohol are used together there may be some counter-
action of central nervous system depressant effects in 
the absence of any real capacity for task performance 
(Taylor, 1991, p. 13).
2.2 Harm minimisation
Harm minimisation is the key philosophy and basis for 
government policy in the management of drug and 
alcohol related issues. The concept is based on the 
acceptance that drug and alcohol use exists, is likely to 
continue, and is widespread across all levels of the 
Australian and international communities. This does not 
preclude abstinence and is interrelated to harm, demand, 
and supply reduction.
Harm minimisation is a way of reducing the impact of 
drug and/or alcohol-related harm to individuals and the 
CHAPTER 2
Overview and general guidelines
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community through a range of cost-effective public health 
policies, strategies and practices. Because of their numbers, 
roles, knowledge and skills, nurses and midwives are 
particularly well-placed to identify risks of harm 
associated with drug and alcohol use, and can apply a 
range of harm reduction strategies and interventions.
Enhancing the clinical knowledge and skills of nurses and 
midwives benefits the community by reducing the burden 
of preventable drug and alcohol problems on the health 
sector and other services. 
This approach does not accept or encourage unsafe 
substance use or in any way abandon the goal or 
importance of abstinence from drugs and alcohol. It simply 
means that abstinence is one of a range of strategies and 
not the only goal.
Harm reduction strategies currently found to be beneficial 
include:
■ providing clean injecting equipment—disposal units, 
needles, syringes, swabs
■ providing information to the community about how to 
access confidential, clean needle and syringe programs.
■ providing access to drug and alcohol withdrawal 
services and rehabilitation services
■ assessing and addressing drug and alcohol use 
problems at the various points of contact across the 
health system—emergency departments, general 
health clinics, pre-admission clinics, diabetes clinics, 
midwifery services, STD clinics, mental health services 
and in General Practice
■ introducing legislative measures—restricting tobacco 
advertising
■ controlling availability of drug and alcohol—not 
selling alcohol to people under 18
■ mass media safety campaigns—not drinking and 
driving a car or boat, health and safety risks from 
binge drinking, the hazards of smoking, the risks 
related to injecting psychoactive drugs
■ educating communities about the harmful effects of 
unsafe drug and alcohol use
■ health promotion campaigns—preventing young 
people taking up smoking, risks of drink spiking in 
pubs and clubs, promoting light beer
■ providing access to abstinence-based services 
■ providing pharmacotherapy treatment—methadone/
buprenorphine for opioid dependence, acamprosate 
for alcohol dependence, nicotine replacement therapy 
for nicotine dependence
2.3 The importance of non-judgmental 
care
Incorrect beliefs and inaccurate information can lead to 
continued stigmatisation, resulting in drug and alcohol 
users being reluctant to seek help. For clinicians to be 
effective, drug and alcohol use needs to be viewed and 
responded to as a health issue not a moral issue.
2.4 Why people don’t seek help
There are a wide variety of reasons why individuals, 
families and communities do not or cannot seek help for 
problems associated with their drug and alcohol use. 
Some of these are:
■ fear of professional judgment—being seen as an 
unfit parent or regarded as undeserving of a hospital 
bed when there are others around who are perceived 
as having ‘legitimate medical conditions’
■ poor access to care—inconvenient opening times for 
people who work, have children, or live far away
■ money problems—being unable to pay for their 
chosen program or travel to a service, or having to 
leave paid work to enter rehabilitation
■ services that are not designed to meet the needs 
of culturally and linguistically diverse people and 
their families, including Aboriginal and Torres Strait 
Islander people, migrant groups and “same sex” 
couples
■ fear of being labeled a “junkie”, “addict” or 
“alcoholic”
■ fear of lack of confidentiality—an employer, 
parent, family member or local community member 
finding out about their drug and alcohol problem
■ age, because most drug and alcohol services are 
unable to address the needs of people under 16 or 
people over 60
■ gender, because few services can meet the needs of 
women and accommodate the children of parents 
who are seeking drug and alcohol treatment
■ fear of professional consequences, because 
professionals with drug and alcohol problems often 
fear being recognised and judged by colleagues and 
supervisors. 
Overview and general guidelines
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2.5 Myths
There are many myths about drug and alcohol use, and 
some beliefs can impact negatively, both on the people 
with the substance use problem and on their families and 
friends. Some common myths are:
■ It is someone else’s problem
 Nurses and midwives are in ideal settings across the 
health system to address drug and alcohol problems 
rather than leaving the problem solely up to the 
specialists (de Crespigny 1996; Ghodse 1995).
■ People who have drug and alcohol problems are 
hopeless people
 Most people with drug and/or alcohol problems have 
or want to have jobs; they manage their households, 
raise their children, and have a range of other 
responsibilities.
■ Addicts are beyond help
 Many people who experience dependence can (and 
do) modify or cease their harmful use. However, this 
usually happens over time and when their situation 
supports it. Many people—often without professional 
help—move away from their drug and/or alcohol 
dependence. Either they abstain completely or they 
reduce their consumption to a safer and more 
manageable level.
■ All substance misusers are dependent on drugs
 Many people use substances socially or recreationally, 
and whilst they may experience problems associated 
with hazardous use (such as intoxication), only a small 
proportion of people become physically and/or 
psychologically dependent on drugs and alcohol 
(Clancy, C. & Coyne, P. 1997).
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Effective, clear, non-judgmental communication 
assists in building rapport and developing a sense of 
trust. This is the key to undertaking a quality assessment, 
understanding the person’s major issues, and managing 
drug and alcohol-related problems.
As primary service providers, nurses and midwives 
often provide the link between the person, other 
members of the multidisciplinary team, the person’s 
family, and other service providers.
This section examines cross-cultural communication, 
and issues related to communicating with special 
population groups, such as people with co-existent 
mental health problems, gender diverse groups, 
Aboriginal and Torres Strait Islander people, the 
ageing population, offenders, people with diverse 
cultural and linguistic backgrounds, rural communities, 
children, and adolescents. 
3.1 General principles of communication
When assessing a person’s drug and alcohol use, be 
aware of the following:
■ In the health care setting, drug and alcohol use is a 
health issue not a moral issue.
■ Whatever their age or circumstances, a person’s 
substance use history should be taken as part of the 
routine clinical assessment. The need for 
confidentiality from family members and/or significant 
others should be considered.
■ Issues related to cultural and linguistic diversity can 
make communication difficult, so the assistance of 
culturally appropriate interpreters (including 
Aboriginal interpreters) should be considered.
■ Be clear and straightforward about who you are. Tell 
the person your name, role, what you need to know, 
and why you are asking about their substance use. 
■ Attend to the person’s immediate concerns before 
addressing sensitive issues that may be unimportant 
to the person.
■ Build rapport and a sense of trust by listening to what 
the person wants, why they may be worried, and 
what they believe will help them. 
■ Show your concern about the person’s drug and 
alcohol use problems without prejudice.
3.2 Improving cross-cultural 
communication
Be aware that people from different cultural groups may 
misinterpret your requests for information or have 
different expectations of your service. 
Responding effectively to cultural and/or linguistic 
diversity requires flexibility of approach and creativity in 
ensuring that services are appropriate for the person and 
their family, rather than requiring the person to comply 
with rigid guidelines that may be inappropriate. Flexibility 
will foster rapport and a greater willingness on the 
person’s part to participate and cooperate in treatment.
Here are some suggestions to help you when working 
with people from cultures other than your own.
■ Always use approved interpreter services.
■ Always follow the guidelines for how to use 
interpreter services.
■ Allow sufficient time to interpret the situation from 
the person’s and their family’s cultural perspective.
■ Provide ongoing evaluation of assessment and care.
■ Be clear, concrete and specific.
■ Respond with respect, immediacy and timeliness.
■ Respect taboo.
■ Be sensitive to embarrassment.
■ Examine your own expectations.
CHAPTER 3
Communication and special population groups
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3.3 Special population groups
Within the community there are specific population 
groups that experience barriers in accessing and receiving 
drug and alcohol interventions. These groups have 
specific needs, and service delivery models for these 
groups are still evolving. 
3.3.1 Co-existing mental health disorders and 
substance misuse
There are a considerable number of people with co-
existing mental health and drug use problems, and its 
prevalence may be increasing. It varies in severity and 
degree of impairment and cannot be defined in terms of 
a specific syndrome with a discrete treatment approach.
Mental health disorders and drug use is associated with a 
host of social, behavioural, psychological and physical 
problems, including: increased symptom severity and 
suicidal behaviour; greater non-compliance with treatment; 
more hostile and aggressive behaviours; increased risk of 
violence to others; higher rates of offending, imprison-
ment and homelessness; and longer duration of admission 
to psychiatric inpatient units. (Hegarty, M., 2004). 
Prevalence rates of drug use issues in mental health settings 
have been consistently reported at between 30 and 80 
percent. (Todd, F.C., Sellman, D. & Robertson, P.J., 2002). 
More than half of the people who use substances have 
experienced psychiatric symptoms significant enough to 
fulfill diagnostic criteria for a mental illness. (Regier et al., 
1990). 
People living with a mental illness are at an increased risk 
of developing problematic alcohol and/or drug use, 
especially those aged between 18 and 25 years. 
3.3.2 Aboriginal and Torres Strait Islander 
people and communities
According to the 2002 National Aboriginal and Torres 
Strait Islander Social Survey (NATSISS):
■ One-quarter of Aboriginal people aged 15 years or 
over in non-remote areas reported having recently 
used an illicit substance. 
■ 40% of Aboriginal people reported having tried at 
least one illicit substance in their lifetime.
■ Substance use was more prevalent among Aboriginal 
males — 43% of males compared with 37% of 
females. 
■ Aboriginal people aged 25–34 years were the most 
likely to have ever tried substances (55%).
■ Marijuana was the most commonly reported illicit 
drug used by Aboriginal and Torres Strait Islander 
people in 2002. 
■ Amphetamines/speed and painkillers or analgesics (for 
non-medical use) was the second most commonly 
reported illicit drug used.
As at 31 December 2004, in NSW there were 1314 
Aboriginal people on the opioid treatment program, 
which equates to 10.7% of the total number of clients 
on the program. This figure is high, as the percentage of 
Aboriginal people in NSW is only 2%. 
Research has consistently shown that while a greater 
proportion of Aboriginal and Torres Strait Islander people 
abstain from drinking alcohol than is the case amongst 
non-Indigenous Australians, those Aboriginal and Torres 
Strait Islander people who consume alcohol are more likely 
to do so at hazardous levels. It should be noted that, accord-
ing to the Australian Institute of Health and Welfare:
■ Heaviest drinking occurs amongst Aboriginal and 
Torres Strait Islander people aged 25–34 years, while 
hazardous drinking in the general population is most 
common amongst people aged 14–24 years.
■ 19.6% of Aboriginal and Torres Strait Islander people 
consume alcohol at high risk of long-term, alcohol-
related harm, compared to 9.7% of non-Indigenous 
Australians, though among urban people who drink, 
68% of Aboriginal and Torres Strait Islander people 
consume alcohol at harmful levels compared to 11% 
of non-Indigenous urban people who drink.
■ 48.7% of Aboriginal and Torres Strait Islander people 
are at risk of long-term, alcohol-related harm, 
compared to 9.7% of non-Indigenous populations.
■ At all ages, Aboriginal and Torres Strait Islander males 
are more likely to drink than women.
■ 20.6% of Aboriginal and Torres Strait Islander people 
abstain from alcohol, compared to 17.3% of non-
Indigenous Australians. 
Like the rest of the community, Aboriginal and Torres 
Strait Islander people live in different settings across 
urban, rural and remote areas. Again, as with all patients, 
the ways Aboriginal and Torres Strait Islander people use 
substances are affected by the environments they live in, 
their access to substances, their history, social situations 
and personal choice.
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Because of this diversity, there is no simple set of 
instructions about working with Aboriginal and Torres 
Strait Islander patients. As with all patients, nursing staff’s 
dealings with Aboriginal and Torres Strait Islander 
patients needs to be respectful, sensitive and flexible.
A thorough and non-judgmental substance use 
assessment remains the key to quality nursing care of 
Aboriginal and Torres Strait Islander patients; however, 
nurses need to be aware of the following specific factors 
in their communication with Aboriginal and Torres Strait 
Islander people.
The following are some hints about communicating 
effectively with Aboriginal and Torres Strait Islander patients:
DO
■ Be polite, respectful, and treat the person as equal to 
yourself.
■ Enlist the help of your health facility’s Aboriginal and 
Torres Strait Islander health liaison worker. Be aware 
that the patient may prefer to have a relative, friend 
or other trusted person present when you speak to 
them.
■ Be very careful about non-verbal signals. Use a 
friendly tone of voice, smile; take some time to show 
your interest in the patient and their family or other 
visitors.
■ Spend a little time chatting generally (e.g. trying to 
find common ground or people that you know in 
common) before asking about the clinical issue at 
hand.
■ Avoid overly medical terms or explain them 
thoroughly if you must use them, trying to ensure the 
person understands what you are saying without 
being threatening or patronising.
■ Be aware that you may subconsciously be using 
power to hide your own insecurity about being 
socially unskilled with Aboriginal and Torres Strait 
Islander clients.
■ Be aware that a patient may be hostile towards your 
role based on their past negative experiences, not 
necessarily towards you personally.
■ Display hope and optimism about a person’s ability to 
change their substance use. Many health workers are 
pessimistic about health outcomes for Aboriginal and 
Torres Strait Islander people, and this is a serious 
barrier.
■ Ensure privacy when talking about substance issues.
■ Be aware that separation from family can be very 
frightening for Aboriginal and Torres Strait Islander 
people. Try to accommodate the patient’s wishes for a 
relative or other trusted person to be with them if 
they wish for it.
DON’T
■ Don’t assume anything. Do not base your responses 
to a patient on any assumptions about their illness, 
their Aboriginality or their behaviour.
■ Make clear clinical judgments and carry out quality 
nursing care of the patient.
■ Don’t use stereotypes. Relying on stereotypes (e.g. 
‘Aborigines all have drinking problems’) is not only 
offensive but dangerous — it can lead to other health 
problems being ignored or misdiagnosed.
■ Don’t be pushy or confrontational when giving health 
advice. Confrontation is likely to be rejected by an 
Aboriginal and Torres Strait Islander patient.
■ Don’t give the impression that you are too busy to 
talk to the patient properly. Aboriginal and Torres Strait 
Islander people often say they wish professionals 
would get to know them a little: “I wanted to ask 
questions of the doctors and I was frightened … You 
walk in and they say ‘What’s wrong with you?’ 
instead of talking to you.” (Eckerman et al, 1995)
3.3.3 Sexual and gender diverse groups
National and international research into Lesbian Gay 
Bisexual and Transgender (LGBT) health highlights a 
strong relationship between homophobia, heterosexism, 
social exclusion and the health status of individuals. 
The percentages of same-sex attracted young people 
injecting drugs dropped from 11% in 1998 to 4% in 
2004. Nevertheless, drug use still remains substantially 
higher than for heterosexual young people, for example, 
double the number of same-sex attracted young people 
have injected drugs. 
3.3.4 Ageing population
As the age of the Australian community increases, it is 
necessary to recognise the needs of the elderly. Elderly 
people with drug and alcohol issues have greater need 
for support services. Their increased age, coupled with 
the effects of drug or alcohol misuse, make them less 
able to cope in the community. 
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For men and women aged 65 years and over on a day when 
alcohol was consumed, 40% of all men and 45% of all 
women had one or two drinks, 23% and 7% had three 
or four drinks, and 15% and 1%, respectively, had five or 
more drinks. 
To examine the prevalence and pattern of alcohol use 
among community-living elderly Australians, a survey was 
conducted of randomly selected non-institutionalised 
people aged 75 years and older living in the inner 
suburbs of Sydney. It was found that: 
■ 72% of men and 54% of women drank alcohol. The 
median usual daily volume of ethanol consumed was 
10 grams for men and 1.3 grams for women. 
■ 11% of male drinkers and 6% of female drinkers 
consumed at defined hazardous or harmful levels. 
Although a sizable majority of these older people were 
either non-drinkers or very light drinkers, a small but 
significant proportion drank in the hazardous to harmful 
range. It remains important to be alert for potentially 
harmful alcohol use among older people. 
3.3.5 Offenders
Approximately 18,000 people are received into custody 
each year in NSW. Of these:
■ over 60% of prisoners in the NSW Correctional 
System are estimated to have been under the 
influence of drugs or alcohol at the time of offending
■ 80% have committed drug-related crimes
■ 60% have a history of injecting drug use
■ 40% are current injectors
■ 20% will continue to inject in prison.
3.3.6 People from diverse cultural and 
linguistic backgrounds
Use of drugs and alcohol can have different meanings for 
particular cultures, and there can be diversity in patterns 
of use within cultural groups. For example, people from a 
European background are more likely to have used both 
alcohol and cannabis than those from an Asian or Arabic 
background.
People from culturally and linguistically diverse 
backgrounds are less likely to have drunk alcohol in the 
past week (44.5% of alcohol users) than in the wider 
community (56.5% of alcohol users). 
3.3.7 Rural communities 
Rural and remote populations have specific challenges in 
providing comprehensive health care, such as distance, 
travelling times, availability of clinicians, and dispersal of 
the population. These factors affect the delivery of an 
integrated drug and alcohol service system. 
Telecommunications and the use of technology in service 
delivery have a special role to play in making services 
accessible to these populations.
In NSW in 2003, 15% of rural people were at high risk of 
harm in the short term as a result of their drinking. The 
proportion of males reporting short-term high-risk 
drinking was greater than the proportion of females 
across all age groups. 
The proportion of people participating in high risk drinking 
behaviours was greatest among those aged 16–24 years 
for both males (34%) and females (27%). High-risk drinking 
declined progressively with age. 15% of both urban 
residents and rural residents reported high risk drinking. 
In rural NSW, 8% of men in rural areas report consuming 
alcohol at a hazardous or harmful level compared to 5% 
in metropolitan areas; 82% of 14–19 year-olds in rural 
communities regularly consume alcohol compared to 
71.5% in metropolitan areas; and 22% of rural road 
fatalities are alcohol-related compared to 14% for 
metropolitan areas.
3.3.8 Children in developmental stages 
Alcohol consumed by mothers during pregnancy can 
seriously affect the health and development of their 
unborn child. Some babies will be born with foetal 
alcohol spectrum disorder (FASD). FASD is used here to 
indicate the full range of possible effects of foetal 
exposure to alcohol. These children may:
■ Be small at birth
■ Have developmental disabilities
■ Have behavioural and learning problems
■ Have abnormalities in the appearance and shape of 
the face
■ Have eye problems
■ Have heart problems.
FASD is more prevalent in Aboriginal and Torres Strait 
Islander than non-Indigenous infants. 
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For further information, refer to the National clinical 
guidelines for the management of drug use during 
pregnancy, birth and the early development years of the 
newborn. (March 2006) www.health.nsw.gov.au/
pubs/2006/ncg_druguse.html
The Department of Community Services (DoCS) Families 
First has received Drug Summit funding for innovative 
prevention and early intervention projects to support 
families, communities and individuals. In a number of 
Area Health Services, DoCS has implemented projects to 
support substance using mothers during pregnancy, and 
during the child’s early infancy.
3.3.9 Young people with emerging problems 
While many young people do not use drugs and alcohol 
at dangerously high levels, there are known harms 
associated with all levels of misuse. It is also recognised 
that some young people will develop chronic patterns of 
drug use and engage in frequent harmful binge use. 
A NSW Health report, The Health Behaviours of 
Secondary School Students in New South Wales 2002, 
found that the number of NSW secondary students 
reporting recent tobacco and cannabis use has almost 
halved in the last 20 years. The data shows that since 
1984 the number of high school students reporting 
recent tobacco use had fallen by 40% while the number 
of students reporting recent cannabis use had fallen by 
47% since 1996.
In 2002, 69% of NSW secondary school students 
reported drinking in the last year, and 45% reported 
drinking in the last four weeks. 
30% of students reported being recent drinkers (within 
the last seven days). As expected, the percentage of 
recent drinkers generally increased as the age of students 
increased, from 13% among students aged 12 years to 
39% among students aged 17 years in 2002. 
Males were more likely to report being recent drinkers 
than females, with 32% of females aged 17 years 
reporting that they were recent drinkers compared with 
46% of males. The exception to this was in female 
students aged 15 years, where the percentage of recent 
drinkers was higher than in males of the same age 
(43% versus 37%) and higher than in females aged 17 
years (33%). 
For alcohol, the mean age of initiation remained relatively 
stable between 1995 and 2004 at 17 years of age. The 
mean age of initiation for first use of all illicit substances 
surveyed either remained stable or increased between 
2001 and 2004.
In 2004, over one-third (38%) of the population aged 14 
years and over had never used an illicit drug. Across all 
age groups, males were more likely than females to have 
recently used an illicit drug with the exception of those 
aged 14–19 years, where females (21.8%) were more 
likely to have used an illicit drug in the preceding 12 
months than their male (20.9%) counterparts. 
More than one in five (21.3%) teenagers had used illicit 
drugs in the past 12 months.
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It is essential that nurses and midwives are well-
equipped to identify presentations that require admission, 
treatment, referral or further investigation. A drug and 
alcohol use assessment is important in order to:
■ establish a correct diagnosis
■ predict the effects of intoxication, assess its life-
threatening potential, and plan appropriate 
intervention
■ assess the possibility of drug interaction between the 
drug taken by the patient and drug(s) administered by 
the nurse, or between those already taken
■ predict the possibility of withdrawal
■ assess risk behaviours, including self harm
■ ensure duty of care
■ gain an understanding of the patient as a whole 
person, not merely in terms of their symptoms
■ select appropriate therapeutic interventions.
Some diagnoses may be confused with alcohol or drug 
intoxication or withdrawal, leading to significant medical 
problems being missed if the nurse or midwife does not 
look for causes beyond alcohol or drugs. Such problems 
include infection, hypoxia, hypoglycaemia and other 
metabolic imbalances, head injury, CVA, liver disease, 
drug overdose and psychosis.
This section outlines steps involved in making a physical 
and mental status assessment, the need for blood-
borne virus screening, issues about child protection, 
and what to do if a person refuses assessment or 
treatment. It also provides some handy techniques to 
elicit information.
4.1 General principles of drug and 
alcohol use assessment
■ Drug and alcohol use assessment must be quantified 
and documented.
■ Systematic assessment of all patients should include a 
thorough examination of:
– indicators of risk
– past medical history
– psychosocial issues
– physical signs and symptoms
– mental health status
– pathology results.
■ No single sign, symptom or pathology test is 
conclusive evidence of an alcohol or drug-related issue.
4.2 Key elements of assessment
The following key elements must be clarified with each 
patient as part of the drug and alcohol use assessment:
■ type of drug (See Appendix 6 for street names)
■ route of administration
■ frequency of use
■ dose
■ duration of use
■ time and amount of the last dose, e.g. grams of 
alcohol, mls and mgs of methadone, grams of 
cannabis, etc.
Note: It is important to ask the person if they are using 
more than one drug at a time, as polydrug use can 
significantly increase the risk involved.
4.3 Physical assessment
The physical assessment involves noting vital signs, fluid 
balance, level of consciousness, blood pressure and pulse. 
Here are some examples of physical signs arising from 
drug and alcohol use.
4.3.1 Signs of drug use administration
■ puncture marks
■ cellulitis
■ phlebitis
CHAPTER 4
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■ skin abscesses
■ erosion or irritation around nostrils/septum
■ irritation or rash around nose and mouth. 
4.3.2 Signs of withdrawal
■ sweating 
■ tremor
■ agitation
■ disturbance of coordination, gait
4.3.3 Consequences of use
■ excessive weight loss
■ signs of numerous old injuries, e.g. bruising
■ general physical health problems such as septicaemia, 
HIV, hepatitis B/C (see following page)
■ jaundice.
4.4 Mental status examination
It is important to include a mental status examination in 
the overall assessment.
Psychoactive drugs affect cognition, emotions and 
behaviour. Depending on the particular substance, they 
can, for instance, induce confusion, disorientation, 
perceptual disturbance, euphoria, agitation, panic, 
emotional lapses, repetitious behaviour or aggression.
A mental status examination involves the assessing the 
following:
MH-OAT (Mental Health Outcomes Assessment Training): 
■ Appearance and behaviour: (including physical 
features, dress, grooming, level of awareness and 
attention, motor activity, gait, posture and attitude 
toward interviewer)
■ Speech: (including quantity, rate, volume, tone, and 
any unusual characteristics)
■ Mood: (internal feeling or emotion, e.g. depressed, 
euphoric, distressed)
■ Affect: (external emotional response, e.g. restricted, 
flattened, inappropriate given circumstances). Does the 
patient seem unduly anxious or depressed? Do the 
patient’s emotions, posture, facial expression seem 
natural for their present situation?
■ Thought form: (including tangentiality, loosening of 
associations, illogical thinking incoherence, thought 
blocking, poverty of thought)
■ Thought content: (including pre-occupations, ideas of 
hopelessness/guilt, obsessions, overvalued ideas, 
delusions, suicidal & homicidal ideation)
■ Perception: (including illusions, derealisation 
depersonalization and hallucinations)
■ Insight and Judgment
All health staff need to complete a preliminary screening 
for suicide risk as part of any assessment. For further 
information about the management and assessment of 
suicide risk, refer to NSW Health Department Policy 
PD2005_121 ‘Management of patients with possible 
suicidal behaviour.’ 
Thorough multidisciplinary assessment is the first step 
towards providing an effective package of medical and 
social care. Practitioners should aim to establish: 
■ The chronology of presenting problems
■ The relationship (if any) between them
■ Whether the disorders require independent treatment 
or 
■ Whether treating one will help alleviate the other
4.5 Quantifying substance use
The nurse or midwife must quantify a person’s drug and 
alcohol use, and include both prescribed and non-
prescribed drugs in the assessment, before determining 
whether the level of use may cause harm, and whether 
withdrawal or progression to overdose is imminent.
For some substances such as alcohol, there is an agreed 
low risk level of consumption. For tobacco there is no 
safe level of consumption. Illicit drugs are difficult to 
quantify because the same drug can differ vastly from 
dose to dose in terms of purity and actual ingredients. 
Nevertheless, for illicit drugs, document e.g. the number 
of injections, bongs, or the dollar cost etc. 
Many medications should only be taken if they are on 
prescription and in the way prescribed.
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4.6 Hints on taking a drug and alcohol 
use history
For many reasons, it can be difficult to discuss personal 
issues with people. 
Here are some points to remember when taking a history:
■ Try to make the environment as quiet and private as 
possible.
■ Be mindful of the patient’s level of physical and 
emotional comfort.
■ Note inconsistencies in what the patient tells you.
■ If a question angers the patient, leave it until later 
when you can rephrase the question.
■ A history of the person’s drug and alcohol use can 
also be elicited from their spouse, friends or family.
■ Examine hospital medical records and speak to other 
health workers to gain supporting information for 
your history.
4.7 Discussion techniques
When discussing drug and alcohol issues with your patient, 
try to remain as non-threatening and non-judgmental as 
possible. The following techniques may help, but be 
mindful that they may not be suitable for every patient. 
Use discretion and professional judgment as to which 
may be useful.
■ Introduce drinking/drug use as a normal, everyday 
experience, e.g. “What do you like to drink each day?”
■ Ask about frequency of drinking e.g. “how often 
would you have a drink?”
■ Use open-ended questions, e.g. “How has your 
drinking changed over time?”
■ Try reflective listening, e.g. “Sounds like your drinking 
has been causing you problems lately.”
■ Do not be distracted away from important points.
■ Do not allow personal attitudes to affect the 
assessment.
■ Be affirmative, e.g. “It takes a lot of courage to open 
up and talk about your drug use.”
■ Be sensitive to the patient’s cultural background and 
language.
■ Suggest high levels of drug and alcohol use, e.g. 
“How much would you normally drink in a session? 
Twenty schooners?” However, when talking with 
adolescents, be careful that they do not perceive the 
overestimated amount as an expected figure, thereby 
encouraging them to exaggerate it further.
■ Summarise, e.g. “On the one hand you like drinking 
because it helps you to relax but on the other hand 
you’re concerned about the effect it will have on 
the kids.”
■ Do not assume that the patient perceives their drug 
and alcohol use as a problem
■ If a question angers the patient, leave it until later 
when it can be rephrased. 
(See Appendix 6 for street names of drugs.)
4.8 HIV, Hepatitis B & C screening 
Hepatitis C is a major public health concern in Australia. 
Approximately 80% of Australian-born people with 
hepatitis C were exposed to the virus through unsterile 
injecting drug use (Crofts, N. et al., 2001). It is therefore 
important to discuss blood-borne viruses and the risk of 
acquisition with patients.
■ Either at the assessment interview or after treatment 
has commenced, offer all patients screening for HIV, 
hepatitis B and hepatitis C and advise on the 
availability of hepatitis B vaccination.   
■ Tests should only be undertaken when patients have 
voluntarily agreed to such testing and at an 
appropriate time in the withdrawal process (not in the 
acute phase).
■ To assist patients to make a decision regarding 
testing, provide sufficient information to allow them 
to give informed consent, and assure them that 
confidentiality will be maintained. 
If patients elect to undergo these tests, pre-test and post-
test counselling must be provided as outlined in:
NSW Health Policy Directive PD2005_048: Counselling 
associated with HIV antibody testing—guidelines.
For further information, see “Nurses and Hepatitis C”—
Australasian Society for HIV Medicine (ASHM).
http://www.ashm.org.au/uploads/File/nurses-supp.pdf
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4.9 Child protection issues 
At assessment, it is important to consider the safety, 
welfare, and well-being of any children within the 
patient’s care. Health care workers have a duty under the 
NSW Children and Young Persons (Care and Protection) 
Act 1998 to notify the Department of Community 
Services whenever they suspect that a child or young 
person may be at risk of harm through abuse or neglect. 
When necessary, this duty overrides the duty to maintain 
patient confidentiality. For further information, refer to:
■ NSW Health Policy Directive PD2005_299. Protecting 
children and young people.
■ NSW Health Frontline Procedures for the protection of 
children and young people. 2000.
Pregnant opioid-dependent women should always be 
referred to Drug Use in Pregnancy Services. For further 
information, refer to the National clinical guidelines for the 
management of drug use during pregnancy, birth and the 
early development years of the newborn. (March 2006) 
http://www.health.nsw.gov.au/pubs/2006/ncg_druguse.html
Inadvertent consumption of methadone by a child is 
a potentially life-threatening situation.
■ Assess the level of consciousness and monitor this 
continuously until the child is in the care of 
ambulance or other qualified staff.
■ Refer the child to a hospital emergency department 
without delay, providing the information available 
about the amount taken and the time.
■ Administer oxygen if available.
■ Consider naloxone administration if the child is 
showing signs of respiratory depression. Document 
any treatment given.
■ Notify the prescriber and the Pharmaceutical Services 
Branch or the Mental Health and Drug & Alcohol 
Office of the incident. If a child has ingested 
methadone or buprenorphine by any means, the 
child has been placed at risk of harm and the 
authorities should be notified:
– A report to DOCS should be made (see section 
7.14, Child protection, on page 76, NSW Opioid 
Treatment Program, Clinical guidelines for 
methadone and buprenorphine treatment of 
opioid dependence. GL2006_019). Concerns for 
the child should be discussed with hospital staff.
–  Police may be involved in exceptional 
circumstances.
4.10  Domestic violence issues 
Amongst those with drug and alcohol issues are 
significant numbers of both victims and perpetrators of 
domestic violence. Responding to this group presents 
particular challenges for nurses. For further information 
about the management of domestic violence and 
assessment of risk, refer to: 
■ NSW Health Policy for Identifying and Responding to 
Domestic Violence, 2003.
■ NSW Health Policy Directive PD2006_084. Identifying 
and responding to domestic violence. 
4.11 Confidentiality
It is important that you are aware of the limits of 
confidentiality. Patients need to be informed that the 
purpose of taking a drug and alcohol history is to obtain 
information that is relevant to their health and that it is 
not a forensic investigation.
In fact, in most cases, information can only be provided 
to third parties (i.e. people other than the clinicians 
treating them) if the patient has provided written 
permission to do so. There are a few exceptions, for 
example, if the person is homicidal or suicidal; if there are 
child protection issues; and if a subpoena has been issued 
for the patient’s notes. 
4.12 If a patient refuses assessment
Patients are unlikely to object to a drug and alcohol use 
assessment if the questions are asked in a matter-of-fact 
manner as part of routine history collection. 
While the patient has a right to refuse, the nurse or 
midwife is obliged to ask about substance use and 
document the response.
Drug and alcohol use assessment
PAGE 20  NSW HEALTH  Clinical guidelines for nursing and midwifery practice in NSW 
Opportunistic intervention can be undertaken in as 
little as a few minutes and can be supported by written 
information and self-help strategies. Studies have shown 
that talking with people at a critical moment such as when 
they are in hospital can be very effective in educating and 
preventing further problems and complications (Heather 
et al. 1996). Pregnancy and around the time of birth also 
provide useful opportunities for appropriate interventions 
if drugs and/or alcohol are an issue.
While opportunistic interventions can be applied at any 
stage in the person’s drug and alcohol using career, it is 
not as likely to be effective for those who experience 
chronic relapsing dependence or a co-morbid mental 
health condition. This group usually requires supportive 
care and longer-term expert treatment.
This section outlines briefly the concept of opportunistic 
intervention and when it may or may not be appropriate. 
Also refer to the Handouts Section after Appendices.
5.1 General principles of opportunistic 
intervention
■ Carrying out a comprehensive substance use 
assessment allows the nurse or midwife to identify 
whether the person is using substances in ways that 
may become damaging in the future.
■ Opportunistic interventions can be done at any time 
during contact with a person who is being assessed 
for substance use.
■ Providing relevant, easy-to-understand information 
such as self-help materials or handouts may help to 
motivate a person to seek further help.
5.2 Unsuitable candidates for 
opportunistic intervention
Not everyone responds favourably to opportunistic 
intervention, for example, the following: 
■ People who show signs and symptoms of serious 
physical illness arising from their substance use. In 
this instance, a physician needs to carry out a further 
assessment. 
■ People who are dependent on substances and need 
comprehensive general and mental health screening, 
specialist assessment, and specialist treatment.
■ People who feel powerless about their situation or 
have concurrent health and social problems that 
require more intensive counselling, intervention and 
support than is possible in a brief intervention.
5.3 Self-help interventions
While opportunistic interventions may be beneficial, 
when staff are pressed for time, self-help approaches 
have been shown to be effective with mild to moderate 
levels of alcohol or other drug use. 
Figure 5.1: Intervention flowchart
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Intoxication occurs when a person’s intake of a substance 
exceeds their tolerance and produces behavioural and/or 
physical changes. Nurses and midwives must be able to 
correctly manage intoxication because it complicates 
assessment and management of patients, even when the 
intoxication is not life-threatening.
Intoxication can be dangerous because:
■ it can mimic or mask serious illness and injury
■ it can be life threatening and cause:
– altered physical functions (e.g. depressed 
respiration, alterations in temperature regulation)
– altered mental functions (e.g. panic or paranoia 
resulting in accidental injuries or self-destructive 
behaviour)
■ psychoactive drugs affect mood, cognition, behaviour 
and physiological functioning
■ aggressive or disruptive behaviour can pose a risk to 
the both the person’s safety and that of other visitors, 
staff, and patients. 
This section discusses the procedure for assessing and 
managing intoxication, and the symptoms and effects 
of specific drugs.
6.1 General principles of managing 
intoxication
■ Maintenance of airways and breathing is of 
paramount importance to the comatose patient.
■ Any patient presenting as incoherent, disoriented or 
drowsy should be treated as per head injury until 
proven otherwise.
■ Intoxicated patients must be kept under observation 
until their intoxication diminishes.
■ A thorough physical and mental status examination 
will reveal the level of a patient’s intoxication to 
provide baseline information.
■ Patients who appear intoxicated may be suffering from 
other conditions, so if the intoxication does not diminish 
with falling serum drug levels, the patient must be 
assessed for other possible causes of their condition. 
If an apparently intoxicated person cannot walk, stand 
or get up from a chair they must continue to be observed. 
■ Treat intoxicated patients with respect. Speak slowly 
and simply, treat them in a quiet place if possible, give 
information clearly, and protect them from accidents.
■ Patients who have stabilised after being intoxicated 
should be further assessed for any possibility of 
withdrawal—early identification and intervention of 
withdrawal management can prevent complications 
that may be life threatening.
■ Alcohol withdrawal can occur before a zero blood 
alcohol reading is noted.
■ Polydrug use is common, so it important to identify 
and observe for the effects of more than one drug in 
the intoxicated person.
■ Any patient presenting with seizures should be 
assessed for alcohol withdrawal, benzodiazepine 
withdrawal or stimulant intoxication as well as other 
possible causes. The seizures must be treated 
according to policy and the patient observed for at 
least four hours post seizure, using the Glasgow 
Coma Scale score (see Appendix 1).
6.2 Assessing intoxication
To assess intoxication:
■ Take a comprehensive drug and alcohol use history 
(see Chapter 4).
■ Observe vital signs—temperature, pulse, blood 
pressure, respiration.
■ Refer to the physical examination conducted by the 
medical officer—ataxia, pupils, gait.
■ Refer to the mental status examination (see Chapter 4).
■ Consider conditions other than intoxication (e.g. head 
injury, CVA, hypoglycaemia, psychosis, severe liver 
disease, etc.).
■ Record observations.
CHAPTER 6
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6.3 If the assessment indicates 
intoxication
■ Maintain vital signs.
■ Continue monitoring the patient’s physical and 
mental state.
■ Ensure that the medical officer is aware of the 
patient’s status.
■ Airway maintenance is of the utmost importance.
Note:  Vomiting is likely to occur in the grossly intoxicated 
patient. This can present a major problem in semi-
conscious or unconscious patients.
6.4 Checking for causes other than 
intoxication
Patients who appear to be intoxicated may be experiencing 
conditions due to other causes. Remember that intoxicated 
patients often present with additional problems such as 
fractures, trauma, lacerations, etc.
You must consider and investigate the possibility of an 
underlying illness. For example, if an apparently 
intoxicated person cannot walk easily, stand or get up 
from a chair, you must continue to observe them, 
regardless of the lack of obvious injury.
Any patient who presents as incoherent, disoriented 
or drowsy should be treated as per head injury until 
proven otherwise.
6.5 Managing intoxicated behaviour
Supportive care will most often prevent an intoxicated 
patient from becoming upset or frightened and/or 
disrupting other patients, staff and visitors. 
■ Approach the patient in a friendly and respectful 
manner. Patronising and authoritarian attitudes can 
often evoke anger and make patients aggressive (this 
is a common response to threats to one’s dignity and 
self-respect).
■ If friends who are also intoxicated accompany the 
patient, ask them to wait outside the room.
■ Introduce yourself to the person and tell them your 
name and your role. 
■ Ask the patient’s name. 
■ Orient the patient and establish rapport.
■ Ask specific questions about the presenting illness or 
injury.
■ Elicit information, do not rely on the patient to 
volunteer it.
■ When possible, postpone questions or procedures 
that antagonise the patient.
■ Avoid information overload and repeat information, if 
necessary.
■ When instructing the patient or seeking cooperation, 
give clear, concrete instructions. If necessary, guide 
them to and from their destination, hand them 
things, etc.
■ Reduce the possibility of accidents.
■ When talking to the patient:
– use the patient’s name
– use slow, distinct speech
– use short, simple sentences
– avoid emotional topics and involved discussions
– use appropriate eye contact (limit, if the patient is 
affected by psychostimulants, or for cultural reasons
– adjust speaking pace to match the patient’s.
6.6 Managing specific behaviours
The following are techniques you can use to manage 
specific behaviours. 
6.6.1 Anxiety/agitation/panic
■ Approach the patient in a calm and confident 
manner.
■ Move and speak in an unhurried way.
■ Minimise the number of staff attending to the 
patient.
■ Provide a quiet environment to reduce stimulation.
■ Reassure the patient frequently, e.g. “It won’t take 
much longer.”
■ Remain with the patient to calm him or her down.
■ Explain interventions.
■ Protect the patient from accidental harm, e.g. don’t 
leave him/her unattended on a trolley.
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6.6.2 Confusion/disorientation
■ Provide frequent reality orientation.
■ Display some object familiar to the patient, such as his 
or her own dressing gown or slippers.
■ Ensure frequent supervision.
■ Accompany the patient to and from places, e.g. 
bathroom, TV lounge.
6.6.3 Altered perception/hallucinations
■ Explain perceptual errors.
■ Create a simple, uncluttered environment.
■ Nurse in well-lit surroundings to avoid perceptual 
ambiguities.
■ Protect the patient from harm.
6.6.4 Anger/aggression
The Zero Tolerance Response to Violence in the NSW 
Health Workplace ensures that in all violent incidents, 
appropriate action is consistently taken to protect health 
service staff, patients and visitors and health service 
property from the effects of violent behaviour. It is 
important that staff are familiar with the strategies 
outlined in this policy document.
■ Use space for self-protection, e.g. don’t crowd the 
patient, keep furniture between yourself and the 
patient if feeling unsafe, etc.
■ Keep own emotions in check. Speak in a calm, 
reassuring way.
■ Use the patient’s name when speaking to him or her.
■ Do not challenge or threaten the patient by tone of 
voice, eyes or body language.
■ Let the patient air his or her feelings, and 
acknowledge them.
■ Determine the source of the patient’s anger and if 
possible, remove it.
■ Be flexible within reason.
■ Be aware of workplace policies on managing 
aggression.
6.7 Signs of mimicking or masking 
intoxication
The following may mimic or mask intoxication:
■ infections
■ respiratory disease, hypoxia
■ head injury, subdural haematoma
■ acute psychosis
■ diabetes, hypoglycemia
■ epilepsy (temporal lobe), post-ictal
■ drug toxicity e.g. phenytoin, digoxin 
■ meningitis
■ CVA or TIA
■ withdrawal
■ Wernicke’s encephalopathy.
6.8 If a patient refuses treatment
If an intoxicated or withdrawing patient wants to leave 
the hospital against medical advice and the nurse or 
midwife does not think it is safe for them to leave, the 
nurse or midwife must exercise a duty of care to ensure 
the patient’s wellbeing. Refer to policies and procedures 
within your service.
6.9 Counselling support for staff 
At times, staff feel stressed when dealing with people 
whose behaviour is difficult or threatening. Refer to an 
employee assistance program (EAP) for staff who need 
counselling and support away from the workplace.
6.10 Symptoms and effects of specific 
drugs
Table 6.1 on the following page outlines the symptoms 
and effects of specific drugs. 
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Table 6.1 (Adapted from DASC 2002, Coyne & Wright 1997)
Intoxicant Symptoms and signs 
of use
Symptoms and signs of 
high doses
Possible indicators Adverse effects/outcomes
Alcohol
Common street 
names: grog, piss, 
booze, sauce
■ loss of inhibition
■ exuberance
■ slurred speech
■ argumentative
■ over-friendly
■ stumbling
■ confusion
■ slurred speech
■ intense moods/ swings
■ aggression
■ lack of coordination
■ increasing drowsiness
■ comatose, possibly 
leading to death
■ tins, cans, bottles, flasks 
nearby
■ smell of alcohol
■ vomit on shoes / clothes
■ alcohol-related injuries 
(e.g. falls, fights, 
pedestrian injuries)
■ drink-driving
■ brain, liver and other 
organ damage
■ withdrawal (tremors, 
sweating, hallucinations, 
seizures, delirium)
■ risks increase if used 
with other drugs, 
especially depressants
Amphetamines
Common street 
names: Speed, 
goey, whiz, 
uppers, oxblood, 
point, crystal, 
crystal meth, ice, 
shabu
■ dilated pupils
■ increased energy
■ loss of appetite
■ hyperactive
■ very talkative
■ may be aggressive
■ feeling of well-being
■ aggression
■ rapid speech
■ pressured speech
■ confusion
■ dehydration
■ shakiness / tremor
■ agitation
■ paranoia
■ capsules, tablets and 
powder, varying colours
■ injecting equipment
■ needle tracks
■ underweight
■ paranoid ideation
■ evidence of lack of 
sleep
■ poor nutrition
■ loss of weight
■ hallucinations
■ drug-induced psychosis
■ depression and suicidal 
ideation following 
withdrawal
■ exacerbation of mental 
illness
■ withdrawal (excessive 
sleep, irritability)
■ impact of unsafe injecting, 
e.g. HIV, hepatitis B/C, 
endocarditis, abscesses, 
vein collapse
Benzo- 
diazepines
Common street 
names: benzos, 
rowies, moggies, 
downers, sleepers, 
tummies, serries, 
pills
■ intoxication
■ drowsiness
■ headache
■ confusion
■ ataxia
■ dazed look
■ sleepiness
■ disinhibition
■ confusion
■ slurred speech
■ lack of coordination
■ stumbling
■ tablets in possession
■ prescriptions in 
possession
■ amnesia
■ falls / injuries
■ impaired thinking
■ withdrawal symptoms 
(nervousness, tremors, 
seizures)
Cannabis
Common street 
names: 
marijuana, grass, 
pot, shit, ganja, 
mull, hash, durry, 
green, dope, cone
■ intoxication
■ very relaxed
■ red eyes
■ silliness
■ distorted sense of time
■ giggles
■ munchies (increased 
appetite)
■ talkative
■ sleepiness
■ disorientation
■ inability to perform 
complex tasks
■ hallucinations
■ increased appetite
■ paranoia
■ time distortion
■ odour of burnt leaves
■ seeds
■ cigarette papers & 
tobacco
■ pieces of foil
■ plastic money / coin 
bags
■ pipes / bongs
■ falls / injuries
■ respiratory problems
■ memory lapse
■ drug driving
■ exacerbation of mental 
illness
■ paranoia
■ withdrawal
Cocaine
Common street 
names: snow, 
coke
■ energy rush
■ heightened awareness
■ confidence
■ chatty
■ affable
■ agitated
■ panic
■ enlarged pupils
■ extreme agitation
■ paranoia/ psychosis
■ drug-induced 
hallucinations
■ nausea and vomiting
■ increased body 
temperature
■ irregular shallow rapid 
breathing
■ tremors
■ chest pain
■ heart attack
■ straws for snorting
■ shiny surface (e.g. tin, 
mirror)
■ pipes
■ needles and syringes
■ needle tracks
■ lethargy
■ fatigue
■ panic
■ paranoia
■ depression, irritability
■ weight loss
■ delusions and violent 
behaviour
■ can lead to collapsed 
veins or skin ulcers at 
the injection site
■ ulceration and permanent 
damage to mucosa of 
nasal passage if snorted
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Intoxicant Symptoms and signs 
of use
Symptoms and signs of 
high doses
Possible indicators Adverse effects/outcomes
Ecstasy
Common street 
names: E, eccies, 
XTC, good speed
PMA: variable 
contents — may 
be sold as ecstasy 
but contains 
speed, PMA or 
GHB
GHB: Common 
street name: 
GBH, liquid 
ecstasy, fantasy
■ increased energy
■ loss of appetite
■ loss of inhibitions
■ wakefulness
■ euphoric feelings
■ sweating
■ grimacing
■ muscle cramps
■ sedation
■ feeling of well-being
■ vigorous activity
■ jaw clenching
■ nausea
■ sweating
■ teeth grinding
■ paranoia
■ severe headaches
■ increase in body 
temperature
■ loss of temperature 
control
■ severe dehydration
■ muscle weakness/cramps
■ brain damage
■ death
■ capsules and tablets, 
usually white, but may 
be coloured with motif 
stamped onto one side 
of tablet 
■ if combined with 
rigorous activity: severe 
dehydration, 
hyperthermia, 
rhabdomyolysis, brain 
damage, death
■ all adverse effects and 
negative consequences 
as yet unknown
■ can occur with short-
term use
Heroin / opioids
Common street 
names: Hammer, 
H, shit, smack, 
horse, harry, 
white, skag, junk, 
slow, rock
■ emotional detachment
■ pain relief
■ comfort
■ euphoria
■ pinpoint pupils
■ drowsy ‘nods off’
■ drowsiness
■ stupor
■ slowing respiration
■ itching
■ constricted pupils
■ nausea and vomiting
■ unconsciousness leading 
to death
■ poor nutritional state
■ poor teeth
■ needle tracks
■ injecting equipment
■ sachets
■ folds / wraps of paper
■ spoons
■ white / beige powder
■ tablets, capsules, syrup 
and vials
■ overdose
■ withdrawal (nausea, pain 
cramps, diarrhoea, 
irritability, dilated pupils)
■ impact of unsafe 
injecting, e.g. HIV, 
hepatitis B/C, 
endocarditis, abscesses, 
vein collapse
Ketamine
Common street 
name: Special K
■ intense hallucinations
■ euphoria
■ depersonalisation
■ temporary paralysis ■ straws
■ needles and syringes
■ cramps
■ fatigue
■ severe depression
■ irritability
■ vomiting
■ heart failure
■ violent reactions
■ flashbacks similar to those 
experienced with LSD
LSD
Common street 
names: trips, acid, 
wangers, tabs, 
dots
■ hallucinations: visual, 
auditory and tactile. 
Can range from being 
extremely pleasant to 
unpleasant
■ ‘bad trip’ (severe 
hallucinations)
■ incoherency
■ uncoordinated
■ vomiting
■ seizures
■ dilated pupils
■ disassociation
■ small paper squares in 
various colours and 
designs (microdots), will 
be kept away from light 
and wrapped in foil
■ risk of self-harm
■ injuries / falls
■ unpredictable behaviour
■ may predispose mental 
illness
■ “flashbacks” some time 
after usage
Solvents
Common street 
names: glue, tol, 
toluene, bute, 
nitrus, amyls, 
petrol, aerosol 
paint-chroming
■ intense intoxication
■ loss of balance
■ auditory and visual 
hallucinations
■ stumbling
■ very similar to alcohol 
intoxication
■ seizures
■ unconsciousness
■ slurred speech
■ drowsy
■ aggression
■ common products 
including adhesives, 
thinners, liquid paper, 
dry cleaning products, 
aerosols, fuels, anti-
freeze, fire extinguisher 
fluids, chrome and 
other spray paint
■ smell of solvent used
■ long-term damage to 
health (liver, kidney, 
brain damage)
■ sudden sniffing death 
syndrome
■ asphyxiation (upper 
airways obstruction, 
swelling of throat)
■ risks increase if used 
with other drugs, 
especially depressants
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Any person who presents as incoherent, disoriented 
or drowsy should be treated as having a cerebral event 
(head injury) until proven otherwise. Overdoses should be 
managed according to the policy of each health facility. 
Overdose can be by accident or as a result of deliberate 
self-harm. Remember:
■ acute poisoning and acute withdrawal can have 
common features
■ accidental overdose is a high risk when a person has 
used more than one depressant drug
■ a person, including someone who is alcohol-
dependent, may overdose from high intake of alcohol 
or from having used other drugs with alcohol.
Overdose can be defined as the state occurring when a 
person has taken more of a substance than the 
recommended therapeutic dose and/or an amount that 
also exceeds his or her tolerance. Overdose indicates 
intoxication to the point of loss of consciousness.
Inexperienced drinkers such as children and adolescents 
can overdose from minimal doses of alcohol due to low 
tolerance.
Anyone who presents with a decreased level of 
consciousness must have their vital signs and neurological 
function monitored carefully. The Glasgow Coma Scale 
(GCS) provides the best method of assessment (see 
Appendix 1). These observations must be done on arrival, 
after checking airway, breathing and circulation, and 
should be continued regularly for at least four hours.
With the use of the GCS and the monitoring of vital 
signs, the nurse or midwife can recognise quickly any 
deterioration in the person’s condition and intervene at 
the earliest possible time.
This section presents guidelines for identifying 
overdose and managing it. It also provides a basic life 
support flowchart.
7.1 Management guidelines for 
overdose
A standard approach should be used for managing 
overdose situations. Alcohol-intoxicated people may have 
ingested other substances that may complicate and 
compromise their condition further. There may also be 
underlying pathology. All these factors must be considered. 
Treatment of overdose should be initiated within the 
following guidelines as routine practice:
■ Do not give food or fluids.
■ Be alert and manage the following conditions 
according to best practice:
– slowing respiration
– respiratory depression or failure
– airway obstruction
– bronchospasm
– aspiration
– pulmonary or cerebral oedema
– haemorrhagic conditions
– acidosis 
– hypoglycaemia
– hyper/hypocalcaemia
– liver failure.
■ Measure or observe the following signs and manage 
according to best practice:
– hypotension
– bradycardia/tachycardia/arrhythmia
– hyperthermia or hypothermia
– oliguria/anuria
– seizures.
7.2 Monitor progression of intoxication 
to overdose
To observe for progression to an overdose state, monitor 
the following:
■ increasing agitation or sedation
CHAPTER 7
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■ changing mental state (hallucinations, panic or deep 
depression)
■ abnormal pulse (irregular, below 60 or above 120 per 
minute)
■ breathing difficulties
■ decreasing levels of consciousness
■ increasing disorientation
■ diminished response to stimuli 
■ seizures.
Note the need to:
■ evaluate risk of self-harm
■ remove any medicines, alcohol, other drugs or 
substances (e.g. solvents) that could be ingested by 
the person.
7.3 Identify type of drug and dose
For assistance with identification of the drug used, check:
■ MIMS
■ Australian Drug Compendium
■ Poisons information service in your State
■ Medical staff or general practitioner
■ Pharmacist.
If a non-pharmaceutical drug has been used:
■ check the label on the container (e.g. aerosol can)
■ ask the poisons information service in your State
■ ask any relevant government agency (e.g. agriculture, 
mining)
■ ask the manufacturer.
Collect a urine sample as soon as possible:
■ to identify the type of drug used, and to verify actual 
ingestion of a drug(s)
■ to assess for qualitative estimates.
Collect a blood sample:
■ for presence of drug(s)
■ for blood alcohol level
■ for serum drug levels.
Take a:
■ history of ingestion of a foreign substance
■ medical history (e.g. epilepsy, diabetes)
■ recent history of drug and alcohol use.
7.4 Potentially lethal overdoses
A person who has had a potentially lethal overdose must 
be assessed early for the need for:
■ urgent urine screening, where possible
■ specific antidotes
■ haemodialysis
■ gastric lavage.
7.5 Medical management
Medical management may consist of the following:
■ Administration of intravenous 100mg thiamine to 
prevent Wernicke-Korsakoff’s syndrome in patients 
determined to be at risk of Wernicke’s, before any 
dextrose loading (e.g. when used to treat 
hypoglycaemia).
■ Naloxone (Narcan) for possible opioid ingestion may 
also be needed. (DASC 1996)
Note: Resuscitation equipment should be available 
immediately when Thiamine is given in the unlikely event 
of anaphylaxis (Thomson et al, 2002, p. 514).
■ IV dextrose 50% 50 millilitres (e.g. when used to treat 
hypoglycaemia) 
■ Intravenous or intramuscular naloxone 0.4 or 0.8 milli-
grams (mg) for heroin or other opioid overdose. A dose 
of 2mgs repeated at two-minute intervals up to a total 
of 10mgs may be required for buprenorphine overdose 
due to buprenorphine binding tightly with opioid 
receptors. Higher doses of naloxone are needed to 
compete with this drug at the receptor site.
■ Methadone overdose—close observation required
Anyone with a depressed or altered level of 
consciousness must have frequent regular monitoring of 
vital signs. This is best achieved by using the Glasgow 
Coma Scale (see Appendix 1) in conjunction with 
monitoring of vital signs (respirations, temperature, blood 
pressure and pulse).
7.6 Vomiting
Presume that any person who is unresponsive has a full 
stomach. Suction should always be available. If it is not, 
place the person in a coma position and monitor closely. 
Electrocardiograph and X-rays can be done after basic 
observations and appropriate support have been ensured.
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7.7 Unconscious persons
Head injuries, overdoses and intoxication must all be 
taken into consideration when assessing the presenting 
state of any unconscious person. Thorough assessment, 
early recognition and intervention are vitally important.
Poisoning must be suspected in all persons presenting as 
unconscious or with a decreasing level of consciousness.
All persons with questionable levels of consciousness must 
have regular monitoring of vital signs. This is best done 
using the Glasgow Coma Scale (see Appendix 1), which 
incorporate vital signs including pupil size and reaction, 
respirations, temperature, blood pressure and pulse. In 
the unconscious person, rectal or axillary temperature 
should be taken. An indwelling catheter should be inserted 
to monitor urine output. Collect urine for drug screening.
7.8 Airway management, Breathing 
and Level of Consciousness
Airway, breathing and level of consciousness (LOC) should 
be assessed regularly, especially where intoxication has a 
sedative effect. The frequency of assessment should be 
increased when abnormalities are detected.
This should include; assessment of gag reflex (patient’s 
ability to swallow their secretions without inducing a 
cough), breathing rate, and especially respiratory effort 
(tidal volume) of each breath. 
The Level of Consciousness (LOC) should be initially and 
then regularly assessed. A formal Glasgow Coma Score 
(GCS) (Appendix 1) should be determined. A GCS of < 9 
increases the risk of airway compromise and requires 
intubation. At this LOC the gag reflex is usually absent 
and pharyngeal tone is so poor that the patient is unable 
to protect their airway from aspiration. 
A GCS of 9 to 13 (especially if fluctuating) requires 
positioning in the coma position and also insertion of an 
oropharyngeal airway, if tolerated. Patients with 
increasing somnolence are at high risk of aspiration. 
Whilst investigations such as ECG and Chest X-ray can be 
delayed, ECG and SaO2 monitoring should commence. 
Those affected by either alcohol or other sedating agents 
have a level of consciousness that may fluctuate. 
Therefore, they should be assessed for respiratory rate 
and effort when approaching the bed rather than after 
waking and stimulating the patient. Increasing somnolence 
may induce hypercarbia, which in turn worsens somnolence.
Similarly, patients that have increased their level of 
consciousness in response to doses of naloxone (Narcan) 
or flumazenil (a benzodiazepine reversing agent) should 
be observed regularly for a deteriorating LOC after the 
effect these short-acting agent(s) wears off.
Collapse
check response to touch and talk
Conscious Unconscious
Breathing Not breathing
Leave on side in stable
position, observe airway,
breathing, circulation
Turn person on back, give 5
full inflations within 10 seconds,
check for carotid pulse
Pulse present Pulse absent
Continue EAR Begin CPR (EAR & ECC)
Make comfortable,
observe airway,
breathing, circulation
Turn person on side, turn face slightly
downwards, clear airway, apply head tilt and
jaw support/jaw thrust, check for breathing
Check carotid pulse and
breathing after one minute and
then at least every two minutes
Check carotid pulse and
breathing after one minute and
then at least every two minutes
Figure 7.1 Basic life support flowchart
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Effective management of withdrawal in its early stages 
can reduce or prevent progression to complicated 
withdrawal. Complicated withdrawal may be life-
threatening due to accidental injury, dehydration, 
electrolyte imbalance, seizures, delirium tremens, or the 
negative impact on other concurrent disorders, including 
acute infection, renal disease or diabetes. 
In the management of withdrawal, it is critical to select 
the appropriate withdrawal scale as indicated by the 
person’s recent drug and alcohol use history. 
It is best to assume that any person who has consumed 
alcohol or other drugs on a daily basis over a significant 
period of time (weeks) can experience some withdrawal 
symptoms on ceasing or reducing their intake.
Severity of withdrawal symptoms can differ depending 
on the person, the drug(s) used, duration of use, past 
experience of withdrawal, other psychological and 
physical conditions (e.g. nutrition, hydration) and acute 
or chronic illness.
Extra support may be required to ensure safe withdrawal in a 
person with significant concurrent illness or acute trauma.
Drugs with short half-lives, such as alcohol or heroin, will 
give rise to withdrawal symptoms at an earlier phase 
after the last dose, and the symptoms will peak and fade 
faster than withdrawal syndromes associated with drugs 
with a long half-life such as diazepam or methadone.
This section gives general guidelines for managing 
withdrawal. Refer to Chapter 9 for specific details of 
withdrawal symptoms and management for the most 
commonly used substances.
For further information, refer to the New South Wales 
Drug and Alcohol Withdrawal Clinical Practice 
Guidelines (2006). Copies of these guidelines can be 
downloaded from the NSW Health website: 
http://www.health.nsw.gov.au
8.1 General principles of withdrawal 
management
■ The primary goal of withdrawal must be patient 
safety, rather than long-term abstinence
■ It is important to know if the person has a history of 
severe withdrawal, such as seizures or delirium 
tremens (DTs).
■ Care may include managing anxiety, completion of a 
comprehensive drug and alcohol history, and 
assessment of past episodes of severe withdrawal.
■ Not all patients will be at risk of withdrawal, however 
care planning should not be diminished 
■ The objectives of withdrawal management are to:
– interrupt a pattern of heavy and dependent use
– promote engagement in treatment.
8.2 Interrupting the pattern
Reduction in tolerance and interruption of a period of 
intensive drug and/or alcohol use are valid goals in 
withdrawal management. When entering treatment, 
many patients with substance use issues are seeking a 
complete change of lifestyle. However, motivation to 
sustain abstinence may fluctuate. 
For example, people who drink heavily for brief periods, 
with considerable health consequences, may seek to 
recover through an episode of withdrawal. However, they 
may have no intention of abstaining long-term, simply of 
recovering in the short-term from being unwell. 
8.3 Promoting engagement in treatment
Dependence is a long-term, relapsing condition, requiring 
more intensive and more prolonged treatment. For most 
substance use problems, regular review and monitoring 
are the most critical parts of effective treatment. 
CHAPTER 8
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8.4 Management guidelines
Management of withdrawal focuses on the following:
■ assessment of withdrawal risk
■ early recognition of withdrawal
■ assessment of psychoses and / or suicidal intent
■ anxiety management. This is a key issue to 
managing all withdrawal syndromes
■ monitoring, documenting and reporting withdrawal 
symptoms
■ preventing withdrawal complications where possible
■ preventing progression to severe withdrawal
■ decreasing risks of any injury to self or others
■ eliminating risk of dehydration, electrolyte or 
nutritional imbalance
■ minimising risk of seizures
■ identifying concurrent illness that masks, mimics or 
complicates withdrawal
■ providing supportive care
■ discharge planning for after-care and referral.
8.5 Early recognition of withdrawal
A withdrawal syndrome develops progressively after 
cessation or significant reduction in drug and / or alcohol 
use. Therefore, history taking and assessment, ongoing 
monitoring, early recognition and prompt management 
of the initial (and milder) withdrawal state can prevent 
progression to more severe stages and complications.
8.6 Prevent progression to severe 
withdrawal
■ Assess and monitor withdrawal.
■ Reassure the person and be supportive.
■ Explain to the person what is happening.
■ Monitor withdrawal symptoms and document 
observations based on a validated withdrawal scale, if 
available. 
■ Effectively manage mild states of withdrawal, for 
example, through relaxation, reassurance, and 
medication as prescribed.
■ Explain the effects of withdrawal medication (e.g. 
diazepam) to the person.
■ Administer medication as prescribed and assess 
effectiveness.
■ Monitor and evaluate effectiveness of interventions.
■ Document and report outcomes.
■ Provide self-help information for the withdrawal 
period.
■ Maintain hydration, nutrition, hygiene, physical safety.
8.7 Decrease risk of injury 
■ Decrease stimuli.
■ Allow the person to move freely if it is safe for them 
to do so and if they are able to do so. 
■ Maintain safety at all times.
■ Maintain privacy and dignity.
■ Ensure safety by removing dangerous objects (e.g. 
chairs, vases, heavy objects, razor blades, knives) and 
assess for suicidal ideation. Suicidal ideation should be 
managed as per hospital or health facility policy. 
■ Supervise adequately. The person may need to be 
restricted to a supervised area.
8.8 Eliminate risk of dehydration 
■ Maintain adequate hydration.
■ Maintain nutritional intake.
8.9 Reduce potential for seizure
■ Assess and monitor withdrawal status regularly.
■ Observe best practice guidelines for seizure 
prophylaxis.
■ Administer medication as ordered.
8.10 Identify presence of concurrent 
illness  
■ Exclude conditions that may mimic or mask 
withdrawal (e.g. hypoglycaemia).
■ Treat concurrent medical and psychological 
conditions, as required.
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8.11 Provide supportive care
■ Explain to the person what is happening and that you 
are there to look after them.
■ Reassure, encourage and support the person.
■ Approach the person in a calm and confident manner.
■ Reduce stimulation and the number of people 
attending the person.
■ Manage confusion and disorientation by frequent 
reality orientation.
■ Ensure frequent supervision. Consider ‘specialling’ if 
required.
■ Manage altered perception/hallucinations by 
explaining perceptual errors.
■ Manage anger/aggression by minimising risk of harm 
to self and others and by:
– using space to protect yourself
– remaining calm and reassuring
– not challenging the person
– acknowledging the person’s feelings
– removing the source of anger, if possible
– being flexible within reason.
■ Obtain advice or consultation from a Drug and 
Alcohol specialist.
8.12 Discharge planning
Discharge planning begins on admission and should 
actively involve the person, who should be made fully aware 
of their treatment and support options after discharge.
Develop strategies to help the person cope with the 
period after withdrawal and to encourage longer-term 
reduction in substance use. Document discharge planning 
in the person’s record. 
When planning discharge:
■ arrange follow-up appointments
■ refer to relevant services—rehabilitation, counselling, 
self help groups e.g. Alcoholics Anonymous, Narcotics 
Anonymous
■ consider stability of accommodation, i.e. whether the 
person lives alone or with others who use drugs and/
or alcohol
■ consider the extent of their social network, i.e. their 
existing links with health professionals in their local 
community
■ provide emergency assistance numbers.
A person has the right to refuse follow-up. If this occurs, 
note the refusal in the person’s record and avoid 
judgmental reactions.  
Managing withdrawal
PAGE 32  NSW HEALTH  Clinical guidelines for nursing and midwifery practice in NSW 
This chapter provides details of the effects and 
treatment of the most commonly used drugs. 
The health, social and economic costs include a wide range 
of adverse outcomes such as medical and psychological 
complications, social and family disruption, specific 
effects on children, violence and drug-related crime and 
problems associated with the black market economy and 
corruption. Providing a range of accessible and effective 
treatments can reduce demand for illicit drugs and 
minimise the adverse consequences.
The information provided includes; risk factors, overdose 
symptoms, withdrawal symptoms, management and 
precautions.
Read this chapter in conjunction with the more general 
guidelines in Chapters 1 to 8.
9.1 Alcohol
Alcohol misuse and dependence refer to patterns of 
alcohol use that cause clinically significant distress or 
health impairment (Degenhardt, Hall et al. 2000).
There is no single set of accepted definitions that can 
accurately describe the range of alcohol problems and the 
level of dependence (Mattick & Jarvis 1993). The general 
groups of use are excessive consumption and dependence.
■ Excessive consumption refers to alcohol 
consumption beyond the currently known “low risk” 
levels as defined by the National Health and Medical 
Research Council (NHMRC) Drinking Guidelines (2001). 
These drinkers do not necessarily suffer from complex 
problems or dependence.
■ Abuse and dependence are diagnostic categories as 
defined in the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) (American Psychiatric 
Association 1994).
It is important that nurses and midwives recognise 
withdrawal symptoms, and assess for the possibility of 
alcohol withdrawal symptoms (Clancy 1997). 
9.1.1 Assessment and quantification of use 
1. Record the frequency, usual quantity, duration, date, 
time and amount last used.
 Gauge use by overestimating the amount, e.g. 20–30 
schooners. With adolescents take care that they do 
not perceive the overestimated amount as an 
expected figure and exaggerate it even further.
2. Do not accept phrases such as “social drinker” or 
“occasional drinker”.
 Say something like “Social drinking means different 
things to different people. What does it mean to you?”
9.1.2 What is a standard drink? 
10 grams of alcohol = 1 standard drink
Table 9.1
Light beer 1 std drink= 1 schooner= 425ml 2.7% Alc./Vol
Ordinary beer 1 std drink= 1 middie= 285ml 4.9% Alc./Vol
Wine 1 std drink= 1 glass= 100ml 12% Alc./Vol
Spirits 1 std drink= 1 nip= 30ml 40% Alc./Vol
Port/ sherry 1 std drink= 1 glass= 60ml 20% Alc./Vol
9.1.3 Risk of harm in the short- and long- term
Tables 9.2 and 9.3 below show the risk of harm in each 
drinking session. Alcohol consumption at levels shown 
below is not recommended: for people who have a 
condition made worse by drinking; are on medication; 
are under 18 years of age; are pregnant; are about to 
engage in activities involving risk or a degree of skill (e.g. 
driving, flying, water sports, skiing, operating machinery). 
CHAPTER 9
The drugs
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9.1.4 Indications and guidelines
Risk factors 
■ Presenting with clinical signs suggesting substance 
use (e.g. decreased level of consciousness, unsteady 
gait, slurred speech).
■ High risk levels of alcohol consumption and/or other 
drugs (seven or more standard drinks a day for men, 
and five or more than six standard drinks a day for 
women).
■ Use of even low amounts of alcohol with other drugs 
— alcohol may increase the effects of other drugs 
such as benzodiazepines.
■ For elderly people, there may be a higher level of risk 
in comparison to rest of the population, for the same 
amount of alcohol consumed.
■ Any signs or symptoms of a withdrawal syndrome 
(e.g. sweating, restlessness, tremor, hypertension) that 
are not due to other causes.
■ Any degree of excessive anxiety not due to other 
factors.
■ Physical trauma possibly attributable to substance use, 
e.g. fractures, head injuries, other injuries resulting 
from pedestrian or motor vehicle accidents.
■ Repeated admissions for possible alcohol or 
substance-related conditions, e.g. liver disease, 
pancreatitis, oesophageal varices.
Intoxication effects 
Alcohol is a CNS depressant. It depresses respiration, 
coughing reflex, gag reflex and cardiovascular function, 
thus inducing various arrhythmias.
Effects of intoxication are:
■ loss of inhibition
■ relaxation, euphoria
■ depression
■ alered mood, behaviour and cognition
■ analgesic and anaesthetic effects
■ ataxia
■ slurred or incoherent speech
■ confusion
■ disorientation
■ inappropriate behaviour/emotional responses
■ altered consciousness.
Alcohol intoxication is a potentially lethal condition. Just 
as with other drugs, people can overdose on alcohol.
Signs of overdose 
Clinical signs of alcohol overdose are:
■ stupor or coma
■ cold and clammy skin
■ lowered body temperature
■ lowered blood pressure
Table 9.2: Risk of harm in the short term
Gender Low Risk (Standard Drinks) Risky (Standard Drinks) High Risk (Standard Drinks)
Males:  On any one day Up to 6 on any one day, no more 
than 3 days per week
7–10 on any one day 11 or more on any one day
Females: On any one day Up to 4 on any one day, no more 
than 3 days per week.
5–6 on any one day 7 or more on any one day
Table 9.3: Risk of harm in the long term
Gender Low Risk (Standard Drinks) Risky (Standard Drinks) High Risk (Standard Drinks)
Males:  Daily
 Overall weekly level
Up to 4 per day 
Up to 28 per week
5–6 on any one day
29–42 per week
7 or more on any one day
43 or more per week
Females:  Daily
 Overall weekly level
Up to 2 per day
Up to 14 per week
3–4 on any one day
15–28 per week
5 or more on any one day
29 or more per week
Australian Alcohol Guidelines: Health Risks and Benefits, The National Health and Medical Research Council (NH&MRC) 2001.
Alcohol
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■ slow and noisy respiration
■ accelerated heart rate or bradycardia
■ strong smell of alcohol
■ positive breath alcohol reading.
Complications of misuse
Wernicke-Korsakoff syndrome
This is a form of brain injury resulting from thiamine 
deficiency, which complicates alcohol dependence. If the 
condition is not treated early it can lead to permanent 
brain damage and memory loss. It can occur in young 
alcohol-dependent people.
Signs and symptoms of Wernicke’s encephalopathy, 
which is usually the first stage of the syndrome, are:
■ ophthalmoplegia (reduced eye movements or 
nystagmus)
■ ataxia
■ confusion.
This condition is reversible if recognised and treated with 
parenteral vitamin B1. If it is not treated it can lead to 
irreversible brain damage. Parenteral thiamine should 
be administered before any form of glucose. 
Glucose in the presence of thiamine deficiency risks 
precipitating Wernicke’s encephalopathy.
In patients with established Wernicke-Korsakoff’s 
syndrome or other alcohol-related brain injury, nursing 
management can be difficult. These patients often have 
impairment of memory, concentration and judgment, 
confabulation and labile mood. These problems may 
coexist with both intoxication and withdrawal.
Assessing withdrawal 
Severe alcohol withdrawal is potentially life threatening. 
The most important thing is to anticipate when it may 
occur and to suspect it when an unexplained acute 
organic brain syndrome is detected. 
Onset and duration of alcohol withdrawal
Onset of alcohol withdrawal is usually 6–24 hours after 
the last drink. Consumption of benzodiazepines or other 
sedatives may delay the onset of withdrawal. In some 
severely dependent drinkers, simply reducing the level of 
consumption may precipitate withdrawal, even if they 
have consumed alcohol recently. Usually, withdrawal is 
brief, and resolves after 2–3 days without treatment; 
occasionally, withdrawal may continue for up to 10 days. 
Withdrawal can occur when the blood alcohol level is 
decreasing, even if the patient is still intoxicated.
Figure 9.1: Progress of alcohol withdrawal 
syndrome
 
The severity of alcohol withdrawal ranges from mild to 
severe. The following questions, known as the Index for 
Suspicion of Alcohol Withdrawal, will help you determine 
whether the patient is likely to move into alcohol withdrawal.
■ Has the patient had a regular intake of 80 grams 
(8 drinks for males) or 60 grams (6 drinks for females) 
of alcohol or more per day?
■ Has the patient taken even smaller amounts of 
alcohol in conjunction with other CNS depressants?
■ Has the patient had previous episodes of alcohol 
withdrawal?
■ Is the patient's current admission for an alcohol-
related reason? 
■ Does the patient’s physical appearance indicate 
chronic alcohol use (e.g. parotid swelling, Cushingoid 
face, facial telangiectasia, eyes reddened or signs of 
liver disease—ascites, jaundice, limb muscle wasting)?
■ Do the patient’s pathology results show raised serum 
GGT and/or raised mean cell volume (MCV)?
■ Does the patient display symptoms such as anxiety, 
agitation, tremor, sweatiness or early morning 
vomiting
extreme agitation
disorientation
confusion
paranoia
hyperventilation
delirium tremens
Mortality: up to 40%
from infections, fever, 
fluid loss if untreated;
less than 1% with 
adequate treatment
Adapted from Frank L., Pead J. New Concepts in Drug Withdrawal: A resource
handbook. © 1995 State of Victoria. Reproduced with permission.
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retching, which might be due to an alcohol 
withdrawal syndrome?
Signs and symptoms of withdrawal 
Alcohol withdrawal is a syndrome of central nervous 
system hyperactivity characterised by symptoms that range 
from mild to severe. The symptoms and signs of alcohol 
withdrawal may be grouped into three major classes:
Table 9.4: Main signs and symptoms of alcohol 
withdrawal
Autonomic 
overactivity
Gastrointestinal Cognitive and 
perceptual changes
Sweating Anorexia Anxiety
Tachycardia Nausea Vivid dreams
Hypertension Vomiting Illusions
Insomnia Dyspepsia Hallucinations
Tremor Delirium
Fever
  
Seizures occur in about 5% of patients withdrawing from 
alcohol. They occur early (usually 7–24 hours after the last 
drink), are grand mal in type (i.e., generalised, not focal) 
and usually (though not always) occur as a single episode. 
Delirium tremens (“the DTs”) is rare and is a diagnosis by 
exclusion. It is the most severe form of alcohol withdrawal 
syndrome, and a medical emergency. It usually develops 
2–5 days after stopping or significantly reducing alcohol 
consumption. The usual course is 3 days, but can be up 
to 14 days. Its clinical features are:
■ confusion and disorientation
■ extreme agitation or restlessness—the patient often 
requires restraining
■ gross tremor
■ autonomic instability (e.g. fluctuations in blood 
pressure or pulse), disturbance of fluid balance and 
electrolytes, hyperthermia
■ paranoid ideation, typically of delusional intensity
■ distractibility and accentuated response to external 
stimuli
■ hallucinations affecting any of the senses, but typically 
visual (highly coloured, animal form).
Alcohol withdrawal scales 
The most systematic and useful way to measure the severity 
of withdrawal is to use a withdrawal scale. These provide 
a baseline against which changes in withdrawal severity 
may be measured over time. Research shows that the use 
of scales minimises both underdosing and overdosing 
with benzodiazepines for alcohol withdrawal syndromes. 
There has been considerable debate about the 
application of withdrawal scales. Two different scales, the 
Alcohol Withdrawal Scale (AWS) and the Clinical Institute 
Withdrawal Assessment for Alcohol (revised) (CIWA-Ar) 
are provided in this document (see Appendices 2 and 3) 
and both are recommended for use.
Note that withdrawal scales do not diagnose 
withdrawal, but are merely guides to the severity of 
an already diagnosed withdrawal syndrome. The 
nurse or midwife should re-evaluate the patient to 
ensure that it is alcohol withdrawal and not another 
condition that is being measured, particularly if the 
patient does not respond well to treatment.
Clinical Institute Withdrawal Assessment for Alcohol 
Revised Version (CIWA-Ar)
The CIWA-Ar (see Appendix 2) is a 10-item scale that can 
be administered as part of supportive care. Several 
studies have shown that the CIWA-Ar scale is a valid, 
reliable and sensitive instrument for assessing the clinical 
course of simple alcohol withdrawal.
This scale allows a quantitative rating (from 0 to 7 with a 
maximum possible score of 67) of the following components 
of withdrawal:
■ nausea and vomiting
■ tremor
■ paroxysmal sweats
■ anxiety
■ agitation
■ tactile disturbances
■ auditory disturbances 
■ visual disturbances
■ headache and fullness in head
■ orientation and clouding of sensoria.
Using the CIWA-Ar in presentation to the emergency 
department:
■ Monitor the patient hourly for at least 4 hours using 
the CIWA-Ar.
■ Contact the medical officer or drug and alcohol nurse 
practitioner for assessment and monitor hourly if:
Alcohol
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– the alcohol score increases by at least 5 points over 
this 4-hour period, or
– the CIWA-Ar total score reaches 10.
Using the CIWA-Ar for hospitalised patients:
■ Monitor the patient 4-hourly, using the CIWA-AR, for 
at least 3 days.
■ If the total score reaches 10, monitor hourly and 
notify the medical officer or drug and alcohol nurse 
practitioner.
Depending on the resources of the local area, these may 
need review.
Alcohol Withdrawal Scale (AWS)
The AWS (see Appendix 3) is a widely used scale in NSW.
If a patient’s history or presentation suggests possible 
withdrawal, the patient’s condition must be monitored 
and documented.
Using the AWS in presentation to the emergency 
department:
■ Monitor the patient hourly for at least 4 hours using 
the AWS.
■ Contact the medical officer or drug and alcohol nurse 
practitioner for assessment and monitor hourly if:
– the alcohol score increases by at least 5 points over 
this 4-hour period, or
– the AWS total score reaches 5.
Using the AWS for hospitalised patients:
■ Monitor the patient 4-hourly, using the AWS, for at 
least 3 days.
■ If the total score reaches 5, monitor hourly and notify 
the medical officer or drug and alcohol nurse 
practitioner.
Depending on the resources of the local area, these may 
need review. 
Pharmacological treatment 
The medical officer or drug and alcohol nurse practitioner 
may prescribe pharmacological treatment to combat acute 
withdrawal symptoms, without over-sedating the patient. 
The most commonly prescribed pharmacological treatment 
for alcohol withdrawal is diazepam because of its cross-
tolerance with alcohol and anti-convulsant properties. 
Contraindications to diazepam include respiratory failure, 
significant liver impairment, possible head injury or 
cerebrovascular accident. In these situations, specialist 
consultation is essential. 
For further information, refer to the New South Wales 
Drug and Alcohol Withdrawal Clinical Practice 
Guidelines (2006). 
Maternal and neonatal care 
Alcohol use during pregnancy
■ Possible pregnancy complications include miscarriage, 
stillbirth and premature birth.
■ Foetal effects are dose-related, from a small decrease 
in cognitive functioning to brain damage, facial 
deformities, and growth deficits. The term Foetal Alcohol 
Spectrum Disorder (FASD) is used in the National 
clinical guidelines for the management of drug use 
during pregnancy, birth and the early development 
years of the newborn (March 2006) to indicate the full 
range of possible effects of foetal exposure to alcohol. 
Foetal Alcohol Syndrome (FAS) is used to indicate the 
severe effects, characterised by intellectual disability, 
poor coordination and motor skills, and slow physical 
growth before and after the birth.
Alcohol use and breastfeeding
■ Women who are breastfeeding are advised not to 
exceed the levels of drinking recommended during 
pregnancy, and may consider not drinking at all.
■ If a breastfeeding mother wants to drink alcohol, it is 
suggested that she breastfeed before drinking alcohol, 
then wait a minimum of three to four hours after the 
last drink before breastfeeding again. In the event 
that the woman exceeds the recommended levels of 
drinking, it is suggested that she wait approximately 
three hours per standard drink consumed before 
breastfeeding again. She may consider expressing and 
storing breastmilk prior to drinking. 
For further information, refer to the National clinical 
guidelines for the management of drug use during 
pregnancy, birth and the early development years of the 
newborn. (March 2006) http://www.health.nsw.gov.au/
pubs/2006/ncg_druguse.html
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9.2 Opioids
Opioids are a class of substances with morphine-like effects 
that can be reversed by the specific antagonist naloxone. 
Some opioids are semisynthetic chemical derivatives of 
morphine (such as heroin) and others are fully synthetic 
(such as pethidine and methadone). They share a 
common core structure that allows them to interact with 
endogenous opioid receptors (Young et al. 2002, p. 79).
Opioids have a depressant effect on the central nervous 
system. They decrease the spontaneous activity of neurones, 
producing drowsiness, mood changes and mental clouding. 
However, they also have features quite distinct from the 
sedative-hypnotics. They are powerful analgesics and can 
cause suppression of reflex cough and constipation.
Prolonged opioid use results in tolerance and lowering of 
pain threshold, therefore apparently mild pain may be 
perceived as more severe. This may be inadvertently 
interpreted as drug-seeking behaviour rather than 
inadequately relieved pain.
Unlike alcohol withdrawal, the syndrome associated with 
the cessation of opioid use is not likely to be life-
threatening except in the case of pregnant women when 
opioid withdrawal is potentially life-threatening for the 
foetus. However, the symptoms can cause the person 
undergoing withdrawal considerable discomfort and may 
lead to resumption of use to avoid or abate the 
symptoms. Early discharge and thus poor intervention 
outcomes are likely results.
9.2.1 Assessment and quantification
1. Record the type of opioid, date, time and amount of 
the last dose as accurately as possible.  Note that 
quantification of illicit substances is difficult because 
they are usually “cut” (mixed) with other substances, 
for example other drugs, sucrose or glucose, so the 
actual dose is always unknown.
 It is important to ask the person if they are using 
more than one drug at a time, as polydrug use can 
significantly increase the risk involved
2. Record how often the patient uses the substance (e.g. 
number of times smoked, injected per day/week) and 
either the dollar cost of the drug or its weight in 
street grams. 
3. Record how long the patient has been using the drug 
and the route of administration.
9.2.2 Indications and guidelines
Overdose 
Prevention
Advice about preventing overdose is important harm 
minimisation information. Patients should be given the 
following advice:
■ never use alone
■ don’t use opioids together with alcohol or other 
drugs, especially CNS depressants such as 
benzodiazepines and/or alcohol
■ buy heroin from a regular, trusted dealer in order to 
be more certain of its strength—try a small amount 
first
■ if using after a break from heroin/opioid use, 
tolerance will be low—use less than you used to in 
order to test tolerance and reduce the risk of 
overdose.
Accidental overdose is not uncommon and may be due to: 
■ varying dose and increased purity of illicit supplies
■ reduction in tolerance after period of abstinence (e.g. 
release from prison, discharge from rehabilitation or 
hospital)
■ mixing drugs (particularly injecting benzodiazepine, 
cocaine) and/or alcohol
■ leakage from poorly wrapped drugs that have been 
ingested (body stuffers and packers)
■ being a novice opioid-injecting drug-user (i.e. with 
low tolerance).
Clinical signs
■ slow respiration
■ subnormal temperature
■ miosis
■ cyanosis
■ weak pulse
■ difficult to rouse, decreased level of consciousness
■ bradycardia
■ muscle twitching
■ possible pulmonary oedema.
Opioids
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Pharmacological/medical management of overdose
Maintenance of airway and breathing are most important 
in overdose management. Follow cardiopulmonary 
resuscitation (CPR) protocol.
■ Naloxone, an opioid antagonist, is used as a reversal 
agent and will reverse the effect of opioid overdoses. 
Patients who were previously sedated may become 
agitated, aggressive and difficult to manage due to 
sudden precipitated withdrawal syndrome.
■ Naloxone is short-acting. In the case of methadone 
overdoses and long acting prescribed opioids (MS 
Contin, oxycontin), the naloxone may wear off and 
the person can become sedated again.
■ Naloxone should always be given in the case of 
respiratory depression (Clancy 1997). 
Overdose in a pregnant woman
In the case of a pregnant woman overdosing, a 
medical emergency should be called. The use of 
naloxone may precipitate opioid withdrawal, which may 
lead to spontaneous abortion, miscarriage or early onset 
of labour in opioid-dependent pregnant women and 
should be avoided. A decision on artificial ventilation may 
need to be made.
Methadone or buprenorphine overdose
The effects of methadone or buprenorphine overdose can 
persist for up to 72 hours, even in circumstances where 
patients have been resuscitated. Depending on the 
magnitude of the overdose, they should be observed for 
a period of up to 72 hours. For high dose intoxication, 
naloxone infusion should be considered (Department of 
Health, Welsh Office et al. 1999). Because of the longer 
half-life of methadone compared with heroin or morphine 
(methadone = 24–48 hours), people who overdose from 
methadone and who are subsequently treated with 
naloxone may seem to recover initially but can relapse 
into respiratory depression and coma if not adequately 
monitored and treated.
Withdrawal
Knowledge of the half-life of each opioid drug (e.g. 
heroin vs. methadone) and the likely time of onset of 
withdrawal symptoms following the last dose assists in 
predicting, identifying, and effectively managing 
withdrawal symptoms.
Onset and duration of withdrawal
Heroin is a relatively short-acting drug. Symptoms of 
withdrawal usually commence 6–24 hours after the last dose, 
reach a peak at 24–48 hours, and resolve after 5–10 days. 
Withdrawal from a long-acting opioid such as 
methadone usually commences 36–48 hours after the 
last dose. The peak severity of withdrawal tends to be 
lower than for heroin withdrawal, but withdrawal may be 
more prolonged, lasting 3–6 weeks. 
The symptoms and signs of withdrawal from 
buprenorphine are similar to those found in withdrawal 
from other opioids, but withdrawal from buprenorphine 
is generally milder than withdrawal from methadone or 
heroin because of its slow dissociation from the opioid 
receptors. Symptoms commence generally within 3–5 
days of the last dose and can last for several weeks
Following acute withdrawal, protracted, low-grade 
symptoms of discomfort (psychological and physical) may 
last many months. 
The following table shows times of appearance of 
withdrawal syndrome in dependent opioid users.
Table 9.5: Withdrawal syndrome
Opioid Time after last 
dose symptoms 
appear
Duration 
withdrawal 
syndrome (days)
Heroin / morphine 6–24 hours 5–10 days
Pethidine 3–4 hours 4–5 days
Methadone 36–48 hours 3–6 weeks
Buprenorphine 3–5 days up to several weeks
Kapanol / MS Contin 
(if intravenous)
8–24 hours 7–10 days
Codeine orally 8–24 hours 5–10 days
(Adapted from NSW Dept of Health, (2000) and (2006)).
The opioid withdrawal syndrome can be very 
uncomfortable and distressing, but not life-threatening 
unless there is a severe underlying disease. Patients may 
have a low tolerance to pain due to the effect of long-
term opioid use and this needs to be acknowledged and 
treated effectively.
The following graph shows the progress of the acute 
phase of opioid withdrawal after last dose. 
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Figure 9.2 Progress of the acute phase of opioid 
withdrawal
Adapted from NSW Health Withdrawal Clinical Practice Guidelines 
(2007).
Table 9.6 Symptoms and signs of opioid withdrawal
Symptoms Signs
Anorexia and nausea Restlessness
Abdominal pain Yawning
Hot and cold flushes Perspiration
Bone, joint and muscle pain Rhinorrhoea
Insomnia and disturbed sleep Dilated pupils
Cramps Piloerection
Intense craving for opioids Muscle twitching (particularly 
restless legs while lying down)
Vomiting
Diarrhoea
Pharmacological treatment for opioid withdrawal
The medical officer or drug and alcohol nurse practitioner 
may prescribe the preferred pharmacological option for 
opioid withdrawal: 
■ buprenorphine 
■ symptomatic medications.
Buprenorphine
Buprenorphine is the drug of choice for a significant 
number of patients undergoing opioid withdrawal 
symptoms. Its trade name is ‘Subutex’ and it comes in 
8mg, 2mg and 0.4mg tablets. 
A combination preparation of buprenorphine-naloxone 
(Suboxone) is now available and will be used in treatment 
of some patients. Its main pharmacological action is that 
of buprenorphine when given sublingually, but if injected, 
the naloxone will precipitate withdrawal in opioid-
dependent persons. (See ‘Naloxone’ in Pharmacological/ 
Medical Management of overdose, in previous section).
As a partial agonist, buprenorphine can offer advantages 
over methadone tapering because withdrawal distress 
may be less intense, and there are often fewer side 
effects than experienced with alternative medication such 
as clonidine. There can be problems with precipitated 
withdrawal with initial doses due to its pharmacological 
properties (Young et al. 2002, p. 89).
Buprenorphine is an opioid used either as a pain reliever 
or as a substitute for drugs such as morphine, heroin or 
methadone, or to medicate someone undergoing opioid 
withdrawal. As a partial agonist (sometimes called ‘mixed 
agonist/antagonist’) it does not produce the same level of 
CNS depression as heroin or methadone. This means that 
overdose may be less life threatening.
Buprenorphine binds very tightly to opioid receptors and 
can displace other opioids. Consequently commencing 
someone who is opioid-dependent on buprenorphine 
may precipitate withdrawal.
First doses should be delayed for at least six hours after 
heroin and 24 hours after methadone, with buprenorphine 
not being administered until withdrawal is evident. Dose 
titration may be required in the event of worsening 
withdrawal symptoms (Young et al. 2002, p. 89).
Buprenorphine blood levels peak at about 90 minutes after 
sublingual absorption, with the onset of clinical effects at 
30–60 minutes and peak clinical effects at one to four hours. 
Duration of effect is eight to 12 hours at low dose (e.g. 
less than 4mg) but at higher doses (greater than 8mg per 
day) effects may last 24–72 hours because of the strong 
receptor binding. The therapeutic effect lasts from one to 
two days. It is eliminated mainly by hepatic metabolism.
The role of buprenorphine in treating opioid withdrawal 
is to reduce symptoms and craving, but not necessarily 
remove all symptoms or intoxicate the person. It is 
important that patients understand that high doses can 
result in increased rebound withdrawal, prolonged 
duration of symptoms and increased side effects. 
Ongoing cravings are not necessarily an indication of 
inadequate doses, and may relate to other cues to 
resume drug use, such as the other people they are with 
or sighting needles and syringes. However, too low a 
dose can result in unnecessary withdrawal symptoms and 
the person ceasing treatment early.
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For most patients, withdrawal from buprenorphine is not 
as uncomfortable as it is from heroin or methadone. 
Most withdrawal symptoms will begin one to three days 
after the last dose.
Use of buprenorphine
It is supplied as sublingual tablets that dissolve under the 
tongue in about five minutes, with the drug being 
absorbed through the mucosa into the bloodstream. 
Crumbling the tablets does not have an impact on 
absorption, but lessens the likelihood of the person giving 
the drug to others or selling it on the black market. If it is 
swallowed, most of the drug will be metabolised by the 
liver before reaching the general circulation.
Contraindications
Buprenorphine should not be taken by people who:
■ are allergic to buprenorphine
■ are breastfeeding (it may reduce milk production, it is 
present in breast milk and so may affect the baby)
■ have severe liver or kidney problems
■ have serious breathing problems
■ are children under 16 years
■ are intoxicated with alcohol or in alcohol withdrawal.
Precautions
■ heavy alcohol drinkers
■ taking any other drugs—benzodiazepines, 
antidepressants (especially monoamine oxidase 
inhibitors), any other central nervous system 
depressants.
■ unlike methadone, the safety of buprenorphine in 
pregnancy has not been demonstrated. Nonetheless, 
treatment guidelines should not restrict obstetric and 
D&A specialists from using buprenorphine as a 
treatment for heroin-dependent pregnant women 
who refuse methadone treatment and can provide 
informed consent. (Commonwealth of Australia, 2006).
■ women wanting to become pregnant are advised to 
consider methadone maintenance, or alternative 
forms of treatment for the management of their 
heroin dependence. Neonates of women exposed to 
buprenorphine should be monitored for neonatal 
abstinence syndrome or any other adverse events. 
Long-term follow-up is required to monitor for 
developmental abnormalities.
Side effects
■ drowsiness, especially if taken with alcohol
■ constipation
■ headaches
■ insomnia
■ nausea and vomiting
■ fainting and dizziness (orthostatic hypotension)
■ sweating
■ respiratory depression
■ hallucinations.
There is a small possibility that it may cause hepatic necrosis 
and hepatitis with jaundice. Liver function tests should be 
performed at regular intervals for those patients receiving 
long-term buprenorphine, i.e. for more than two months.
Buprenorphine treatment for opioid withdrawal 
Hospital setting
Buprenorphine is well suited in the hospital setting as it 
alleviates symptoms of withdrawal without significantly 
prolonging the duration of symptoms. There should be 
some ability to tailor doses to degree of withdrawal as 
assessed by the Clinical Opiate Withdrawal Scale (COWS) 
(see Appendix 4). 
Buprenorphine should not be commenced until objective 
withdrawal is present (COWS score greater than eight) to 
reduce likelihood of precipitating withdrawal.
The following table shows an example of a 
buprenorphine dosing schedule.
Table 9.7 Example of buprenorphine dosage
Day Buprenorphine sublingual tablet 
regime
Total daily 
dose
1
4mg at onset of withdrawal and additional 
2–4mg as necessary (four-hourly)
4–8mg
2
4mg in the morning, additional 2–4mg 
evening dose, as necessary
4-8mg
3
4mg in the morning, additional 2mg 
evening dose, as necessary
4–6mg
4
2mg in the morning, if necessary, 2mg 
evening  dose, as necessary
0–4mg
5 2mg prn 0–2mg
6 no dose
7 no dose
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Buprenorphine should not be administered if there are 
features of intoxication or sedation; otherwise it should 
be given on client request as per the above protocol 
(there is no need for objective withdrawal for subsequent 
doses, only for the first). Observations should include 
COWS scores at every observation occasion, and just 
prior to discharge (see Appendix 4). Other symptomatic 
medications may be administered in the usual way. 
Clonidine will not be necessary.
Refer to NSW Health Policy Directive PD 2006_ 049. 
Opioid-dependent Persons Admitted to Hospitals in NSW 
– Management.
Community setting
Buprenorphine has been used successfully in community 
settings and its long duration of action and relative safety 
makes it well-suited to this application. The objective is to 
cover the period of most intense withdrawal symptoms 
and discontinue buprenorphine quickly to minimise rebound 
withdrawal phenomena and limit duration of symptoms. 
As with admission and management, flexibility with 
individual tailoring of dose is ideal.
Buprenorphine overdose 
General supportive measures should be used, including 
monitoring respiration and cardiac status. The main danger 
is respiratory depression, which could lead to arrest. Naloxone 
can be used but much higher doses will be needed than 
would be the case with heroin or methadone overdose. 
The long duration of action should be considered when 
determining length of treatment. Most fatal overdose cases 
have involved multiple drug use, especially benzodiazepines.
Seek specialist Drug and Alcohol advice or consult a Drug 
and Alcohol nurse practitioner. (See Drug and Alcohol 
Specialist Advisory Service (DASAS) in Contacts and 
Resources Section).
See Appendix 7 for Drug interactions with methadone.
Symptomatic medications
Neither buprenorphine nor clonidine block all withdrawal 
symptoms (although buprenorphine is more effective) and 
are both used with appropriate additional symptomatic 
medications.
Medication of symptoms and supportive care are often 
sufficient in treating mild withdrawal. Adjunctive therapies 
(such as hot baths) are also helpful.
Opioid maintenance treatment in the acute 
hospital setting 
Effective nursing care includes appropriate management 
of a person receiving opioid maintenance treatment 
during their hospital stay. Because they are taking 
methadone or buprenorphine, the continued provision of 
their opioid maintenance treatment is important as it will 
help maintain their comfort and safety, assist in planning 
pain management, and prevent the harms associated 
with poorly managed opioid withdrawal, thus reducing 
the risk of relapse and/or unplanned early discharge.
Table 9.8 Symptomatic treatment
Symptoms Suggested treatments
Muscle aches/pains Paracetamol 1000 mg, every 4 hours as required (maximum 4000 mg in 24 hours) or Ibuprofen 
400 mg 6 hourly as required (if no history of peptic ulcer or gastritis).
Nausea Metoclopramide 10 mg, 4–6 hourly as required, reducing to 8th hourly as symptoms reduce or 
Prochlorperazine 5 mg, every 4–6 hours as required reducing to 8th hourly as symptoms reduce. 
Second line treatment for severe nausea/vomiting: Ondansetron 4–8 mg, every 12 hours as required.
Abdominal cramps Hyoscine 20 mg, every 6 hours as required. Second line treatment for continued severe 
gastrointestinal symptoms: Octreotide 0.05–0.1 mg, every 8–12 hours as required by subcutaneous 
injection. (For use in a hospital setting only).
Diarrhoea Kaomagma® or loperamide 2mg as required.
Sleeplessness Temazepam 10–20 mg at night. Cease the dose after 3–5 nights.
Agitation/Anxiety Diazepam 5 mg four times daily as needed.
Restless legs Diazepam (as above) or Baclofen 10–25 mg every 8 hours.
Sweating, sedating agitation Clonidine 75 mcg every 6 hours.  
Note: Caution is recommended in exceeding stated duration of benzodiazepine use to avoid substituting for heroin dependence. Duration of 
treatment may need to be longer than stated above for withdrawal from long-acting opioid (e.g. methadone, Kapanol etc). 
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General principles
■ Consult with the drug and alcohol specialist or drug 
and alcohol nurse practitioner about the care of all 
patients admitted to hospital who are receiving opioid 
maintenance treatment.
■ Ensure that their methadone or buprenorphine dose 
is known and confirmed with prescriber and dosing 
point, and that the dose is quoted in both mg and 
mls for methadone.
■ Find out from the prescriber &/or the dispensing 
pharmacy the timing of the last dose of medication 
and any takeaway doses.
■ Ensure that adequate pain relief is provided and that 
it is individually tailored to the person’s clinical 
presentation and expressed need.
Refer to NSW Health Policy Directive PD 2006_ 049. 
Opioid-dependent Persons Admitted to Hospitals in NSW 
– Management.
Procedure
1. Take a drug and alcohol use history on admission.
2. Assess for signs of alcohol and other drug 
intoxication, overdose or withdrawal and take 
appropriate action. 
3. If the person is receiving opioid maintenance 
treatment, confirm:
– the name of their program/clinic/prescribing doctor
– what medication regime they are on, e.g. 
methadone or buprenorphine 
– where they receive their medication, e.g. at the 
drug clinic or community pharmacy
– dose (ensure doses are recorded in mgs and mls)
– date and time of last dose (ensure methadone 
doses are recorded in mgs and mls)
– dosage and number of takeaway doses usually 
provided, e.g. three a week (ensure doses are 
recorded in mgs and mls for methadone)
– whether the person has brought any takeaway 
doses to hospital.
4. Phone the prescriber to confirm enrolment in an 
opioid treatment service.
5. Contact the program or the dispenser to confirm the 
details given above, including takeaway doses, and 
inform them of the person’s admission to hospital. 
 If the person cannot supply telephone numbers, call 
an alcohol and drug information service for details of 
opioid treatment services, accredited doctors licensed 
to prescribe, or contact Pharmaceutical Services 
Branch during office hours on (02) 9879 5246.
6. If the person has previously been issued with 
takeaway doses for the days they subsequently spend 
in hospital, the doses should be handed in to ward 
staff. Their methadone or buprenorphine should be 
dispensed through the hospital pharmacy. This allows 
closer monitoring of the person’s clinical condition 
and certainty about the dose they are receiving.
 If methadone or buprenorphine is not available from 
the hospital pharmacy, the prescribed takeaway dose 
may be administered to the patient, provided that the 
takeaway dose is verified, there is no evidence of 
tampering with the container, and this does not 
contravene local area policies. Takeaway doses must 
be stored and dispensed by the hospital or removed 
from the hospital. Takeaway doses should not be 
given back to the person on discharge except by 
arrangement with the person’s authorised prescriber.
7. Notify the opioid treatment service (GP and/or 
chemist) of the person’s impending discharge from 
hospital so that continuity of care, in particular the 
opioid treatment regime, can be maintained. 
8. Inform the person in a timely manner about what 
they can expect and what has been planned.
9. Arrange for prescription of an opioid treatment by the 
appropriate medical officer or drug and alcohol nurse 
practitioner and dispensing by the hospital pharmacy.
 Ensure that methadone syrup (not physeptone tablets) 
is used for patients on methadone maintenance.
 Where oral methadone is contraindicated (e.g. nil-by-
mouth), physeptone or an alternative opioid should 
be administered parenterally (at a decreased dose). 
Buprenorphine can still be given sublingually when on 
a nil-by-mouth order. If other medical contraindications 
occur, such as head injury, contact the senior medical 
officer and follow the appropriate local policy guidelines.
10. Monitor the potential for drug interactions with 
methadone. 
 If the person is on a maintenance opioid treatment 
program and requires pain relief:
11. Follow the above steps.
12. In addition to authorised methadone dose, provide 
the person with such opioid analgesics as are 
necessary to control pain. 
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Such patients often have altered tolerance to opioids and 
may require higher doses of analgesia than normal. Usual 
doses should be tried first and if ineffective expert advice 
sought. (See D&A Specialist Advisory Service (DASAS) in 
Resources Section.)
Altered tolerance and effective pain management
Pain management can be problematic, particularly for 
patients who have altered tolerance. Lack of knowledge 
about altered tolerance and concern about contributing 
to patients’ opioid dependence has sometimes resulted in 
patients receiving inadequate analgesics.
Tolerance is the neurological process that occurs with 
prolonged daily use of psychoactive drug/s, and where the 
person needs increasingly higher dosages of the drug to 
produce the same effect or intoxicating feeling as first 
experienced with lower doses. The first indication of tolerance 
is decreased duration, then decreased analgesic effect of 
the drug — this is an involuntary physiological response.
The patients most likely to have altered tolerance are:
■ those who have been on regular prescribed opioid 
medication for long periods—they may be said to 
have iatrogenic dependence 
■ those currently receiving opioid maintenance treatment 
program or who are currently dependent on opioids
■ those who regularly take liver enzyme-inducing drugs 
(e.g. alcohol, dilantin, interferon and rifampicin etc.).
Acute pain management
While it is not a nursing responsibility to prescribe 
analgesics, it is crucial that nursing staff assess for and 
attend to pain relief effectively, recognising the significant 
impact of altered tolerance on clinical management of 
pain, and explaining to the person the consequence of 
any necessary changes in their pain medication. Clear 
communication regarding changes in their medication 
will help to lessen any anxiety and provide reassurance.
It is critical that analgesia is not withheld from the 
person unless medically indicated. Providing pain relief 
will not make the person more drug dependent.
Patients on methadone
If the person is taking part in a methadone program 
their usual daily dose must be continued—this will 
not provide pain relief. They will need another 
analgesic prescribed as well as their methadone. 
Opioid-dependent people (e.g. heroin users, those 
receiving opioid treatment, and those with chronic pain) 
and people currently using heroin will have increased 
tolerance to opioid analgesics. They should be given 
appropriate analgesics for their medical condition, and 
alleviation of any drug withdrawal. Because of their 
neurological tolerance, they may require higher doses of 
opioids or other analgesics than people who are not 
opioid-dependent, particularly if they are receiving daily 
methadone as opioid treatment for opioid dependence. 
Effective pain management starts with the dose usually 
required for an opioid naive individual, and then titrating 
doses upwards until adequate pain relief is achieved. If 
usual doses are ineffective advice should be sought from 
a medical officer or drug and alcohol nurse practitioner 
experienced in treating patients in these circumstances.
Analgesics should not be withheld unless the person is 
becoming over-sedated. To ensure that adequate analgesics 
are given, it is essential to consider the following issues:
■ Ensure an adequate history is taken to determine 
whether the person is likely to have altered tolerance.
■ Allay fears regarding pain relief while in hospital.
■ Discuss the proposed management plan with the person.
■ Intravenous or intramuscular administration may be 
appropriate initially. As pain control needs lessen, 
change to oral medication of equivalent strength.
■ Patient-controlled analgesic systems may assist in 
achieving rapid relief of pain.
■ Should analgesic needs be prolonged (weeks), it is 
appropriate to change from short-acting to long-acting 
medication to achieve more constant pain relief through-
out the day (e.g. MS Contin, Kapanol or Physeptone).
■ Change from PRN medication (as necessary) to set 
times if possible.
■ Adjuvant medication may be helpful, particularly if 
prolonged use of analgesics is required. Adjuvant 
medications include:
– tricyclic antidepressants
– non-steroidal anti-inflammatory drugs
– anti-convulsants.
■ Other supportive methods of pain relief can be useful 
in acute or chronic pain states. They include:
– transcutaneous electrical nerve stimulation (TENS) 
machine 
– relaxation techniques and meditation 
– diversion techniques
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– massage
– hydrotherapy.
■ Consult a pain management clinic or a specialist 
clinical advisory line.
All patients who have undergone withdrawal from opioids 
during hospitalisation, or under supervised withdrawal, 
should be educated and warned about the risk of overdose 
if they use opioids again, even with much smaller doses 
or amounts than they were using previously.
Patients on buprenorphine
Opioids should not be prescribed to opioid-dependent 
people outside a regulated opioid treatment program 
except in rare instances (e.g. to treat severe pain of trauma 
or other medical emergency).
Buprenorphine binds strongly with opioid receptors and 
there is a theoretical risk that it may interfere with the 
effectiveness of other opioids prescribed for pain relief. 
Patients receiving buprenorphine treatment who require 
acute pain relief can be managed as for patients who are 
not opioid-dependent, although doses of analgesic drugs 
may need to be higher.
Some patients with chronic pain develop opioid 
dependence and may be appropriately treated by 
admission to an opioid treatment program. Patients on 
buprenorphine treatment who experience chronic pain 
may require specialist management.
Opioid withdrawal precipitated by naltrexone  
Naltrexone is an antagonist that blocks the effects of 
opioids on the central nervous system. It can block the 
effects of heroin completely. Naltrexone is registered for 
treatment of opioid and alcohol dependence in Australia. 
Although uncommon, there have been a number of 
reports of opioid-dependent people self-administering 
naltrexone, precipitating a severe withdrawal reaction 
requiring hospital treatment.
Planned naltrexone-assisted opioid withdrawal is a 
validated and valuable treatment option for some 
patients. It should be conducted only in highly supervised 
specialist environments. 
It should also be noted that buprenorphine alone or 
buprenorphine and naloxone can also precipitate 
withdrawal if taken sub-lingually or intravenously (or 
potentially orally) for those who are opiate-dependent on 
drugs other than buprenorphine. 
Precipitated withdrawal 
■ Onset of naltrexone-precipitated withdrawal occurs 20–
60 minutes following ingestion of a naltrexone tablet.
■ Gastrointestinal symptoms are usually predominant. 
Severe vomiting and diarrhoea may occur.
■ People become agitated and distressed and delirium 
with confusion is common.
■ Signs of sympathetic overactivity, particularly profuse 
sweating and piloerection, may occur.
■ If a person has taken sedative drugs in conjunction 
with naltrexone, as commonly occurs, delirium is 
exacerbated but other signs may be less clear.
There are significant risks associated with precipitated 
withdrawal:
■ Most deaths associated with precipitated withdrawal 
appear to have been the result of aspiration 
associated with high doses of sedative drugs.
■ Fluid and electrolyte problems secondary to vomiting 
and diarrhoea.
■ During acute delirium, a confused person must be 
considered at risk and require emergency medical care.
Diagnosis and assessment
■ A history may be difficult to obtain from patients who 
are confused, particularly if they are reluctant to 
disclose their heroin/opioid use.
■ Clinicians should suspect naltrexone-precipitated 
withdrawal in anyone presenting with signs of opioid 
withdrawal in conjunction with delirium or intractable 
vomiting.
■ A history of opioid dependence should be gained 
from the person, significant others or by inspection of 
injection sites for recent track marks. An absence of 
track marks should not exclude this diagnosis, as 
substances may be smoked or ingested.
■ Careful assessment of the degree of sedation, and of 
the person’s capacity to protect their airway, is essential.
■ The use of flumazenil to reverse sedation is not 
recommended, due to the chance of the person 
having concurrent benzodiazepine dependence and 
the risk of inducing life-threatening seizures.
■ Patients who are deeply sedated or vomiting may require 
intubation and intensive care unit management.
■ It may be desirable to check electrolytes and arterial 
blood gases.
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Management
■ There is a risk of delirium and agitation for a period of 
approximately four hours with naltrexone-precipitated 
withdrawal. Treatment is supportive and symptomatic.
■ Patients with vomiting may require fluid and 
electrolyte replacement.
■ Although most patients will experience fluid loss to 
some degree, the insertion of intravenous cannulae 
and administration of fluids should be balanced 
against potential problems.
■ Patients in delirium frequently remove intravenous lines.
■ Most patients will be capable of tolerating oral fluids 
within 12 hours of ingestion of naltrexone.
■ During naltrexone-induced withdrawal delirium, most 
patients can be reoriented. This is critical in both 
obtaining a history and in clinical management.
■ The most important part of management is reassurance 
that symptoms, although severe, will be short-lived.
■ Nursing staff should be aware that the antagonist-
induced withdrawal syndrome is extremely traumatic 
and that patients expressing fear of death, for 
example, should not be treated with contempt but 
given appropriate, repeated assurance.
■ The administration of opioid agonists is unlikely to be 
helpful. Patients should be warned that taking heroin 
will not alleviate symptoms.
■ In managing vomiting and diarrhoea, clinical 
experience indicates that conventional anti-emetics 
provide little relief. Octreotide 100mcg is the drug of 
choice in reducing vomiting and diarrhoea.
■ Agitation and sympathetic over-activity can be treated 
with clonidine (150mcg oral or 100mcg intramuscular, 
repeated after two hours if agitation persists and 
hypotension is not a problem).
■ When urgent sedation is imperative (where patients 
are violent and confused), midazolam 5–10mg 
intramuscular may be helpful.
■ When abdominal cramps are a problem, a single dose 
of 20mg hyoscine-butylbromide (Buscopan), oral or 
IM, can help.
Additional management
■ The person and their families should be informed that 
residual symptoms may persist for up to seven days.
■ Patients need to be warned of the high risk of 
overdose if they use heroin or other opioids following 
naltrexone-induced withdrawal.
For further information, see NSW Opioid Treatment 
Program, Clinical guidelines for methadone and 
buprenorphine treatment of opioid dependence. 
GL2006_019
Maternal / neonatal care 
Opioid use during pregnancy
■ Opioid use during pregnancy is associated with 
increased risk of prematurity, growth retardation, 
foetal distress, meconium aspiration and jaundice. 
These outcomes may be more lifestyle-related or due 
to fluctuation in dose, leading to repeated intoxication 
and withdrawal episodes, rather than due to the 
opioids themselves. Blood-borne viral infections can 
be vertically transmitted to the baby.
■ Opioid withdrawal in pregnancy carries a serious risk 
of miscarriage or stillbirth, particularly if withdrawal is 
sudden and occurs in the first or third trimester.
■ The preferred treatment for pregnant women 
dependent on opioids is to stabilise them on 
methadone maintenance.
Breastfeeding
■ Opioids are present in breast milk. Breastfeeding 
should be interrupted for 24 hours after using heroin, 
owing to the uncertain composition of street heroin.
■ Breastfeeding is recommended for women who are 
maintained on methadone. However, breastfeeding is 
not recommended if methadone is being used in 
combination with other drugs.
■ The safety of buprenorphine is not yet established for 
breastfeeding. Women requesting to breastfeed on 
buprenorphine should be advised of this, and of the 
risks. If they choose to continue to breastfeed, and 
can make an informed decision, they should sign a 
disclaimer stating that they have been advised of the 
lack of research into this area but have chosen to 
breastfeed. The amount of buprenorphine in breast 
milk is small and considered to be clinically insignificant. 
■ Women should wean infants over at least a one-week 
period to prevent any risk of withdrawal in the infant.
For further information, refer to the National clinical 
guidelines for the management of drug use during 
pregnancy, birth and the early development years of the 
newborn. (March 2006) http://www.health.nsw.gov.au/
pubs/2006/ncg_druguse.html
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9.3 Benzodiazepines
Benzodiazepines (often called “benzos”) belong to the 
sedative-hypnotic group of drugs. They have a general 
CNS depressant effect that is dose dependent. As the 
dose increases there is progression from sedation through 
hypnosis to stupor. Benzodiazepines cause respiratory 
depression, but this effect is minimal unless other central 
nervous system depressants are taken (e.g. alcohol and 
opioids). This may result in respiratory depression that 
may be life-threatening.
People who use large amounts of benzodiazepines may 
experience withdrawal seizures on cessation of use or severe 
reduction in dose. Benzodiazepine use should not cease 
abruptly. A dose reduction regime should always be used.
Uncomplicated benzodiazepine withdrawal can be 
accomplished at home with a gradual diazepam 
reduction regime. However, anyone who presents already 
exhibiting symptoms of withdrawal (e.g. agitation, 
confusion, convulsions, and delirium) should be admitted 
for assessment and treatment. The following guidelines 
focus on inpatient withdrawal and management.
9.3.1 Criteria for in-hospital management
Patients may need admission because:
■ they present in withdrawal
■ they have an illness or injury which warrants 
admission and withdrawal becomes an additional 
clinical issue
■ they are unable to take responsibility for the self-
administration of their medication in the home.
9.3.2 Assessment and quantification
There are two main patterns of benzodiazepine 
dependence, the most common being low dose 
dependency over many years, particularly among women 
and elderly people. High dose dependence, often in the 
context of polydrug use, can also occur.
Record the following information:
■ type of benzodiazepine, route of administration
■ dose (in milligrams) and frequency of use
■ duration of use
■ date, time and amount last used.
9.3.3 Indications and guidelines
Managing benzodiazepine intoxication 
As the dose increases, effects move from sedation through 
hypnosis to stupor. People who use benzodiazepines on a 
regular basis may develop tolerance to the sedative effect. 
In some people benzodiazepines produce a paradoxical 
reaction of violence and disinhibited behaviour.
Effects of benzodiazapines 
Effects
■ decreased anxiety
■ sleepiness
■ sedation
■ anti-convulsant effects.
Side effects
■ poor motor coordination
■ ataxia
■ slurred speech
■ vertigo
■ blurred vision
■ lethargy
■ poor memory recall
■ confusion
■ drowsiness
■ stupor
■ drooling
■ in rare cases: agitation, hostility, bizarre uninhibited 
behaviour.
Absorption rates, half-life and equivalent daily 
dose 
The following table shows absorption rates, half-life, and 
equivalent daily doses of common benzodiazepines, 
which is based on the manufacturer’s product 
information.
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Benzodiazepine withdrawal 
Very few users of prescribed benzodiazepine become 
dependent with periods of use of less than 3 months. 
Longer-term use may result in withdrawal symptoms that 
can last from six months to one year, with gradual 
diminishing intensity of symptoms. Patients vary in the 
rate of developing dependence. With between 3 and 12 
months of use, 10%–20% of patients will become 
dependent, rising to 20%–45% after more than a year. 
(NSW Health 2006)
If low dose therapy is continued for longer than six weeks, 
physical dependence and symptoms of withdrawal will 
affect 15-50% of people (studies vary). Not everyone will 
experience symptoms, and of those who do, the 
symptoms are not always disabling. This information can 
be reassuring when discussing the need for withdrawal.
Abrupt withdrawal from high doses use (greater than 
50mg diazepam or equivalent per day) without 
withdrawal symptoms has been observed clinically, but 
the incidence is unknown. Use of higher doses is more 
likely to produce a withdrawal syndrome with more 
severe symptoms.
Many people who are using high doses of 
benzodiazepine, and who also use opioids, report that 
benzodiazepine withdrawal is worse than opioid 
withdrawal, commenting that benzodiazepine 
withdrawal is ‘mentally’ worse. Withdrawal symptoms 
may be more severe for people who use more than one 
kind of benzodiazepine, perhaps because of the 
unpredictable effects of withdrawal from drugs with 
varying half-lives.
Table 9.9: Absorption rates, half-life, and equivalent daily doses of common benzodiazepines*
Generic name Trade name Time to peak concentration Elimination half life† Equivalent dose‡
Diazepam Antenex
Ducene
Valium
Valpam
30–90 min Biphasic: rapid phase half-life, 
3 hours; elimination half-life, 
20–48 hours
5 mg
Alprazolam Alprax
Xanax
Kalma
1 hour 6–25 hours 0.5–1.0 mg
Bromazepam Lexotan 0.5–4 hours 20 hours 3–6 mg
Clobazam Frisium 1–4 hours 17–49 hours 10 mg
Clonazepam Paxam
Ritrovivl
2–3 hours 22–54 hours 0.5 mg
Flunitrazepam Hypnodorm 1–2 hours 20–30 hours 1–2 mg
Lorazepam Ativan 2 hours 12–16 hours 1 mg
Nitrazepam Alodorm
Mogadon
2 hours 16–48 hours 2.5–5 mg
Oxazepam Alepam
Murelax
Serepax
2–3 hours 4–15 hours 15–30 mg
Temazepam Euhypnos
Normison
Temaze
Temtabs
30–60 min after tablets, 
2 hours after capsules
5–15 hours 10–20 mg
Triazolam Halcion 1–3 hours Biphasic: rapid phase half-life, 
2.5–3.5 hours; elimination half-
life, 6–9 hours
0.25 mg
Zolpidem Stilnox 0.5–3 hours 2.5 hours Not known
* Based on manufacturer’s product information. 
† Elimination half-life: time for the plasma drug concentration to decrease by 50%. 
‡ Equivalent dose: approximate dose equivalent to diazepam 5 mg.
Benzodiazepines
PAGE 48  NSW HEALTH  Clinical guidelines for nursing and midwifery practice in NSW 
Onset and duration of benzodiazepine withdrawal
Onset of withdrawal depends on the half-life of the 
particular benzodiazepine used by the person. Withdrawal 
from short-acting benzodiazepines generally occurs earlier 
and is more severe. Withdrawal symptoms do not necessarily 
decrease steadily from a peak, but can follow a fluctuating 
course with good and bad periods. Eventually the good 
periods will last longer and become more frequent.
Signs and symptoms of benzodiazepine withdrawal
Subjective symptoms with few observable signs of with-
drawal are a feature, particularly of low dose withdrawal. 
Individuals may report feeling extremely mentally distressed 
(as though they are “going mad”), although they may not 
have any obvious signs of physical discomfort. This may 
result in the person not receiving the care that would be 
appropriate during this time.
The following table shows signs and symptoms of 
benzodiazepine withdrawal:
Table 9.10: Symptoms of benzodiazepine withdrawal
Common 
symptoms
Less common symptoms Uncommon 
symptoms
Anxiety Nightmares, agoraphobia Delusions
Insomnia Feelings of unreality Paranoia
Restlessness Depersonalisation Hallucinations
Agitation Panic attacks Seizures
Irritability Nausea, dry retching, 
decreased appetite, weight 
loss, sweating, lethargy
Persistent 
tinnitus
Poor 
concentration
Increased sensory 
perception, aches and pains, 
headaches, palpitations, 
tremor, blurred vision
Confusion
Poor memory Increased temperature, 
ataxia
Depression Gastrointestinal unrest
Muscle tension, 
aches, twitching
Menstrual changes
NSW Health (2007)
Major complications of withdrawal
The major complications of withdrawal are:
■ progression to severe withdrawal
■ delirium with risk of injury (to self or others) 
■ risk of dehydration or electrolyte imbalance
■ potential for seizures
■ presence of concurrent illness, which masks or mimics 
withdrawal
■ orthostatic hypotension.
Course of withdrawal 
Withdrawal from short-acting benzodiazepines (e.g. 
oxazepam, temazepam, alprazolam, and lorazepam) 
typically produces a faster and more severe onset of 
symptoms than withdrawal from long-acting benzo-
diazepines (e.g. diazepam, nitrazepam), and may be 
more difficult to undergo and complete.
Figure 9.3: Withdrawal from short and long-acting 
benzodiazepines
Rebound phenomena
Abrupt withdrawal from benzodiazepines can result in 
rebound anxiety and insomnia, which may last 2–3 days. 
The onset time is related to the half-life of the drug.
Symptom re-emergence
Symptom re-emergence may be difficult to distinguish 
from rebound phenomena and occurs after cessation of 
benzodiazepines. The symptoms that re-emerge may be 
the same as those for which the benzodiazepine was 
prescribed e.g. anxiety and panic disorder.
Managing benzodiazepine withdrawal 
Undertake nursing observations to identify and manage 
withdrawal symptoms and prevent the progression to 
severe withdrawal. In particular, offer:
■ reassurance regarding distorted sensory stimuli
■ heat and massage for muscle aches 
■ symptomatic management to reduce the severity of 
symptoms.
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life benzodiazepines
Onset: 1 – 2 days
Duration: 2 – 4 weeks
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Adapted from Frank L., Pead J. New Concepts in Drug Withdrawal: A resource
handbook. © 1995 State of Victoria. Reproduced with permission.
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Incidental withdrawal
Patients in hospital may undergo benzodiazepine 
withdrawal from even low doses of regular, long-term 
benzodiazepine use. Benzodiazepines should not be 
abruptly ceased because of the risk of precipitating 
withdrawal. 
If there are no medical or psychological indications for 
continuing benzodiazepine use, discuss with the patient 
the problems of dependence and the advantages of with-
drawing the drug. Patients taking low doses who wish to 
withdraw can begin a reduction regimen while in hospital.
However those taking high doses should be assessed and 
their dose should be stabilised. Reduction and withdrawal 
should follow once their other medical condition has 
been dealt with.
Monitoring 
There is no validated tool for recording benzodiazepine 
withdrawal symptoms in an inpatient setting. The 
symptoms listed in Table 9.10 need to be monitored.
Pharmacological treatment
A therapeutic relationship is required prior to 
benzodiazepine withdrawal and generally this should be 
managed by the patient’s general practitioner. 
However, it is not recommended that general practitioners 
attempt to manage benzodiazepine withdrawal in 
polydrug users, nor prescribe benzodiazepines for this 
group, even as a temporary measure.
Initial stabilisation of dose (preferably with a long acting 
benzodiazepine like diazepam) in an inpatient setting is 
followed by a gradual reduction in dose over time as an 
outpatient. Contraindications to outpatient reduction 
exist when:
■ the safety of the patient would be at risk (e.g. history 
of seizures, alcohol dependence, or significant mental 
or other illness; the elderly)
■ the patient reports very high doses of benzodiazepine 
use and has not been stabilised.
■ the likelihood of a successful outcome is poor in an 
ambulatory setting (repeated inability to complete 
outpatient reductions, other drug use, unstable social 
environment) 
■ the patient will not consider withdrawal in an 
ambulatory setting.
During the initial stabilisation period the dose of 
benzodiazepine should reduce severity of withdrawal 
symptoms without over sedating. There should be close 
observation for signs of intoxication, as this indicates that 
the prescribed dose is too high. The initial reduction of about 
10% of the dose per day can be commenced to get the 
patient down to a lower stable dose before discharge. 
Withdrawal is then completed as an outpatient. 
The use of drugs that exhibit cross-tolerance with 
benzodiazepines (such as alcohol) or those that lower the 
seizure threshold (e.g. phenothiazines, tricyclic anti-
depressants) may warrant a higher stabilisation dose and 
a more conservative reduction rate. 
People who have not taken benzodiazepines for a few 
days can begin on the dose that they would have been 
on had they commenced dose reduction at the time of 
stopping. 
Maternal and neonatal care 
The health risks of benzodiazepines in pregnancy have 
not been clearly established. Regular benzodiazepine use 
during pregnancy may cause neonatal abstinence syndrome, 
which may be of delayed onset. Babies born to 
benzodiazepine dependent women should be observed 
for 1 week prior to discharge and should have weekly 
outpatient review for 1 month. The Finnegan scale may 
be used to monitor withdrawal and if medication is 
required, the drug of choice is phenobarbitone.
The safety of benzodiazepines in breast milk is not 
known therefore the potential risks should be weighed 
up against benefits of breastfeeding. Women on short 
acting benzodiazepines should be advised not to 
breastfeed immediately post dose because of the risk of 
falling asleep and potentially smothering the baby and 
the risk of the infant receiving a maximum dose and 
becoming excessively drowsy.
For further information, refer to the National clinical 
guidelines for the management of drug use during 
pregnancy, birth and the early development years of the 
newborn. (March 2006) http://www.health.nsw.gov.au/
pubs/2006/ncg_druguse.html
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9.4 Psychostimulants
Drugs labelled as “psychostimulants” include a diverse 
range of CNS stimulants such as amphetamine (speed), 
cocaine (coke, snow), methamphetamine (crystal meth, 
speed, ice), methylphenidates—Ritalin, and methylene 
dioxy-methamphetamine (MDMA—ecstasy). Nicotine is 
also a psychoactive stimulant.
Stimulants activate the CNS, having a peripheral 
sympathomimetic action, and are often used for effects 
such as euphoria, increased sense of well-being, increased 
energy, more confidence or over-confidence, improved 
cognitive and psychomotor performance, suppression of 
appetite and insomnia (Latt et al. 2002, p. 125).
See also: NSW Health 2006. Psychostimulant Users —
Clinical Guidelines for Assessment and Management: 
GL2006_001
9.4.1 Assessment and quantification
Quantification of illicit drugs used, including psycho-
stimulants, can be difficult because they are often ”cut” 
(mixed) with other substances including other drugs, glucose 
and sucrose, and the actual dose is always unknown.
Record the following information:
■ type of psychostimulant (e.g. speed, cocaine, MDMA, 
methamphetamine)
■ frequency (e.g. daily, weekly, binges/runs)
■ dose (record in dollars spent to buy or grams)
■ duration of use
■ last dose/used (date, time and amount)
■ route/s of administration (smoking, injecting, snorting, 
swallowing).
9.4.2 Indications and guidelines
Onset and duration of acute effects 
Speed—amphetamine: Onset of action when taken 
orally is about 30–60 minutes, with peak cardiovascular 
effect at 60 minutes and CNS effects about two hours. 
Duration of effect is about 4–6 hours. Intranasal (snorting) 
produces effects within a few minutes; smoking and 
intravenous use produces even faster effects.
Ecstasy—MDMA: Onset of action when taken orally is 
30-60 minutes with peak effect at 90 minutes. Duration 
of effect is about 4–6 hours.
Coke—cocaine: Despite concerns during the 1980s 
about the emergence of other forms of cocaine such as 
“crack” onto the illicit drug market, this form of the drug 
is rarely seen in NSW and there is no evidence of its 
commercial distribution. Onset of action when snorted is 
within minutes. When ”crack” is inhaled or when cocaine 
is taken intravenously, action is within seconds. There is 
an immediate and marked "rush" that is highly pleasurable 
with heightened cognitive awareness, energy and euphoria 
lasting for about 30 minutes. Rapidly diminished effects 
due to short half-life. 
Managing psychostimulant intoxication
Table 9.11: Psychostimulant effects
Immediate effects Effects of higher doses
Increased alertness Headaches
Increased energy Pale skin
Increased confidence Restlessness
Euphoria Dizziness
Increased talkativeness Rapid or irregular heartbeat
Loss of appetite Paranoia
Insomnia Anxiety
Increased heart rate and 
breathing
Panic attacks
Nausea/vomiting Depression
Headaches Confusion (feeling “scattered”)
Jaw clenching
Hot and cold flushes
Sweats
 
Binges or “runs” involve repeated excessive use (multiple daily 
doses over several days). This can result in a psychotic state 
resembling acute paranoid schizophrenia characterised by:
■ severe agitation
■ anxiety
■ restlessness
■ paranoid delusions
■ hallucinations—predominantly visual but can be 
auditory or tactile
■ repetitive stereotypical behaviours
■ hostility and violence
■ loosening of association and ideas in a setting of clear 
consciousness.
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Although psychotic symptoms generally subside soon 
after the drug use ceases, some people may experience 
persistent symptoms for weeks or months (Latt et al. 
2002, pp. 130–131).
Managing psychostimulant withdrawal 
Repeated and prolonged use of psychostimulants leads to 
marked tolerance, neuroadaption and dependence, and 
withdrawal on cessation.
Withdrawal from cocaine or amphetamines is not life-
threatening, but depression resulting from withdrawal 
can lead to suicidal ideation, self-harm and possibly 
death. Suicidal ideation should be managed as per 
hospital policy and NSW Department of Health Policy 
Directive No. PD2005_121 Suicidal Behaviour – 
Management of Patients with Possible Suicidal Behaviour 
at http://www.health.nsw.gov.au/policies/PD/2005/
PD2005_121.html 
Also refer to the Framework for Suicide Risk Assessment 
and Management for NSW Health Staff at http://www.
health.nsw.gov.au/pubs/2005/suicide_risk.html 
Withdrawal is characterised by three phases: crash, 
withdrawal and extinction.
Table 9.12 shows the phases of amphetamine and 
cocaine withdrawal.
Monitoring
Four-hourly monitoring is recommended as nurses/midwives 
need to be aware of changing signs and symptoms that 
the patient may present with as they pass through the 
crash and withdrawal phases. Mood and energy levels 
may fluctuate e.g. a patient may initially present with a 
low mood and psychomotor retardation and then swing 
towards being restless and agitated later the same day.
Assess for underlying mental health problems as these may 
have been masked during the crash phase but become 
evident later in the withdrawal period. Withdrawal scales 
have not been routinely used in clinical practice.
Pharmacological treatment 
To date, no broadly effective pharmacological therapy has 
been identified. However, symptomatic medication may 
be beneficial, for example:
■ Benzodiazepines for anxiety, agitation, insomnia and 
aggressive outbursts. Benzodiazepines should not be 
used for more than two weeks without review. 
Table 9.12: Amphetamine withdrawal
Phase Time since last stimulant use Common signs and symptoms
Crash Amphetamines: typically commences 
12–24 hours after last amphetamine use, 
and subsides by days 2–4. 
Cocaine: occurs within hours of last use, 
with short duration (up to 48 hours). 
Some individuals do not report a 
significant crash on stopping cocaine.
Exhaustion, fatigue.
Sleep disturbances (typically increased sleep, although insomnia or restless 
sleep may occur).
Mood disturbances—typically flat mood or dysphoria; may be associated 
with anxiety or agitation.
Low cravings.
Generalised aches and pains.
Wthdrawal Amphetamines: typically commences 2–
4 days after last use, peaks in severity 
over 7–10 days, and then subsides over 
2–4 weeks. 
Cocaine: typically commences 1–2 days 
after last use, peaking in severity over 4–7 
days, then subsides over 1–2 weeks.
Strong cravings.
Fluctuating mood and energy levels, alternating between: Irritability, 
restlessness, anxiety, and agitation.
Fatigue, lacking energy, anhedonia.
Disturbed sleep, including vivid dreams, insomnia.
General aches and pains, headaches.
Muscle tension.
Increased appetite.
Poor concentration and attention.
Disturbances of thought (e.g. paranoid ideation, strange beliefs) and 
perception (misperceptions, hallucinations) can re-emerge during 
withdrawal phase after having been masked during crash.
Extinction Weeks to months Gradual resumption of normal mood with episodic fluctuations in mood 
and energy levels, alternating between: irritability, restlessness, anxiety, 
agitation, fatigue, lacking energy and anhedonia.
Episodic cravings.
Disturbed sleep.
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■ Antipsychotic medication for psychotic symptoms 
(delusions, hallucinations etc). Psychiatric consultation is 
recommended if symptoms are severe or do not resolve 
within days. Caution is required when the patient is 
intoxicated with psychostimulants as some anti-
psychotic medications (butyrophenones like haloperidol, 
olanzapine, etc) may lower the seizure threshold.
■ Antidepressants for symptoms of depression that 
persist after stimulant withdrawal. Specialist assessment 
and a treatment plan combining counselling (e.g. 
cognitive behavioural therapy) and antidepressants 
should be considered. The side effect profile of the 
various antidepressants may be important in choosing 
an antidepressant. 
Maternal and neonatal care 
The health risks of psychostimulant use during pregnancy 
have not been clearly established. However, a history of 
use (especially IV use) should be considered as a high-risk 
pregnancy. Use during pregnancy is associated with higher 
rates of obstetric complications (spontaneous abortion, 
miscarriage and placental abruption) If amphetamines are 
used close to the birth, the baby may be born affected and 
have agitation and be overactive. There are only limited 
reports of neonatal abstinence syndrome, however, the need 
for medication for withdrawal has not been reported.
A mother who wishes to breastfeed should be supported 
unless she is using regularly and is unstable. Women who 
rarely use or binge use should be informed of the risks 
and provided with information on minimising harm to 
the baby, for example:
■ Express and discard milk after psychostimulant use.
■ Do not breastfeed for 24 hours after amphetamine or 
cocaine use.
■ Do not breastfeed for 24–48 hours after using ecstasy.
For further information, refer to the National clinical 
guidelines for the management of drug use during 
pregnancy, birth and the early development years of the 
newborn. (March 2006) http://www.health.nsw.gov.au/
pubs/2006/ncg_druguse.html
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9.5 Cannabis
Cannabis is the generic name given to the psychoactive 
substances found in the marijuana plant cannabis sativa. 
The main active constituent is Delta 9-tetra-hydrocannabinol 
(THC). It is difficult to classify due to its mixture of mood, 
cognitive, motor and perceptual effects. It does not clearly 
belong to any other drug class, as it has a mixture of 
stimulant and depressive effects. People may also experience 
perceptual distortions (e.g. sharpening of the senses or 
altered sense of time), however, full hallucinations are rare.
9.5.1 Assessment and quantification
Cannabis is difficult to quantify, but noting the following 
may help:
■ cannabis type, e.g. leaf, head or hash; bush bud or 
hydroponic
■ amount used, e.g. in bongs or joints per day
■ frequency and duration of use
■ number of hours the patient is stoned in a day
■ method of administration (e.g. joint, bong, eaten)
■ date/time and amount last used.
9.5.2 Time of onset and duration of effects
The effect of one bong/joint may last three to five hours. 
If the drug is eaten, the acute effects start about one 
hour after ingestion and can last up to eight hours or 
more. THC is stored in fat cells hence produces an 
accumulating effect over time. Urine drug screen positive 
for THC only confirms that cannabis has been used 
recently (e.g. in the last few weeks) and does not confirm 
or eliminate intoxication. Cannabis has relatively weak 
effects on the cardiovascular, respiratory and thermo-
regulatory systems
9.5.3 Indications and guidelines
Signs and symptoms of cannabis use
Effects of using cannabis include:
■ euphoria
■ relaxation
■ sleepiness
■ hunger (munchies)
■ feeling of well being
■ perceptual distortions e.g. (altered sense of time and 
sharpened senses)
■ impaired memory, cognition and skill task 
performance
■ depersonalisation
■ raised pulse (approx increase of 20bpm)
■ vasodilation (especially conjunctiva—red eyes)
■ orthostatic hypotension
■ reduced intra-ocular pressure
■ bronchodilatation
■ anti-emetic
■ muscle relaxation
■ analgesia
■ anticonvulsant effects.
Acute toxicity can result in:
■ anxiety
■ confusion
■ panic attacks
■ persecutory delusions
■ visual hallucinations
■ impairment of short-term memory and attention.
Psychosis can occur but is usually only associated with 
those who have a predisposition to mental illness. The 
psychotic state generally resolves within a week of 
ceasing cannabis. Cannabis induced psychosis can be 
difficult to distinguish from precipitation of a psychosis in 
those with predisposition to mental illness.
Overdose from cannabis is rare and clinical signs are not 
clearly defined.
Managing cannabis withdrawal 
Onset and duration of cannabis withdrawal
Most symptoms commence on day 1, peaking at day 2–3, 
returning to baseline after a week or two. However, there 
is temporal variation in the profile of specific symptoms, 
with the late onset of aggression (day 4) and anger (day 6) 
being particularly significant, with the former often 
peaking after 2 weeks of abstinence. 
Special considerations include:
■ Patients with a comorbid mental health condition. 
There may be unmasking of the mental illness during 
withdrawal. Appropriate assessment and 
management is required.
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■ Patients who use cannabis for chronic pain may 
require assessment for adequate pain management 
and referral to specialist pain services.
Patients with a history of aggression may require closer 
monitoring and a higher dose of benzodiazepine.
The following table illustrates common and less common 
withdrawal symptoms.
Table 9.13: Cannabis withdrawal symptoms
Common symptoms Less common symptoms / 
equivocal symptoms
Anger or aggression Chills
Decreased appetite or 
weight loss
Depressed mood
Irritability Stomach pain
Nervousness/anxiety Shakiness
Restlessness Sweating
Sleep difficulties, including 
strange dreams
(Budney et al., 2004:1975)
Monitoring
Cannabis withdrawal can be monitored by using a 
withdrawal assessment scale such as the Cannabis 
Withdrawal Assessment Scale  (see Appendix 5).
Pharmacological treatment 
Not all patients will require medication for withdrawal. 
The following table lists medications for symptomatic 
relief of cannabis withdrawal.
Table 9.14: Medications for relief of cannabis 
withdrawal
Symptom Medication
Sleep problems benzodiazepines, zolpidem 
zopliclone, promethazine 
Restlessness, anxiety,  
irritability
diazepam
Stomach pains buscopan, atrobel
Physical pain, headaches paracetamol, non-steroidal 
anti-inflammatory agents
Nausea promethazine, metoclopramide
(NSW Health 2007)
Maternal and neonatal care 
While the health risks of cannabis use in pregnancy have 
not been clearly established, some studies have 
suggested that children born to cannabis-dependent 
parents may have development problems, such as:
■ subtle differences in higher cognitive processes and 
perceptual organisation
■ sleep disturbances in three-year-olds
■ reduced memory and verbal scales at three years
■ reduced height at six years
■ increased child hyperactivity, impulsivity and 
inattention at 10 years. 
Cannabis is often mixed with tobacco and the risks of 
tobacco in pregnancy are considerable.
Due to a lack of evidence it is not possible to make a 
recommendation about cannabis and breastfeeding. 
Potential risks should be weighed up against benefits of 
breastfeeding.
For further information, refer to the National clinical 
guidelines for the management of drug use during 
pregnancy, birth and the early development years of the 
newborn. (March 2006) http://www.health.nsw.gov.au/
pubs/2006/ncg_druguse.html
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9.6 Tobacco
Tobacco is the major cause of drug-related deaths in 
Australia. There are over 4000 chemicals in tobacco smoke, 
many of which are poisonous and 43 that have been proven 
to be carcinogens. These chemicals include nicotine (the 
addictive component); tar (which causes throat and lung 
cancer); and carbon monoxide (together with nicotine, 
increases the risk of heart disease, atherosclerosis, and 
other circulatory problems). There is no safe level of 
tobacco consumption.
9.6.1 Assessment and quantification
To assess nicotine dependence, use the following 
Fagerstrom Test for Nicotine Dependence (Table 9.15).
9.6.2 Indications and guidelines
Effects of smoking tobacco 
Immediate
■ increased heart rate
■ temporary rise in blood pressure
■ decreased blood flow to extremities
■ increased acid in the stomach
■ brain and nervous system activity stimulated then reduced
■ weaker appetite, taste and smell
■ paralysed cilia in lungs and airways
■ kidneys produce less urine
■ dizziness, nausea, watery eyes.
Long term
■ shortness of breath, coughing
■ respiratory infections, such as pneumonia and chronic 
bronchitis
■ increased risk of emphysema
■ increased risk of cancer of lungs, mouth, larynx, pharynx, 
oesophagus, bladder, kidney, pancreas and cervix 
■ atherosclerosis
■ increased risk of peripheral vascular disease
■ increased risk of heart disease and myocardial infarction
■ increased risk of stomach ulcers
■ increased risk of infertility (can cause impotence in 
men; women less fertile also) 
■ earlier signs of ageing: wrinkles, dry skin, etc.
■ may inhibit some symptoms of Parkinson’s disease. 
(Wirdefeldt, 2005)
Table 9.15: Nicotine Dependence Test
Question Answer Score
1. How soon after waking up do you smoke your first cigarette? Within 5 minutes
6–30 minutes
31–60 minutes
3
2
1
2. Do you find it difficult to abstain from smoking in places where it is forbidden? Yes
No
1
0
3. Which cigarette would you hate to give up? The first one of the day
Any other
1
0
4. How many cigarettes a day do you smoke? 10 or less
11–20
21–30
31 or more
0
1
2
3
5. Do you smoke more frequently in the morning than in the rest of the day? Yes
No
1
0
6. Do you smoke even though you are sick in bed for most of the day? Yes 
No
1
0
Total
 
Score: 1–2 = very low dependence, 3–4 = low dependence, 5 = medium dependence, 6–7 = high dependence, 8+ = very high 
dependence (NSW Health, 2002, p.10)
What the score means: The higher the score on the Fagerstrom test, the more likely the person is to benefit from using nicotine 
replacement therapy (NRT) or bupropion to assist with withdrawal symptoms and to quit. Those with a score above five should consider 
higher dose NRT. Those with a score of four or less may still benefit from lower dose NRT.
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Opportunistic intervention and harm reduction 
Health professionals can provide brief cessation advice 
opportunistically as a minimal clinical intervention during 
routine consultations with smokers, whether or not they 
are seeking help with stopping smoking. Each session 
usually lasts three to five minutes and follows a stepped 
process described as the 5As: Ask, Advise, Assess, Assist, 
Arrange (Miller and Wood, 2002). 
Harm reduction
It would seem that smoking lower tar (and nicotine) or 
fewer cigarettes should reduce harm, but in reality smokers 
tend to titrate the dose of nicotine from a cigarette in 
order to maintain a particular level of nicotine in the body. 
Thus, smokers who reduce the nicotine and tar content or 
the number of cigarettes will often breathe in deeper and 
hold the smoke in the lungs longer, which unfortunately 
causes more harm to the lungs (Benowitz, 1998). The best 
way to reduce harm is to change the method of delivery 
of nicotine from smoking to prescribed nicotine replacement 
therapy (NRT), or to stop “cold turkey”. Exposing others 
passive smoking can be avoided by smoking outside the 
home and car.
Nicotine withdrawal—Signs and symptoms
Onset of withdrawal is usually within a few hours of the 
last cigarette, and withdrawal symptoms peak at 24–72 
hours. Withdrawal symptoms vary, but can include the 
following: 
■ irritability 
■ cravings
■ increased nervousness and tension
■ sleep disturbance
■ stomach upsets
■ bowel disturbance
■ loss of concentration
■ muscle spasm
■ changes in taste
■ headaches
■ cough 
■ increased appetite.
Pharmacological treatment 
Treatment: Indication for inpatient nicotine 
withdrawal
There is generally no indication for admission into an 
inpatient facility for management of nicotine withdrawal 
in its own right.  Many patients will, however, be 
admitted to hospital, and experience withdrawal from 
nicotine consequently. Patients should be informed of the 
NSW Health Smoke Free Workplace Policy (1999) and 
offered support to stop. NRT should be used when not 
contraindicated.  Information on offsite / outdoor 
designated smoking areas should be provided, if available, 
if patients wish to continue to smoke. Assessment, 
information, education, support, NRT and referral should 
be offered to all patients in this situation whether they 
intend to continue smoking on discharge not. If they 
intend to stop, a referral to the QUIT Line and a GP or 
Pharmacist should be made.
Supportive counselling, accurate information, pharma-
cotherapy options and appropriate planning should be 
used during the withdrawal period. A range of resources 
is available including facts sheets, self help booklets and 
the QUIT Line for use during and after the withdrawal 
period. Counselling is also provided by some services. 
Refer to NSW Health Guidelines GL2005_036: 
Nicotine Dependent Inpatients (The Guide for the 
Management of). 
Pharmacotherapies
A holistic approach to smoking cessation is important 
and a pharmacotherapy should be seen as one part of 
this approach. Pharmacotherapy options are:
■ Nicotine Replacement Therapy (NRT)
■ Bupropion 
■ Other options such as clonidine, and nortriptyline 
The tables below (Table 9.16 and 9.17) outline the dose, 
duration, side effects and contraindications of NRT and 
bupropion. 
Nicotine Replacement Therapies (NRTs)
NRT provides lower nicotine levels than those achieved by 
smoking. This provides a relief from physiological 
withdrawal symptoms of smoking, reducing the urge to 
smoke cigarettes. NRT options are gum, patches and an 
inhaler. A combination of a NRT patch and another self-
administered form of NRT may be more efficacious than 
one form alone. 
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Because NRTs are available without prescription at 
pharmacies, pharmacists can play an important role in 
providing information to people wanting to use this 
option. In general, issues such as the type of NRT, 
previous withdrawal symptoms and patterns, the need 
for a combination of agents and regular review should be 
explored in all settings. Not smoking while using NRT 
should be strongly encouraged.
Combination therapy
Combining the nicotine patch with a self-administered 
form of short-acting NRT may be more efficacious than a 
single form of nicotine replacement and patients should be 
encouraged to use combined treatments if they are unable 
to remain abstinent, or if they are still experiencing 
withdrawal symptoms using a single type of 
pharmacotherapy (Fiore 2000).
Bupropion
Bupropion is a non-nicotine-based alternative to NRT, an 
atypical antidepressant that can only be prescribed for 
adults. It is the only smoking pharmacotherapy available on 
the Pharmaceutical Benefits Scheme. Because Bupropion 
is initiated approximately one week prior to the quit day, 
it will have limited practical application for inpatient 
settings. However, it may be an option for patients to 
discuss with their GP after discharge. It can be used in 
combination with short-acting NRT. 
Clonidine and nortriptyline 
Clonidine and nortriptyline should be considered if the 
above options are contraindicated, but they may have 
more severe side effects.
Maternal and neonatal 
Tobacco use during (and after) pregnancy
Risks may include:
■ pregnancy complications such as ectopic pregnancy, 
miscarriages, stillbirth, placental problems, bleeding 
during pregnancy and premature birth 
■ low birth weight
■ increased foetal heart rate, decreased foetal movements 
and impaired ‘rehearsal breathing’ in the foetus
■ respiratory complications and middle ear infections in 
the baby’s first weeks
Table 9.16: Pharmacotherapy of nicotine replacement therapies
Type Dose and Duration Side Effects Contraindications
Less than 10 
cigs per day
10–20 cigs per 
day
More than 20 
cigs per day
Patches None Nicobate® 14 mg
Nicorette® 10 mg
Nicobate® 21 mg 
Nicorette® 15 mg
Transient skin irritation, itching, 
dreams, sleep disturbance, 
indigestion, diarrhoea
Relative: 
■  Ischaemic heart disease
Absolute: 
■ Recent MI 
■ Serious arrhythmias
■ Unstable angina 
■ Pregnancy
Gum None 2 mg, 
8–12 per day
4 mg, 
8–12 per day
Jaw discomfort, nausea, 
indigestion, hiccups, excess 
saliva, sore throat
Inhaler None Nicorette® 6–12 
cartridges per day
Not recommended Mouth and throat irritation, 
cough, nausea and indigestion
Table 9.17: Pharmacotherapy of bupropion (Zyban®)
Type Dose and Duration Side Effects Contraindications
Less than 10 
cigs per day
10–20 cigs per 
day
More than 20 
cigs per day
Bupropion 150 mg for 3 days, then 150 mg b.d. for 7 weeks Headaches, dry mouth, 
impaired sleep, seizures, 
nausea, anxiety, constipation, 
and dizziness
1. seizure disorders or 
significant risk of seizure
2. bulimia
3. anorexia nervosa, 
4. bipolar disorders
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■ later asthma, possibly related to passive smoking effects
■ sudden infant death syndrome.
Nicotine replacement therapy (NRT)
There is currently a lack of evidence on the safety of NRT 
in pregnancy but reports of expert committees have 
recommended its use in certain circumstances.
NRT should be considered when a pregnant woman is 
otherwise unable to quit, and when the likelihood and 
benefits of cessation outweigh the risks of NRT and 
potential continued smoking.
Pregnant smokers who have been unable to quit using 
behavioural methods and are considering the use of 
pharmacotherapy to quit smoking should be advised to 
discuss the implications with their medical practitioner. 
NRT should commence as soon as inability to quit is 
identified, after two or more weeks of trying without 
success.  
■ NRT is recommended in the form of intermittent-use 
formulations (gum, lozenge, inhaler, sublingual 
tablets) during pregnancy.
Breastfeeding
■ Mothers who are breastfeeding should be advised not 
to smoke during breastfeeding, and ensure that no 
one smokes in the house or car with the baby
■ Mothers who wish to breastfeed while continuing to 
use NRT should breastfeed first, then use one of the 
intermittent delivery methods of NRT.
For further information, refer to the National clinical 
guidelines for the management of drug use during 
pregnancy, birth and the early development years of the 
newborn. (March 2006) http://www.health.nsw.gov.au/
pubs/2006/ncg_druguse.html
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9.7 Hallucinogens
Hallucinogens (also known as psychedelics) include 
naturally occurring and synthetic compounds. They 
produce distortions in thoughts, mood and perceptions— 
typically inducing illusions or hallucinations. They are 
most commonly used in one-off social contexts such as 
dance or rave parties, clubs and pubs, or at home. 
There are a number of drugs that come into this category. 
They include lysergic acid diethylamide (LSD), phencyclidine 
(PCP), psilocybin (magic mushrooms), and dimethyl 
tryptamine (DMT). 
Note: MDMA (methylene dioxy-amphetamine) (ecstasy) 
is a psychostimulant that also has hallucinogenic 
properties.
See Appendix 6 for the street names of hallucinogens.
9.7.1 Assessment and quantification
Quantification of hallucinogens is difficult because purity 
is uncertain. In assessing hallucinogen use, record:
■ the substance name
■ how often the person uses the substance
■ either the cost of the drug, or how many tabs are 
used
■ how long the person has been using the drug
■ the date and time of last use.
9.7.2 Indications and guidelines
Managing hallucinogen intoxication 
In some cases users can experience pronounced mood 
swings: detachment may alternate with fear, paranoia, 
distress and panic. The nurse may need to provide 
reassurance and supportive care so the patient does not 
injure himself or others during a panic episode. 
Effects of hallucinogens 
Immediate effects
■ A sense of increased clarity or sharpness
■ Altered perception, thought, emotions:
– unusual and vivid perception of shapes, colours, 
sounds
– blurred boundary between self and surroundings
– feeling of detachment, one part of self passively 
observes the other part experiencing psychedelic 
illusions
■ Dizziness
■ Weakness
■ Nausea
■ LSD results in signs of CNS hyperactivity (dilated 
pupils, raised BP, pulse and body temperature, tremor, 
gooseflesh, nausea, hyper-reflexia and tremor). 
In addition, it can cause dizziness, weakness, 
drowsiness, paraesthesia and emotional lability.
■ Psilocybin can result in agitation, panic attacks, 
psychosis and ataxia.
■ Phencyclidine use is very uncommon. The effects may 
mimic alcohol intoxication, i.e. euphoria, disorientation, 
ataxia, slurred speech, nystagmus, numb extremities, 
hostile and bizarre behaviour, signs of CNS hyperactivity 
(increased heart rate and blood pressure, sweating, 
fever, convulsions), respiratory depression and coma.
■ Overdose from hallucinogens is rare. Animal studies 
have found that overdose can result in death via 
respiratory failure and hyperthermia.
Long-term or chronic effects
■ Flashbacks (similar to the drug effect, some time after 
last use) may persist for years after use depending on 
the number and magnitude of doses the person has 
taken over time. Flashbacks can be precipitated by 
cannabis use, anxiety and fatigue – they are most 
commonly associated with LSD and PCP.
■ PCP can result in personality changes, chronic 
psychosis, and persistent difficulties with memory, 
thinking and speech.
Dependence and withdrawal 
These drugs are not usually associated with dependence 
arising from long term, high-level use. 
There is no evidence of a withdrawal syndrome from 
hallucinogens even after abrupt cessation or substantial 
reduction in their use.
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9.8 Solvents (inhalants, volatile 
substances)
Solvents are also known as “inhalants” or “volatile 
substances”, and are products that vaporise in the air, 
causing a “high” feeling when the fumes are inhaled. 
The product is inhaled through the nose or mouth. It is 
often sprayed into a plastic bag or soaked onto a cloth or 
sleeve and then inhaled. It can also be inhaled directly 
from the container or a cool drink bottle. 
This group includes gases (e.g. nitrous oxide) and highly 
volatile compounds or mixtures of compounds (petrol, 
paint—“chroming”, glues, aerosol propellants, and paint 
thinners).
9.8.1 Assessment and quantification
As with other substances, record the frequency, quantity, 
date and time of last use. 
However, quantification of solvent use is extremely 
difficult. Record the type of solvent used and how many 
times it is inhaled in a session. 
9.8.2 Indications and guidelines
Managing solvent intoxication  
If a person is inhaling solvents, do not frighten or startle 
them. 
Approach in a very calm manner. Sudden movements 
(e.g. running) by the solvent-affected person can cause 
severe cardiac arrhythmia. 
Remove the inhalant and make sure the person gets 
plenty of fresh air.
If there are significant problems with memory or 
concentration, arrange for a neuropsychiatric test. It is 
acknowledged that such a test cannot always be accessed.
Effects of solvents 
While individual components of solvents can differ in 
their effects, their overall action is the depression of the 
CNS. Onset of action is rapid and the CNS impairment 
generally clears within a few hours of inhalation. 
However, if high doses are inhaled they can result in 
coma and death. 
Solvent intoxication resembles alcohol intoxication. Initial 
exhilaration and euphoria is followed by: 
■ slurred speech
■ ataxia 
■ drowsiness
■ dizziness
■ increased salivation
■ nausea
■ vomiting
■ confusion
■ disorientation
■ perceptual disorders
■ hallucinations 
■ delusions (can result in harm to self, others, property)
■ respiratory depression
■ cardiac arrhythmia
■ lead poisoning (from leaded petrol)
■ convulsions (high doses).
Overdose is rare. Toxicity varies greatly, depending on the 
substance. Generally, signs are cardiac arrhythmia, hypoxia, 
and neurological impairment. 
Withdrawal 
Withdrawal syndrome can occur in some cases, but it is 
generally mild. Symptoms include:
■ anxiety 
■ depression 
■ headache
■ nausea
■ dizziness
■ drowsiness
■ chills
■ abdominal pains 
■ muscular cramps.
Sometimes, confusion and hallucinations can occur after 
chronic solvent use. 
 
NSW HEALTH  Clinical guidelines for nursing and midwifery practice in NSW   PAGE 61
9.9 Ketamine
Ketamine is commonly called K, or Special K. Ketamine 
Hydrochloride, a derivative of phencyclidine (PCP), is a 
dissociative anaesthetic that has stimulant properties 
when taken in low doses. The effects appear subjective 
depending on individual characteristics of the user and 
the setting in which it is used.
Ketamine is a drug with multiple mechanisms of action, 
but the degree to which each contributes to the different 
effects experienced through the use of ketamine is not 
clear (White & Ryan 1996). Ketamine is used mainly for 
its euphoric effect.
Ketamine is commonly swallowed, snorted, smoked or 
injected.
9.9.1 Assessment and quantification
Quantification of illicit drugs can be difficult and the 
actual dose is always unknown. Noting the following may 
be helpful:
■ the amount the patient states he or she has taken
■ frequency of ketamine use (daily, weekly, binges)
■ duration of use
■ date and time of last use
■ route of administration
■ other drugs the patient may have used in combination 
with ketamine.
9.9.2 Onset and duration of effect
Peak effects depend on the route of administration and 
occur from 30 seconds (IV) to 20 minutes (oral) after 
usage. Duration of effect is typically 1–3 hours. The half-
life is three hours (White et al. 2002).
9.9.3 Indications and guidelines
Effects of ketamine 
Short term
Short-term effects at low doses can produce a state 
resembling alcohol intoxication, with:
■ ataxia
■ euphoria
■ slurred speech
■ nystagmus
■ numbness of the extremities
■ cardiovascular and respiratory stimulation.
Higher doses
At higher doses the predominant acute effects include:
■ sweating
■ drowsiness
■ hypersalivation
■ fever
■ myoclonus
■ blurred vision
■ apathy
■ dissociative ‘out of body’ sensations (flying or floating 
—detachment from the immediate environment)
■ muscle rigidity
■ reduced response to pain
■ risk of respiratory collapse or failure
■ feelings of aggression
■ hostile and bizarre behaviour
■ stimulation
■ disorganised thoughts
■ temporary paralysis
■ hallucinations
■ euphoria
■ seizures
■ confusion and disorientation
■ coma.
Longer term effects
■ weight loss
■ loss of appetite
■ flashbacks
■ possible memory, attention and vision impairment
■ possible psychological dependence
■ possible development of tolerance to some 
behavioural and toxic effects.
Physical dependence can occur (Shapiro 1992, p.7).
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Ketamine overdose 
Possible symptoms of ketamine overdose are:
■ respiratory depression may occur where there has 
been rapid intravenous administration, but can occur 
with slower administration
■ hyperthermia
■ seizures may occur in people with known seizure 
disorders (literature reports that ketamine may induce 
or terminate seizures).
Managing ketamine intoxication 
See Chapter 6, Managing Intoxication.
Ketamine withdrawal 
Abrupt withdrawal can occur after cessation of long-term 
daily use (White et al 2002).
Symptoms
Symptoms of withdrawal are:
■ fear
■ tremors
■ facial twitches
■ craving.
Animal studies show seizures, irritability and weight loss 
during ketamine withdrawal.
Monitoring
There is no validated tool for recording ketamine 
withdrawal symptoms.
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9.10 Gamma hydroxybutyrate (GHB)
Gamma hydroxybutyrate (GHB) was originally developed 
as an intravenous anaesthetic induction agent in 1964, 
however, it was found to cause unacceptably high levels 
of vomiting and tonic—clonic seizures. For the last two 
decades it has been used in a variety of clinical and 
recreational settings such as:
■ a supplement for body builders
■ a sleep agent
■ a detoxification agent (alcohol and opioids)
■ a party drug.
It is a CNS depressant with similar action to benzo-
diazepines and its effects are known to be highly dose 
dependent. It is usually used in the form of liquid, 
capsules, powder or crystals. It is colourless, odourless, 
with a slightly salty, acidic taste. GHB is commonly 
swallowed as a liquid, diluted in orange juice or some 
other strongly flavoured drink.
Polydrug use is common. Drugs may interact thereby 
increasing the effects of each other with an increased 
potential for toxicity and overdose e.g. GHB and heroin, 
GHB and alcohol, GHB and other CNS depressants.
Street names include fantasy, grievous bodily harm, GHB, 
liquid E, liquid ecstasy and liquid X.
9.10.1 Assessment and quantification
Quantification of illicit drugs can be difficult and the 
actual dose is always unknown. Noting the following may 
be helpful:
■ the amount the patient states he or she has taken.
■ frequency of GHB use (daily, weekly, binges)
■ duration of use
■ date and time of last use
■ route of administration
■ other drugs the patient may have used in combination 
with GHB.
9.10.2 Onset and duration of acute effects
GHB has a rapid onset of action (<15 minutes) with peak 
effects after 60 minutes and a total duration of action of 
2–4 hours. 
9.10.3 Indications and guidelines
Effects of GHB 
Short-term effects of low doses:
■ euphoria
■ relaxation and tranquility
■ drowsiness
■ dizziness
■ increased sociability
■ decreased inhibition
■ enhanced sense of touch
■ nausea
■ increased confidence
■ tendency to verbalise
■ blurred vision
■ sweating
■ hot / cold flushes.
Short-term effects of high doses
■ rapid onset intense drowsiness
■ ataxia
■ aggression if stimulated despite near respiratory apnoea
■ impaired movement and speech
■ uncontrollable twitching
■ disorientation / confusion
■ agitation
■ nausea and vomiting
■ nystagmus
■ hallucinations
■ muscle stiffness
■ seizures (tonic-clonic)
■ coma of short duration
■ respiratory collapse / arrest
■ death.
GHB overdose 
Concurrent use of alcohol or other CNS depressants is 
common in GHB overdose. Patients typically regain 
consciousness spontaneously within five hours of ingestion. 
GHB overdose should be considered in any case of 
unexplained sudden coma.
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Symptoms
■ decreased level of consciousness / coma
■ acute delirium
■ severe respiratory depression
■ hypothermia
■ respiratory acidosis
■ vomiting
■ hypotension
■ bradycardia.
Nursing management of GHB intoxication 
See Chapter 6, Managing Intoxication.
Medical management of GHB overdose 
Atropine may be used for persistent bradycardia. (Li et al. 
1998)
Neostigmine may be considered as a reversal agent. (Li et 
al. 1998
One study of a small sample of cases reported reversal 
with the administration of a low dose of physostigmine. 
(Caldicott & Kuhn 2001)
GHB withdrawal
GHB use should be suspected in particular groups such as 
clubbers and body builders who present with signs 
compatible with alcohol intoxication (such as nystagmus, 
ataxia, nausea, nausea, vomiting, bradycardia and 
hypotension), but record a breath alcohol level of zero.
Withdrawal presents as rapid onset, prolonged alcohol 
withdrawal picture, with less autonomic arousal and risk 
of seizures, but marked confusion, delirium and 
hallucinations, waxing and waning over a two week 
period. Management may require the use of both short 
and long acting benzodiazepines. Additional sedation 
with propofol may be required in some patients.
Monitoring
There is no validated tool for recording GHB withdrawal 
symptoms.
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9.11 Anabolic androgenic steroids (AAS)
Anabolic androgenic steroids are synthetically modified 
derivatives of testosterone available in oral or parenteral 
form. Users of anabolic steroids may not consider 
themselves as illicit drug users, and often have tertiary 
qualifications, are in well paid jobs, in stable relationships 
and are generally older than other illicit drug users. Many 
steroid users are health conscious, some to the point of 
obsession, and use of other illicit drugs is low. However, 
some groups may also use psychostimulants.
Anabolic substances are those that have the ability to 
synthesise body tissue and increase muscle mass and/or 
strength. Androgenic substances promote the 
development of male sexual characteristics.
9.11.1 Assessment and quantification
Steroid use may include multiple steroid use. Whether the 
person has just commenced using steroids or is 
recommencing, ask: 
■ type of AAS—number and type taken simultaneously
■ beliefs about use
■ dose
■ time of last dose
■ administration regime (e.g. tablets or injecting—ask 
size of needle)
■ pattern and duration of use (e.g. cycling)
■ periods of abstinence or “spells”
■ wanted effects (reason for using)
■ adverse effects
■ risk factors (e.g. unsafe injecting techniques such as 
sharing of steroid solution and injecting equipment, 
skin hygiene, polydrug use such as multiple AAS and/
or other drugs).
9.11.2 Indications and guidelines
Indicators of risk  
Risks may increase with the type of steroid used, dose, 
duration of use, route of administration, and the number 
and types of steroids and other drugs used simultaneously. 
The physical and psychological status of person is also 
influential.
There are a number of direct risks associated with the use 
of anabolic steroids. These include:
■ the range of physiological responses to abnormal 
hormone levels
■ the risks related to the route of administration (e.g. 
exposure to blood-borne viruses, and bacterial infections 
resulting in abscesses at the injection site, cellulitis 
and endocarditis due to unsafe injecting practices)
■ unsafe intramuscular injection techniques
■ problems arising from using supplies for veterinary 
use only and the unknown effects on the human 
male or female body
■ unreliable labelling and accuracy, purity, dose, 
ingredients and sterility of the drug
■ not checking drug expiry dates
■ combining anabolic steroids with other drugs (e.g. 
psychostimulants, diuretics or other performance-
enhancing drugs)
■ not practising safe sex (condoms).
Adverse effects of AASs  
Signs and symptoms of AASs adverse effects may include:
■ mood swings
■ violent behaviour
■ rage
■ depression and suicidal ideation
■ lethargy
■ decreased appetite
■ weight loss
■ decrease in physical strength
■ decrease in libido.
Some people who use steroids may have damage to 
testosterone production and may need hormone 
replacement therapy (Taylor 1999).
Withdrawal 
Generally, physical dependence does not appear to occur 
with steroid use.
Use with other drugs 
The concomitant use of steroids with other drugs is not 
recommended. These are examples of AAS polydrug 
interactions.
Stimulants
Some effects are similar to those caused by steroids, 
although physiological processes are different. When 
combined there may be:
Anabolic androgenic steroids (AAS)
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■ increased heart rate
■ increased blood pressure
■ depression.
The following are dangerous and can be fatal.
Cocaine
Effects are similar to those of amphetamines (see Table 9.11, 
Chapter 9, Psychostimulants) although for a shorter period 
of time. When combined with steroids, there may be:
■ increased heart rate, blood pressure and body 
temperature
■ euphoria.
When used together, steroids and cocaine can:
■ mask pain
■ produce hypertension, myocardial infarct and CVA
■ provoke feelings of aggressiveness and 
competitiveness
■ increase libido.
Psychological depression may occur when ceasing 
combined use of cocaine with steroids.
CNS depressant drugs 
For example, benzodiazepines, opioids, alcohol.
Use of steroids with diuretics can reduce responsiveness 
to pain that can cause athletes to rupture muscles and 
damage the skeletal system.
Diuretics
Use of steroids with diuretics can:
■ alter the sodium/potassium balance in the body. This 
may cause, exhaustion, kidney damage, muscle 
weakness, cardiac arrest and death.
■ increase sodium levels and cause fluid retention.
Nolvadex 
An anti-oestrogen drug that is used concurrently with 
AAS to prevent the effects of oestrogen metabolites, 
which result from steroids being aromatised. It may not 
be reliably effective in preventing gynaecomastia because 
there may be a number of physiological mechanisms that 
cause this disorder. Women using Nolvadex with steroids 
can experience menopausal symptoms.
Clonidine
If used in combination with AAS, there is an increased 
risk of kidney and liver disease and impotence.
Insulin
Does not assist in an increase in muscle mass and 
definition. There have been reports of several insulin-
related deaths in Australia and other parts of the world 
due to the ill informed belief that insulin, when used in 
combination with AAS, will increase muscle mass and 
definition (Queensland Department of Health 1997).
Signs and symptoms of steroid use 
People use steroids for many reasons, such as:
■ pursuit of body excellence
■ improved athletic performance
■ capacity to train at high levels—high intensity 
workouts with rapid recovery, diminished fatigue
■ increased strength
■ lean muscle mass
■ heightened libido
■ greater self confidence
■ a sense of well being
■ sexual arousal
■ social acceptability amongst peers.
(Hulse, Basso & Wodak 2002; NSW Health 2002; Henry-
Edwards & Ali 1999)
Maternal and neonatal care 
Steroids can be teratogenic and masculinise female 
foetuses. Women should be advised not to use before, 
during or after pregnancy or whilst breastfeeding.
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There is a range of pharmacological therapies that are 
effective in the treatment of alcohol, opioid and nicotine 
dependence in Australia. Evidence-based pharmaco-
therapies are yet to be developed for psychostimulant 
dependence.
All nurses, midwives, medical officers and allied health 
professionals need to know about these treatments, the 
rationale and benefits of use.
While some people can achieve abstinence without the 
use of medication, others require prescribed medication 
for weeks, months or years.
Longer-term prescribing of specific medications in this 
domain is known as ‘replacement pharmacotherapy’ (e.g. 
methadone for opioid dependence, nicotine patches for 
nicotine dependence). Pharmacotherapy requires 
extensive medical and psychosocial assessment, 
supervision, monitoring and regular review (at least three 
monthly for stable clients, more frequently for those at 
risk), and should be part of a broader program of general 
health care (including dental), counselling, management 
of comorbid conditions and social support. It may or may 
not be a treatment of first choice for a person presenting 
to a GP or drug and alcohol specialist service for the first 
time, and where other options have not been explored.
This section outlines pharmacotherapies for opioid 
dependence and alcohol dependence.
10.1 Opioid pharmacotherapies
Opioid maintenance pharmacotherapy (sometimes 
referred to as “substitution therapy”) is very effective for 
a significant number of people who are dependent on 
opioids such as heroin.
10.1.1 Methadone 
Methadone is an agonist and has been the ‘gold 
standard’ pharmacotherapy for opioid dependence for 
over 30 years. It is very cost effective for clients, service 
providers and government. 
The use of methadone maintenance has a strong 
evidence base particularly in areas of reducing criminal 
activity and illicit opioid use, thus reducing the cost to 
society and improving health and well being of 
individuals. Methadone is one of the most researched 
treatment modalities for dependence, and an overall 
assessment of its effectiveness can be made with more 
confidence than for other treatments.
Methadone is more effective at higher daily doses (at 
least 60mgs) as a maintenance therapy. It is a synthetic 
opioid with a long half-life, e.g. longer acting than 
heroin. It is active orally as syrup, can be administered 
once a day under medical or nursing supervision at a 
clinic, or dispensed from a specified community pharmacy 
or hospital.
There are criteria for admission into methadone 
maintenance programs. A specialist doctor or GP 
prescribes methadone, with the client being registered 
with the local relevant authority such as the health 
department.
Methadone should be used as part of a program that 
includes treatment for a comorbid psychiatric disorder, 
and where counselling for personal problems is available.
Caution needs to be observed regarding patients 
receiving high doses if there is concurrent alcohol or 
benzodiazepine dependence as there is a risk of 
respiratory depression.
The incidence of injecting and using additional opioids 
such as heroin while on methadone drops significantly.
Should a lapse to opioid use occur, high doses of 
methadone blunt the euphoric effects of illicit opioids 
therefore there is less reinforcement to continue illicit 
opioid use.
Poor outcomes have been demonstrated in patients with 
antisocial personality disorder, poor social support, 
polydrug dependence, and genetic risk of substance 
dependence (Young et al. 2002, p. 91).
SECTION 10
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Pain relief
If a person is being prescribed methadone as a 
maintenance pharmacotherapy for opioid dependence, 
even at high doses, they will require additional opioids 
over and above their daily methadone dose for effective 
pain relief due to tolerance. Accident and emergency and 
other nursing and medical staff need to know that a 
person is taking methadone so that effective pain relief 
can be offered.
Refer to NSW Health Policy Directive PD 2006_ 049. 
Opioid-dependent Persons Admitted to Hospitals in NSW 
– Management.
Safety
There is a risk of overdose if additional opioids are taken 
with methadone. Dose tolerance reduces with abstinence, 
so the person needs to be reassessed if they have not had 
methadone for more than three days. Methadone has no 
severe long-term effects on health, however, it is a drug of 
dependence and expert advice should be sought if there 
is abrupt cessation of use. Most patients can remain in 
treatment over a long term with no ill effects on health.
Side effects of methadone
Short term
Related to the central nervous system depressant 
properties of opioids:
■ constipation
■ nausea/vomiting
■ drop in body temperature
■ bradycardia, palpitations
■ hypotension.
Long term
■ weight gain
■ tooth decay due to decreased oral secretions.
Contraindications
■ kidney disease
■ liver disease.
For further information, see Appendix 7: Drug 
interactions with Methadone.
10.1.2 Buprenorphine
Buprenorphine is a partial opioid agonist—an opioid 
analgesic with both agonist and antagonist properties. 
Buprenorphine is as effective as methadone for people 
with moderate levels of dependence, and possibly for those 
with higher levels (Hulse et al. 2002, p. 91). However, 
retention on buprenorphine appears to be less than that 
achieved with methadone. Patient selection is important.
Buprenorphine is available in two forms: buprenorphine 
(Subutex) and buprenorphine-naloxone (Suboxone). Both 
forms are usually administered sublingually (usually takes 
5 minutes to dissolve). The tablet(s) can be used whole or 
in crushed form, as this does not affect sublingual 
absorption directly. The drug reaches its peak effect after 
about 3 hours.
It is easier to taper buprenorphine than methadone, and 
as a partial agonist is safer in overdose. It results in less 
respiratory depression than full agonists, such as methadone.
A wider safety margin and strong receptor binding 
leading to a long half-life make alternate day dosing a 
convenient option for many patients. 
Buprenorphine is cost effective and has a relatively low 
likelihood of being sold on the street as it can precipitate 
withdrawal in opioid-dependent people. The combination 
product has been produced to reduce street acceptability 
further as the product will induce severe withdrawal if 
injected due to the presence of naloxone.
It has been found to be highly effective, thus offering a 
greater choice for clients in the context of high quality, 
well supervised and medically supervised services.
As a partial agonist it induces lower-level physical 
dependence than methadone so cessation is more 
comfortable. (Hulse et al. 2002, pp. 91–92)
Pain relief
Standard doses of opioid analgesia are not likely to be 
effective in any patient who has used buprenorphine 
within the 3–4 days prior to requiring such analgesics. 
Advice should be sought from a Medical Officer skilled in 
drug and alcohol or D&A nurse practitioner in these 
instances. Accident and emergency and other nursing and 
medical staff need to know if a person is taking bupre-
norphine so that effective pain relief can be provided by 
using non-opioid analgesics, local anaesthetic approaches 
or higher dose opioid prescriptions in these situations.
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Safety
Buprenorphine is relatively safe; there have been no 
deaths in Australia attributed to buprenorphine alone.
Side effects of buprenorphine
Some side effects have been reported, however, these are 
relatively mild. They include:
■ headache
■ sedation
■ nausea
■ constipation
■ anxiety
■ dizziness
■ itching.
10.1.3 Naltrexone
Naltrexone is an opioid antagonist registered for use in 
relapse prevention in Australia. As an antagonist, 
naltrexone blocks both the euphoric and analgesic effects 
of opioids. It is long acting, with effects lasting between 
24 and 72 hours.
Research into the effectiveness of long-term naltrexone 
pharmacotherapy for opioid abstinence maintenance 
shows that there is a high drop-out rate from treatment. 
This therapy may be selected for a person who is highly 
motivated, abstinent and psychologically stable, and not 
likely to cease naltrexone and relapse into opioid use, 
thus running the risk of overdose due to reduced opioid 
tolerance (Gowing et al. 2001; Young et al. 2002).
As a maintenance pharmacotherapy treatment for opioid 
dependence, naltrexone is prescribed for daily use for up 
to two years to help prevent relapse to opioid use, and is 
administered orally.
It should always be used in conjunction with counselling 
and support and access to other psychotherapy. It has 
also been used in rapid detoxification (see below). There 
are particular issues for nurses in managing withdrawal 
from opioids precipitated by naltrexone when this drug 
has been self-administered by opioid users.
Safety
There is a high risk of death from opioid overdose if the 
person takes opioids after ceasing naltrexone due to 
reduced tolerance to opioids.
Use of naltrexone while still opioid-dependent will bring 
on severe withdrawal symptoms. Patients must have 
completed detoxification prior to using naltrexone 
(Clinical Opiate Withdrawal Scale score is less than or 
equal to 5), unless undergoing rigorously supervised rapid 
opioid detoxification (see below). 
As naltrexone use can be associated with psychological 
depression, medical staff should be informed of any history 
of depression. A referral to a psychologist or psychiatrist 
may be required. Naltrexone is not the pharmacotherapy 
of choice for patients who have a pre-existing depression.
Pain relief
Opioid analgesia is not likely to be effective in any patient 
who has used naltrexone within the previous 7 days. In 
these instances, advice should be sought from a Medical 
Officer skilled in drug and alcohol or a D&A nurse 
practitioner. Accident and emergency and other nursing 
and medical staff need to know if a person is taking 
naltrexone so that effective pain relief can be provided by 
using non-opioid analgesics in these situations.
Side effects of Naltrexone
Naltrexone is generally well tolerated. Some of the side effects 
may be due to residual withdrawal symptoms associated 
with heroin or other opioid dependence. If depression 
occurs as a side effect of Naltrexone, an alternative pharma-
cotherapy is often considered. Side effects may include:
■ depression
■ sleep disturbances
■ headaches
■ loss of energy
■ nausea and vomiting
■ abdominal pain
■ constipation
■ loss of appetite
■ anxiety.
Withdrawal from naltrexone
No withdrawal syndrome occurs when naltrexone 
treatment stops.
Rapid opioid detoxification (ROD)
This form of detoxification is known by a number of 
names, including “ultra-rapid detoxification”, 
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PAGE 70  NSW HEALTH  Clinical guidelines for nursing and midwifery practice in NSW 
“accelerated detoxification”, “sedated detoxification” 
and “detoxification under anaesthetic”.
Rapid opioid detoxification is the process of accelerating 
acute withdrawal by administration of an opioid 
antagonist, while providing symptomatic relief to enable 
patients to tolerate the procedure. The detoxification is 
followed with daily naltrexone treatment.
ROD has been trialed at a number of sites in Australia. 
Some significant risks have been associated with sedation 
during ROD, including death as a result of aspiration or 
respiratory depression.
Naltrexone is not registered in Australia for the indication  
of accelerating detoxification. (NSW Health 2005)
For treatment guidelines for the management of opioid 
withdrawal inadvertently precipitated by naltrexone, see 
the relevant section in Chapter 9, Opioids.
For further information on methadone and buprenorphine 
treatment, refer to: NSW Opioid Treatment Program: 
Clinical Guidelines for methadone and buprenorphine 
treatment. Doc No. GL2006_019. www.health.nsw.gov.
au/policies/gl/2006/GL2006_019.html
10.1.4 Pharmacotherapies for dependence and 
maternal/neonatal care
For information regarding pharmacotherapies for 
dependence and maternal/neonatal care, refer to the 
National clinical guidelines for the management of drug 
use during pregnancy, birth and the early development 
years of the newborn. (March 2006)
http://www.health.nsw.gov.au/pubs/2006/ncg_druguse.
html
10.2 Alcohol pharmacotherapies
Pharmacotherapy for alcohol dependence is more 
effective when provided in conjunction with other 
therapies (e.g. cognitive behavioural therapy, narrative 
therapy, counselling, other supportive programs).
10.2.1 Acamprosate (Campral)
Acamprosate is a pharmacotherapy used to prevent 
alcohol relapse post-withdrawal. The mechanisms of 
action are yet to be clearly identified. It assists in the 
reduction of cravings for alcohol, where the person is 
seeking to abstain or reduce their consumption.
Acamprosate should be initiated as soon as possible 
following withdrawal. Daily dose is calculated according to 
body weight with average daily dose between 1.3–2 grams 
per day for a person weighing greater than 60 kgs. 
Compliance can be an issue as dosage is usually two 
tablets x three times/day (333mg in each tablet). The 
recommended length of treatment is at least one year.
Acamprosate does not interact with alcohol, and does 
not have hypnotic, anxiolitic or antidepressant effects.
It is considered safe in the absence of liver disease or 
renal insufficiency.
Acamprosate can be given concomitantly with disulfiram, 
and interactions with other drugs have not been noted.
Acamprosate has been shown to be effective by increasing 
non-drinking days and nearly doubling abstinence rates 
in study populations. It is not yet known which particular 
groups will particularly benefit from this therapy.
Safety
Acamprosate is well-tolerated—no adverse effect if alcohol 
is consumed. Acute overdose with acamprosate is usually 
benign with diarrhoea being the major symptom identified.
Side effects
These are usually mild and transient.
■ diarrhoea
■ nausea
■ vomiting
■ dyspepsia
■ itching skin rash
■ changes in libido.
Contraindications
■ allergy
■ severe liver disease
■ pregnancy
■ breastfeeding
■ kidney disease (renal insufficiency where serum 
creating is more than 120 micromol/L).
Withdrawal
No withdrawal syndrome occurs on cessation of 
acamprosate.
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10.2.2 Naltrexone
Naltrexone suppresses the priming effect of alcohol (blunts 
the euphoric effects of alcohol and reduces the positive 
reinforcement of alcohol use) and can assist in achieving 
goals of reduction in consumption and/or abstinence.
Monitoring the liver profile is recommended during the 
course of naltrexone treatment, which is usually 3–6 months.
A dose of 50mg daily has shown positive outcomes with 
relapse rates, craving and number of non-drinking days.
Naltrexone is effective, safe and well tolerated. Naltrexone 
is best commenced following alcohol withdrawal, 
however, there are no contraindications in commencing 
naltrexone while the person is still drinking. In this 
situation efficacy in assisting someone to reduce or cease 
his or her use is not known.
Safety
Has the capacity to cause hepatocellular injury when 
given in excessive doses. Caution is required if 
transaminases are above three times the normal range.
Side effects of naltrexone
Side effects are generally dose-dependant and include:
■ gastrointestinal tract (nausea, vomiting)
■ headache
■ dizziness
■ nervousness
■ fatigue
■ anxiety
■ depression.
Contraindications
The principal contraindication for naltrexone use is when 
there is coexisting use and dependence on opioids as a 
withdrawal episode may be induced. Other contra-
indications include:
■ oral hypoglycaemic medication
■ acute hepatitis or liver failure
■ concomitant therapy with thioridazine
■ opioid analgesic use.
Caution should be exercised when combining naltrexone 
with other drugs associated with potential liver toxicity.
10.2.3 Disulfiram (Antabuse)
The goal in prescribing disulfiram is to provide a powerful 
disincentive to drink. It is usually prescribed for 3–6 months 
following withdrawal and is provided in combination 
with monitoring, support, and psychosocial interventions.
It is dispensed in 200mg dispersible tablets, with the 
usual dose being 200mg daily. The usual recommended 
length of treatment is six weeks to six months.
Disulfiram inhibits the ALDH in the liver, and if the person 
drinks alcohol, causes an accumulation of acetaldehyde. 
Within 15 minutes of drinking the person may experience 
the following:
■ flushing
■ feeling heat and sweating
■ nausea
■ vomiting
■ palpitations and rapid pulse
■ headache
■ difficulty breathing
■ blood pressure may rise steeply initially followed by a 
drop in blood pressure resulting in pallor, weakness, 
dizziness, nausea and vomiting.
Ideally it is commenced post-withdrawal or at least 48 
hours after the last drink (with evidence of zero blood 
alcohol level). Alcohol should not be consumed for one 
week following the last dose. 
Indications for use are for a person who is alcohol 
dependent, wishes to achieve immediate abstinence, and 
who clearly understands the nature of the drug and its 
effects. To be successful this therapy requires a method 
of supervision of daily doses.
Safety
Liver function tests need to be done fortnightly for the 
first two months, then monthly. Patients with major co-
existing psychiatric disorders such as bipolar, depression 
and psychotic illness need close supervision as disulfiram 
may worsen these disorders by affecting the brain 
dopamine systems. However 200mg daily is generally 
considered safe for these patients.
Patients commencing on disulfiram should be advised of 
the following:
■ Do not consume or use any alcohol or alcohol 
Pharmacotherapies for dependence
PAGE 72  NSW HEALTH  Clinical guidelines for nursing and midwifery practice in NSW 
containing products of food including medicines, 
cough mixtures, marinated meat, wine trifle and food 
essences.
■ After-shave, mouthwashes, alcohol rubs and 
perfumes are usually safe unless swallowed.
■ Always read the labels on all food and medicines to 
ensure they don’t contain alcohol.
Side effects
Short-term effects, which may occur in the first two 
weeks, include:
■ initial drowsiness
■ fatigue
■ metallic taste
■ rash/acne
■ headache
■ sexual dysfunction
■ stomach upset.
These side effects usually disappear by themselves. 
Other side effects or adverse reactions include:
■ peripheral neuropathy
■ changes in vision, eye tenderness/pain
■ mood changes
■ yellowing of the skin/eyes
■ abdominal pain.
Contraindications
The drug is teratogenic and contraindicated in pregnancy.
Aversion reaction may cause tachycardia and hypertension, 
and precipitate a coronary event or serious arrhythmia.
Older patients need a cardiac history (an electrocardiogram) 
prior to commencing disulfiram.
Complications may result if the person has a history of:
■ coronary artery disease
■ history of arrhythmia
■ heart failure
■ severe liver disease (disulfiram can cause toxic 
hepatitis although this is rare).
Drug interactions
Disulfiram interacts with:
■ phenytoin
■ warfarin
■ diazepam
■ anti-tuberculous medication.
(Lopatko et al. 2002, pp. 192–193)
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Appendix 1. Glasgow Coma Scale
110.050
FOR MEDICAL RECORD STAFF ONLY
HOSP MRN:
SURNAME:
OTHER NAMES:
D.O.B: SEX: AMO:
GLASCOW COMA SCALE
NEUROLOGICAL CHART MRN BAR CODE G
L
A
S
C
O
W
C
O
M
A
S
C
A
L
E
N
E
U
R
O
L
O
G
I
C
A
L
C
H
A
R
T
1
1
0
.
0
5
0
Affix Addressograph Label
Frequency
Date/Sign
Date
Time
Eye
Opening
Spontaneously 4
To speech 3
To pain 2
None 1
Orientated 5
Confused 4
Inappropriate words 3
Incomprehensible sounds 2
None 1
Obeys commands 6
Localises 5
Withdraw from pain 4
Abnormal flexion 3
Extension 2
None 1
TOTAL SCORE
Best
Verbal
Response
Best
Motor
Response
Pupils Right Size
 Response
Left Size
 Response
Normal power
Mild weakness
Severe weakness
Spastic flexion
Extension
No response
Normal power
Mild weakness
Severe weakness
Extension
No response
COMMENTS:
Pupil Scale (mm)
NO WRITING
Recorded
Right  (R)
& Left (L)
separately
if there is a
difference
LEGEND:
Eyes clossed
Swelling
= C
Endotrachial
tube or
Tracheotomy
= T
Record beat
Arm response
Record size
in mm
+ brisk
S sluggish
– none
C eyes closed
O not testable
C
O
M
A
S
C
O
R
E
L
I
M
B
M
O
V
E
M
E
N
T
A
R
M
S
L
E
G
S
1 2 83 4 5 6 7
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Appendix 2. Clinical Institute Withdrawal Assessment for Alcohol (revised)  (CIWA-Ar)
Patient ..................................................  Date ......................................................  Time .................................................
Pulse or heart rate, taken for one minute: ..........................................................................................................................
Blood pressure: …...........…/…..........…  Rater’s initials ....................................
See following pages for key to scoring.
Nausea and vomiting (0–7)
Tremor (0–7)
Paroxysmal sweats (0–7)
Anxiety (0–7)
Agitation (0–7)
Tactile disturbances (0–7)
Auditory disturbances (0–7)
Visual disturbances (0–7)
Headaches, fullness in head (0–7)
Orientation and clouding of sensorium (0–4)
Total (maximum possible is 67)
Withdrawal severity: 
Mild = <10
Moderate = 10–20
Severe = >20
Nausea and vomiting
Ask “Do you feel sick to your stomach? Have you 
vomited?” and observe.
0 No nausea and no vomiting
1 Mild nausea with no vomiting
2
3
4  Intermittent nausea with dry heaves
5
6
7  Constant nausea, frequent dry heaves and vomiting
Tremor
Observe patient’s arms extended and fingers spread 
apart.
0  No tremor
1  Not visible, but can be felt fingertip to fingertip
2
3
4  Moderate, with patient’s arms extended
5
6
7  Severe, even with arms not extended
Paroxysmal sweats
0  No sweat visible
1  Barely perceptible sweating, palms moist
2
3
4  Beads of sweat obvious on forehead
5
6
7  Drenching sweats
Anxiety
Observe, and ask, “Do you feel nervous?”
0  No anxiety, at ease
1  Mildly anxious
2
3
4  Moderately anxious, or guarded, so anxiety is inferred
5
6
7  Equivalent to acute panic states as seen in severe   
 delirium or acute schizophrenic reactions
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Agitation
0  Normal activity
1  Somewhat more than normal activity
2
3
4  Moderately fidgety and restless
5
6
7  Paces back and forth during most of the interview, or 
 constantly thrashes about
Tactile disturbances
Ask “Have you any itching, pins and needles 
sensations, any burning, any numbness or do you 
feel bugs crawling on or under your skin?”
0  None
1  Very mild itching, pins and needles, burning or numbness
2  Mild itching, pins and needles, burning or numbness
3  Moderate itching, pins and needles, burning or numbness
4  Moderately severe hallucinations
5  Severe hallucinations
6  Extremely severe hallucinations
7  Continuous hallucinations
Auditory disturbances
Ask “Are you more aware of sounds around you? Are 
they harsh? Do they frighten you? Are you hearing 
anything that is disturbing to you? Are you hearing 
things you know are not there?”, and observe.
0  Not present
1  Very mild harshness or ability to frighten
2  Mild harshness or ability to frighten
3  Moderate harshness or ability to frighten
4  Moderately severe hallucinations
5  Severe hallucinations
6  Extremely severe hallucinations
7  Continuous hallucinations
Visual disturbances
Ask “Does the light appear to be too bright? Is its 
colour different? Does it hurt your eyes? Are you 
seeing anything that is disturbing to you? Are you 
seeing things you know are not there?”, and observe.
0  Not present
1  Very mild sensitivity
2  Mild sensitivity
3  Moderate sensitivity
4  Moderately severe hallucinations
5  Severe hallucinations
6  Extremely severe hallucinations
7  Continuous hallucinations
Headaches, fullness in head
Ask “Does your head feel different? Does it feel like 
there is a band around your head?” Do not rate for 
dizziness or lightheadedness. Otherwise, rate 
severity.
0  Not present
1  Very mild
2  Mild
3  Moderate
4  Moderately severe
5  Severe
6  Very severe
7  Extremely severe
Orientation and clouding of sensorium
Ask “What day is this? Where are you? Who am I?”
0  Orientated and can do serial additions
1  Cannot do serial additions or is uncertain about date
2  Disorientated for date by no more than 2 calendar days
3  Disorientated for date by more than 2 calendar days
4  Disorientated for place and/or person
From: Clinical institute withdrawal assessment for alcohol — 
revised. Sullivan J, Sykora M, Schneiderman J, et al. Assessment 
of alcohol withdrawal: the revised Clinical Institute withdrawal 
for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353–1357.
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Appendix 3. Alcohol withdrawal scale (AWS)
Patient ..................................................  Date ......................................................  Time .................................................
Pulse or heart rate, taken for one minute: ..........................................................................................................................
Blood pressure: …...........…/…..........…  Rater’s initials ....................................
See following pages for key to scoring.
Perspiration (0–4) 
Tremor (0–3)
Anxiety (0–4)
Agitation (0–4)
Axilla temperature (0–4)
Hallucinations (0–4)
Orientation (0–4) 
Total (maximum possible is 27)
Withdrawal severity: 
Mild = <4
Moderate = 5–14
Severe = >15
Perspiration
0 No abnormal sweating.
1 Moist skin.
2 Localised beads of sweat, e.g. on face, chest.
3 Whole body wet from perspiration.
4 Profuse maximal sweating—clothes, linen are wet.
Tremor
0 No tremor.
1 Slight tremor.
2 Constant slight tremor of upper extremities.
3 Constant marked tremor of extremities.
Anxiety
0 No apprehension or anxiety.
1 Slight apprehension.
2 Apprehension or understandable fear, e.g. of 
withdrawal symptoms.
3 Anxiety occasionally accentuated to a state of panic.
4 Constant panic-like anxiety.
Agitation
0 Rests normally during day, no signs of agitation.
1 Slight restlessness, cannot sit or lie still. Awake when 
others asleep.
2 Moves constantly, looks tense. Wants to get out of 
bed but obeys requests to stay in bed.
3 Constantly restless. Gets out of bed for no obvious 
reason.
4 Maximally restless, aggressive. Ignores requests to 
stay in bed.
Axilla temperature
0 Temperature of 37.0°C.
1 Temperature of 37.1°C.
2 Temperature of 37.6–38.0°C.
3 Temperature of 38.1–38.5°C.
4 Temperature above 38.5°C.
Hallucinations (sight, sound, taste or touch)
0 No evidence of hallucinations.
1 Distortions of real objects, aware that these are not 
real if this is pointed out.
2 Appearance of totally new objects or perceptions, 
aware that these are not real if this is pointed out.
3 Believes the hallucinations are real but still orientated 
in place and person.
4 Believes himself to be in a totally non existent environ-
ment, preoccupied, cannot be diverted or reassured.
Orientation
0 The patient is fully orientated in time, place and person
1 The patient is fully orientated in person but is not sure 
where he is or what time it is
2 Orientated in person but disorientated in time and 
place
3 Doubtful personal orientation, disorientated in time 
and place; there may be short periods of lucidity
4 Disorientated in time, place and person. No mean-
ingful contact can be obtained.
Adapted from NSW Dept of Health (2000).
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Appendix 4. Clinical Opiate Withdrawal Assessment Scale (COWS)
Clinical Opiate Withdrawal Scale
For each item, circle the number that best describes the patient’s signs or symptoms. Rate on just the apparent 
relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior to 
assessment, the increased pulse rate would not add to the score. 
  Patient’s name: .......................................................................................... Date and time:  ......................................................
  Reason for this assessment: ......................................................................................................................................................
Resting Pulse Rate: ______________ beats/minute
Measured after patient is sitting or lying for one minute.
0  pulse rate 80 or below
1  pulse rate 81–100
2  pulse rate 101–120
4  pulse rate greater than 120
GI Upset: Over last half-hour
0  no GI symptoms
1  stomach cramps
2  nausea or loose stool
3  vomiting or diarrhoea
5  multiple episodes of diarrhoea or vomiting
Sweating: Over past half-hour not accounted for by room 
temperature or patient activity.
0  no report of chills or flushing
1  subjective report of chills or flushing
2  flushed or observable moistness on face
3  sweat streaming down face
Tremor: Observation of outstretched hands
0  no tremor
1  tremor can be felt but not observed
2  slight tremor observable
4  gross tremor or muscle twitching
Restlessness: Observation during assessment
0  able to sit still
1  reports difficulty sitting still, but is able to do so
3  frequent shifting or extraneous movements of legs/arms
5  unable to sit still for more than a few seconds
Yawning: Observation during assessment
0  no yawning
1 yawning once or twice during assessment
2  yawning three or more times during assessment
4  yawning several times per minute
Pupil size
0  pupils pinned or normal size for room light
1  pupils possibly larger than normal for room light
2  pupils moderately dilated
5  pupils so dilated that only the rim of the iris is visible
Anxiety or irritability
0  none
1 patient reports increasing irritability or anxiousness
2  patient obviously irritable or anxious
4  patient so irritable or anxious that participation in the 
assessment is difficult
Bone or joint aches: If patient was having pain previously, 
only the additional component attributed to opiates 
withdrawal is scored
0 not present
1 mild diffuse discomfort
2 patient reports severe diffuse aching of joints/muscles
4 patient is rubbing joints or muscles and is unable to sit still 
because of discomfort
Gooseflesh skin:
0 skin is smooth
3 piloerection of skin can be felt or hairs standing up on arms
5 prominent piloerection
Runny nose or tearing: Not accounted for by cold 
symptoms or allergies
0 not present
1 nasal stuffiness or unusually moist eyes
2 nose running or tearing
4 nose constantly running or tears streaming down cheeks
Total score:......................................................................
The total score is the sum of all 11 items.
Initials of person completing
assessment: ......................................................................
Score: 5–12 = mild; 13–24 = moderate; 25–36 = moderately severe; more than 36 = severe withdrawal.
This version may be copied and used clinically.
From: Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35(2), 253–259. 
/ /             :
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Appendix 5. Cannabis Withdrawal Assessment Scale
Patient MRN label here
Cannabis Withdrawal Checklist
Date:
Time:
SCORES: 0 – not at all, 1 – mild, 2 – moderate, 3 – severe
SYMPTOM
Craving for marijuana
Decreased appetite
Sleep difficulty
Increased aggression
Increased anger
Irritability
Strange dreams
Restlessness
Chills
Feverish feeling
Stuffy nose
Nausea
Diarrhoea
Hot flashes
Dizziness
Sweating
Hiccups
Yawning
Headaches
Shakiness
Muscle spasms
Stomach pains
Fatigue
Depressed mood
Difficulty concentrating
Nervousness
Violent outbursts
TOTAL SCORE
Person completing 
assessment – INITIAL
           
Note: This is not a validated tool but serves as a useful chart for monitoring withdrawal. 
Taken from Budney, A. et al, Archives of General Psychiatry, Volume 58 (10) October 2001, 917–924. 
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Appendix 6. Street names of drugs
Approved name of drug Street name Price in NSW, 2004–5 *
Alcohol Grog, piss, booze, sauce
Amphetamines Speed, goey, whiz, uppers, oxblood, point, crystal, 
crystal meth, ice, shabu
1 weight gram $90–$500
Benzodiazepines Benzos, rowies, moggies, downers, sleepers, tummies, 
series, pills
Cannabis Marijuana, grass, pot, shit, ganja, mull, hash, durry, 
green, dope, cone
Leaf– Ounce (28 g) $150
Head – Ounce (28 g) $200
Hydroponic – (28 g) $250
Hash/resin- Deal (1g ) $50
Cocaine Snow, coke 1 gram $150–$300
Ecstasy E, eccies, XTC, fantasy, GBH, liquid ecstasy, good 
speed
1 tablet/capsule $30–$70
Heroin/ opioids Hammer, H, shit, smack, horse, harry, white, skag, ju 1 taste/cap (0.1–0.3 g) $50 
Full gram $200–$500
Ketamine Special K Varied across States: 
ACT – $65 
S.A. – $200
Lysergic acid diethylamide (LSD) Acid, blotter, trips, wangers, tabs, dots $10 to $25 per tab
Methylene Dioxyamphetamine 
(MDA)
Adam 1 tablet/capsule $30–$70
Methylene
Dioxymethamphetamine (MDMA)
Ecstasy, Utopia, E, XTC 1 tablet/capsule $30–$70
Phencyclidine (PCP) Angel dust
PMA Dr Death
Psilocybin Magic mushrooms, gold tops
Solvents Glue, tol, toluene, bute, nitrus, amyls, petrol, super, 
aerosol paint-chroming
* Adapted from the Illicit Drug Data Report. 2004–05 Australian Crime Commission
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Appendix 7. Drug interactions with methadone
The following table shows drug interactions with methadone. (Adapted from Department of Health, Welsh Office et al. 
1999).
Drug Degree of interaction Effect Mechanism
Alcohol Increased sedation Additive CNS depression
Barbiturates Moderate Reduced methadone levels, 
raised sedation
Raised hepatic metabolism, 
additive CNS depression
Benzodiazepines Enhanced sedative effect Additive CNS depression
Buprenorphine Antagonist effect Can only be used safely in low 
doses (20mg or less daily) 
methadone treatment
Carbamazepine Moderate Reduced methadone levels Raised hepatic metabolism,  
methadone may  need twice 
daily dosing regime
Chloral hydrate Increased sedation Additive CNS depression
Chlormethiazole Increased sedation Additive CNS depression
Cimetidine Moderate Possible increase in methadone 
levels
Inhibits hepatic enzymes involved 
in methadone metabolism
Cisapride
Domperidone
Metoclopramide
Morphine has an increased rate 
of onset of action and increased 
sedative effect when used with 
these drugs
Unknown
Cyclizine Severe Injection with opiates causing 
hallucinations reported
Unknown
Codeine Enhanced sedative effect Additive CNS depression
Desipramine Moderate Raised desipramine levels (x2) Unknown. Interaction not seen 
with other tricyclic anti-
depressants
Dextropropoxyphene Enhanced sedative effect Additive CNS depression
Disulfiram Avoid in combination with 
methadone formulations 
containing alcohol (check with 
manufacturers)
Very unpleasant reaction to 
alcohol which can be alarming
Inhibits alcohol metabolism 
allowing metabolites to build up
Erythromycin In theory, should interact but 
combination has not been studied
Increase in methadone levels Decreased methadone 
metabolism
Fluconazole In theory, same as  
ketoconazole
Fluoxetine Clinically important Raised methadone methadone 
levels but not as significant as for 
fluvoxamine
Decreased methadone 
metabolism
Grapefruit juice In theory, should interact and 
there have been several 
anecdotal reports
Raised methadone levels Decreased methadone 
metabolism
Indinavir Clinically important Raised methadone levels Decreased methadone 
metabolism
Ketoconazole Clinically important Raised methadone levels Decreased methadone 
metabolism
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Drug Degree of interaction Effect Mechanism
Monoamine oxidase 
inhibitors anti-
depressants including 
moclobamide and 
selegiline
Severe with pethidine although 
rare with methadone. 
Concurrent use should be 
avoided
CNS excitation: delirium, 
hyperpyrexia, convulsions or 
respiratory depression 
Unknown
Naltrexone Severe Reverses the effects of metha-
done in overdose (long-acting)
Opiate antagonist works by 
competing for opioid receptors
Naloxone Severe Reverses the effects of methadone 
in overdose (long-acting)
Opiate antagonist works by 
competing for opioid receptors
Nevirapine Clinically important Decreased methadone levels Increased methadone 
metabolism
Nifedipine Has been demonstrated in vitro 
only
Increased methadone levels Methadone increases the 
metabolism of nifedipine
Omeprazole To date, demonstrated in 
animals only
Increased methadone levels Possibly an effect upon metha-
done absorption from the  gut
Other selective 
seretonin in 
re-uptake inhibitors
Theoretical
Phenobarbitone Moderate Reduced methadone levels Raised hepatic metabolism (see 
carbamazepine)
Phenytoin Moderate Reduced methadone levels, 
withdrawal symptoms
Raised hepatic metabolism (see 
carbamazeine)
Rifabutin Occasionally clinically important Decreased methadone levels Increased methadone metabolism
Rifampicin Severe Reduced methadone levels, 
withdrawal symptoms
Increased metabolism
Ritonavir Clinically important May reduce or increase plasma 
methadone levels
Increased or reduced 
methadone metabolism
Tricyclic anti-
depressants, e.g. 
amitriptyline
Moderate Increased sedation Unknown
Urine acidifiers, e.g. 
ammonium chloride
Reduced methadone levels Raised urinary excretion
Zidovudine Possible raised levels of zidovudine Unknown
Zopiclone Increased sedation Additive CNS depression
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Q Alcohol use disorders identification test screening instrument (AUDIT)
Q Drug Quiz – ASSIST (Cannabis)
Q Drug Quiz – ASSIST (Psychostimulants)
Q Drug Quiz – ASSIST (Heroin)
Q Making changes
Q Minimising harm from alcohol or other drug use
Q Cocaine
Q Heroin
Q Cannabis (Marijuana)
Q Amphetamines (Speed)
Screening tools, handouts
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Alcohol use disorders identification test screening instrument (AUDIT)
Thank you for agreeing to take part in this brief survey about alcohol. Below are some questions about your experience of 
drinking alcohol during the past 12 months. Please be assured that information on your drinking will be treated as strictly 
confidential. Please circle your answer to each question. Please see below for examples of “standard drinks”.
 Light beer Ordinary Beer Wine Spirits Port/Sherry
 =  =  =  = 
 1 schooner 1 middie 1 glass 1 nip 1 glass
 425mls 285mls 100ml 30ml 60ml
 2.8% alcohol 4.5% alcohol 12.5% alcohol 42% alcohol 21% alcohol
1. HOW OFTEN DO YOU HAVE A DRINK CONTAINING ALCOHOL?
  Never Monthly or less 2–4 times a month 2–3 times a week 4 or more times a week
  (0)  (1) (2) (3) (4)
2. HOW MANY DRINKS CONTAINING ALCOHOL DO YOU HAVE ON ATYPICAL DAY WHEN YOU ARE DRINKING?
  1or2 3or4 5or6 7to9 10 or more
  (0) (1) (2) (3) (4)
3. HOW OFTEN DO YOU HAVE SIX OR MORE DRINKS ON ONE OCCASION?
  Never Less than monthly Monthly Weekly Daily or almost daily
  (0)  (1) (2) (3) (4)
4. HOW OFTEN DURING THE LAST YEAR HAVE YOU FOUND THAT YOU WERE NOT ABLE TO STOP DRINKING ONCE YOU 
HAD STARTED?
 Never Less than monthly Monthly Weekly Daily or almost daily
  (0)  (1) (2) (3) (4)
5.  HOW OFTEN DURING THE LAST YEAR HAVE YOU FAILED TO DO WHAT WAS NORMALLY EXPECTED FROM YOU 
BECAUSE OF DRINKING?
  Never Less than monthly Monthly Weekly Daily or almost daily
  (0) (1) (2) (3) (4)
6.  HOW OFTEN DURING THE LAST YEAR HAVE YOU NEEDED A FIRST DRINK IN THE MORNING TO GET YOURSELF GOING 
AFTER A HEAVY DRINKING SESSION?
  Never Less than monthly Monthly Weekly Daily or almost daily
  (0)  (1) (2) (3) (4)
7. HOW OFTEN DURING THE LAST YEAR HAVE YOU HAD A FEELING OF GUILT OR REMORSE AFTER DRINKING?
  Never Less than monthly Monthly Weekly Daily or almost daily
  (0)  (1) (2) (3)  (4)
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8.  HOW OFTEN DURING THE LAST YEAR HAVE YOU BEEN UNABLE TO REMEMBER WHAT HAPPENED THE NIGHT BEFORE 
BECAUSE YOU HAD BEEN DRINKING?
  Never Less than monthly Monthly Weekly Daily or almost daily
  (0)  (1) (2) (3)  (4)
9. HAVE YOU OR SOMEONE ELSE BEEN INJURED AS A RESULT OF YOUR DRINKING?
  No Yes, but not in the last year  Yes, during the last year
  (0) (2)  (4)
10. HAS A RELATIVE OR FRIEND OR A DOCTOR OR OTHER HEALTH WORKER, BEEN CONCERNED ABOUT YOUR DRINKING 
OR SUGGESTED YOU CUT DOWN?
  No Yes, but not in the last year  Yes, during the last year
  (0) (2)  (4)
Add up all the points you have circled and write the Total below.
TOTAL SCORE: ................................................................................................................................................................
What your score means...
If you scored 0–5 (women) 0–6 (men) then you are drinking at a “low risk” level. This means that if you continue to 
drink this amount in the long term there is only a minimal risk of harm and for some people the possibility of health 
benefits. No intervention is needed but feel free to read the handout Minimising harm from alcohol or other drug use.
If you scored 6–12 (women) 7–14 (men) then you are drinking at a “risky” level. This means that if you continue to 
drink this amount in the long term the risk of harm to your health is significantly increased. It is recommended that you 
read the handout “Minimising harm from alcohol or other drug use”. Please consider talking to a drug and alcohol 
counsellor to help you control, cut down or stop your drinking.
If you scored 13 or more (women) 15 or more (men) then you are drinking at a high-risk level. This means that if you 
continue to drink this amount there is a substantial risk of serious harm to your health in both the short and long term.  
It is recommended that you see a drug and alcohol counsellor, to help you control, cut down or stop your drinking. Please 
read the handout “Minimising harm from alcohol or other drug use”. If you are drinking 6 (women) or 8 (men) drinks or 
more nearly every day, then you are advised to seek medical advice before reducing your drinking, as stopping or 
significantly reducing your drinking suddenly, when drinking this amount can be dangerous.  
Phone  for further advice/support
Source: World Health Organisation 
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Drug Quiz — ASSIST (Cannabis)
Thank you for agreeing to take part in this brief survey about cannabis.  Below are some questions about your experience 
of using cannabis throughout your lifetime and in the past 3 months. Please be assured that information on your cannabis 
use will be treated as strictly confidential. We are only interested in helping you to keep safe and as well as possible.  
Please circle your answer to each question.
Question 1
1.  During your lifetime have you ever used cannabis? No (score 0)           Yes (score 1)
Questions 2 – 5 Never Once or 
twice
Monthly Weekly Daily or 
almost daily
2.  In the past 3 months, how often have you used cannabis? 0 1 2 3 4
3.  During the past 3 months, how often have you had a strong 
desire or urge to use cannabis?
0 1 2 3 4
4.  During the past 3 months, how often has your cannabis use led 
to health, social, legal or financial problems?
0 1 2 3 4
5.  During the past 3 months, how often have you failed to do what 
was normally expected of you because of your cannabis use?
0 1 2 3 4
Questions 6 – 8 No Never Yes in the past 
3 months
Yes but not in the 
past 3 months
6.  Has a friend or relative or anyone else ever expressed concern 
about your cannabis use?
0 2 1
7.  Have you ever tried and failed to control, cut down or stop 
using cannabis?
0 2 1
8.  Have you ever used any drug by injection? 0 2 1
Add up all the points you have scored from 1–8 then see what form of treatment is recommended for your score or level 
of problem. Total Score:
What your score means
If you scored 0–3 then no intervention is needed but feel free to read the cannabis handout.
If you scored 4–15 then it is recommended that you read the cannabis handout. Please consider talking to a drug and 
alcohol counsellor to help you control, cut down or stop your drug use.
If you scored 16–20 then it is recommended that you see a drug and alcohol counsellor to help you control, cut down or 
stop your drug use.  Please read the cannabis handout.  
If you scored 2 for question 8 then it is recommended that you see a drug and alcohol counsellor.  
Phone   for further advice/support
Source:  World Health Organisation
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Drug Quiz — ASSIST (Psychostimulants)
Thank you for agreeing to take part in this brief survey about psychostimulants (e.g. amphetamine and cocaine). Below are 
some questions about your experience of using psychostimulants throughout your lifetime and in the past 3 months.  
Please be assured that information on your psychostimulant use will be treated as strictly confidential.  We are only interested
in helping you to keep safe and as well as possible.  Please circle your answer to each question.
Question 1
1.  During your lifetime have you ever used psychostimulants? No (score 0)           Yes (score 1)
Questions 2 – 5 Never Once or 
twice
Monthly Weekly Daily or 
almost daily
2.  In the past 3 months, how often have you used psychostimulants? 0 1 2 3 4
3.  During the past 3 months, how often have you had a strong 
desire or urge to use psychostimulants?
0 1 2 3 4
4.  During the past 3 months, how often has your psychostimulants 
use led to health, social, legal or financial problems?
0 1 2 3 4
5.  During the past 3 months, how often have you failed to do what was 
normally expected of you because of your psychostimulant use?
0 1 2 3 4
Questions 6 – 8 No Never Yes in the past 
3 months
Yes but not in the 
past 3 months
6.  Has a friend or relative or anyone else ever expressed concern 
about your psychostimulant use?
0 2 1
7.  Have you ever tried and failed to control, cut down or stop 
using psychostimulants?
0 2 1
8.  Have you ever used any drug by injection? 0 2 1
Add up all the points you have scored from 1-8 then see what form of treatment is recommended for your score or level 
of problem. Total Score:
What your score means
If you scored 0–3 then no intervention is needed but feel free to read the Cocaine and Amphetamine handouts.
If you scored 4–15 then it is recommended that you read the Cocaine and Amphetamine handouts. Please consider 
talking to a drug and alcohol counsellor to help you control, cut down or stop your drug use.
If you scored 16–20 then it is recommended that you see a drug and alcohol counsellor to help you control, cut down or 
stop your drug use.  Please read the Cocaine and Amphetamine handouts.
If you scored 2 for question 8 then it is recommended that you see a drug and alcohol counsellor.  
Phone  for further advice/support
Source:  World Health Organisation
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Drug Quiz — ASSIST (Heroin)
Thank you for agreeing to take part in this brief survey about heroin. Below are some questions about your experience of 
using heroin throughout your lifetime and in the past 3 months. Please be assured that information on your heroin use 
will be treated as strictly confidential.  We are only interested in helping you to keep safe and as well as possible. Please 
circle your answer to each question.
Question 1
1.  During your lifetime have you ever used heroin? No (score 0)           Yes (score 1)
Questions 2 – 5 Never Once or 
twice
Monthly Weekly Daily or 
almost daily
2.  In the past 3 months, how often have you used heroin? 0 1 2 3 4
3.  During the past 3 months, how often have you had a strong 
desire or urge to use heroin?
0 1 2 3 4
4.  During the past 3 months, how often has your heroin use led to 
health, social, legal or financial problems?
0 1 2 3 4
5.  During the past 3 months, how often have you failed to do what 
was normally expected of you because of your heroin use?
0 1 2 3 4
Questions 6 – 8 No Never Yes in the past 
3 months
Yes but not in the 
past 3 months
6.  Has a friend or relative or anyone else ever expressed concern 
about your heroins use?
0 2 1
7.  Have you ever tried and failed to control, cut down or stop 
using heroin?
0 2 1
8.  Have you ever used any drug by injection? 0 2 1
Add up all the points you have scored from 1-8 then see what form of treatment is recommended for your score or level 
of problem. Total Score:
What your score means
If you scored 0–3 then no intervention is needed but feel free to read the heroin handout.
If you scored 4–15 then it is recommended that you read the heroin handout.  Please consider talking to a drug and 
alcohol counsellor to help you control, cut down or stop your drug use.
If you scored 16–20 then it is recommended that you see a drug and alcohol counsellor to help you control, cut down or 
stop your drug use.  Please read the heroin handout.  
If you scored 2 for question 8 then it is recommended that you see a drug and alcohol counsellor.  
Phone  for further advice/support
Source:  World Health Organisation
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Making changes
You have been given this sheet because you have discussed your alcohol or drug use with a health worker.  After you have 
completed the exercise below, you’ll be clearer about your use of alcohol or other drugs and whether or not you may have 
problems in this area.
Have a go at doing this brief exercise and after you have finished you may want to speak to a drug and alcohol counsellor. 
Positive things about using alcohol tobacco or other 
drugs e.g. helps me to relax
Negative things about using alcohol tobacco or other 
drugs e.g. fights with my loved ones
Positive things about changing e.g. I will have more 
energy and feel proud 
Negative things about changing e.g. Feeling shy 
around other people
Some other things you may want to consider at this stage include:
Q “What do your loved ones think about your alcohol/drug use”?
Q “How long do you think you can use alcohol/drugs before you start to do damage”?
Q “If you were to do something, what do you think you could do or might do”?
Phone  for further advice/support
Source: Adapted from Treatment Approaches for Alcohol and Drug Dependence: An Introductory Guide by Tracey J. Jarvis, 
Jenny Tebbutt and Richard P. Mattick, NDARC UNSW. 
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The safest way to minimise harm from many drugs is to 
not use the drugs. Following are things for you to think 
about before using alcohol, tobacco or other drugs:
Q Use alcohol or drugs in a safe place with trusted 
people.
Q Ask friends or partner to always call an ambulance if 
you become ill or overdose.
Q Don’t mix different drugs as this increases the risk of 
overdose and death.
Q Maintain an otherwise healthy lifestyle—good diet, 
exercise, sleep etc.
Q Drink plenty of fluids like water while using 
substances to help keep yourself well hydrated.
Q Don’t drive a car or boat or operate machinery, 
including household machines, after or while using 
substances.
Q Be informed about substance use by obtaining 
accurate information and health education resources.
Alcohol
Q Take Thiamine (Vitamin B1) 100mg tablets every day.
Q Fill in and score the survey Alcohol use disorders 
identification test screening instrument (AUDIT) (ask 
the nurse for one of these) and follow the 
recommendations. 
Q Set a limit and count drinks.
Q Try to have drinks in standard drink size glasses.
Q Have a non-alcohol spacer (e.g. water or soft drink) 
between alcoholic drinks.
Q Eat before drinking.
Q Plan ahead—catch a taxi, stay overnight, arrange a 
non-drinking driver.
Q Try low-alcohol alternatives such as light beers.
Q Quench thirst with water or soft drinks.
Q Avoid topping-up your drink—keep your own glass.
Q Avoid drinking in rounds or “shouts”.
Q Avoid salty snacks.
Q Drink one sip at a time, and put the glass down in-
between each sip.
Q Buy your own drink and do not leave it unattended.
Q Don’t drink your drink if it tastes funny, different or 
more bitter than usual.
Q If you are with someone who may have a drink that 
has been spiked:  stay with your friend; alert bar staff; 
seek medical help; and notify police.
Q If you are drinking six (women) or eight (men) drinks 
or more nearly every day, then you are advised to seek 
medical advice before reducing your drinking, as 
stopping or significantly reducing your drinking 
suddenly when drinking this amount can be 
dangerous.  
Q Be aware of low risk drinking levels.
Q Avoid drinking while pregnant.
Q Have two alcohol-free days per week at minimum.
Drinking patterns and levels of risk
There are enormous variations in levels and patterns of 
drinking, from not drinking at all, drinking at levels ranging 
from low to high risk, as set out in the following tables.
Q Low risk levels define a level of drinking at which 
there is only a minimal risk of harm. At this level, 
there may be health benefits for some of the 
population.
Q Risky levels are those at which risk of harm is 
significantly increased beyond any possible benefits.
Q High risk drinking levels are those at which there is 
substantial risk of serious harm, and above which risk 
continues to increase rapidly.
Minimising harm from alcohol or other drug use
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Short-term health consequences
MALES on any one day
Low risk Risky High risk Acute harm—risks from excessive drinking on a single day
up to 6 on 
any one day, 
no more 
than 3 days 
per week
7 to 10 on 
any one 
day
11 or 
more on 
any one 
day
Harms to physical health:
Q risk-taking behaviour, accidents, falls, injury and death, as consequences of the 
brain’s reduced control over reaction time, coordination, thinking and speech, 
and—at highest levels—all systems of the body, leading to unconsciousness
Q some types of heart problems and stroke, by affecting heart rate, blood pressure 
and blood flow
Q gut irritation and diarrhoea
Q inflamed pancreas
Q sexual problems.
Harms to mental health
Q suicidal behaviour
Q interacting with stress in some situations
Q aggravating sleep disorders.
FEMALES on any one day
up 4 on any 
one day, no 
more than 3 
days a week
5 to 6 on 
any one 
day
7 or more 
on any 
one day
Long-term health consequences
MALES on an average day
Low risk Risky High risk Chronic harm—risks from regular excessive drinking  
up to 4 per 
day
5 to 6 per 
day
7 or more 
per day
Harms to physical health:
Q cirrhosis of the liver
Q cancer, especially of the mouth, throat and oesophagus
Q range of diseases affecting the heart and blood, and including stroke and 
hypertension
Q problems with the nerves of the arms and legs
Q harm to the unborn baby
Q sexual problems, especially male impotence.
Harms to mental health
Q alcohol dependence
Q problems with memory and reasoning
Q alcohol related brain injury.
MALES overall weekly level
up to 28 per 
week
29 to 42 
per week
43 or more 
per week
FEMALES on an average day
up 2 on per 
day
3 to 4 per 
day
5 or more 
per day
Commonwealth Department of Health and Ageing, National Alcohol Strategy, A Plan for Action 2001 to 2003-04.
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Q Buy heroin from a regular, trusted dealer in order to 
be more certain of its strength—try a small “test” 
dose before using to gauge the strength and likely 
effect before using the whole amount to avoid 
accidental overdose or a “dirty deal” where the drug 
is contaminated with other substances.
Q If using after a break from heroin/opioid use, 
tolerance will be low—use less than you used 
previously in order to test tolerance and reduce the 
risk of overdose.
Q Fill in the survey ASSIST (Alcohol, Smoking and 
Substance Involvement Screening Test)—ask the nurse 
for one of these
Q Only use new needles and syringes with small bore to 
protect skin and veins.
Q Do not share injecting equipment (i.e. needles, 
tourniquets, syringes, spoons, filters or water for 
mixing drugs) due to the risks of transmission of 
blood-borne viruses like HIV AIDS and hepatitis C.
Q Avoid becoming too hot when using drugs such as 
ecstasy.
Q Mix powders with sterile water and filtering solution 
before injecting.
Q Avoid using alone.
Q Always wash hands and immediate environment 
(table or bench top) before and after injecting self or 
someone else and when handling injecting equipment 
including tourniquets, swabs.
Q Always inject into a vein and rotate injecting sites to 
avoid tissue and vein damage.
Q Avoid injecting into neck, groin, breast, feet, and 
hand veins or into infected areas.
Q Do not inject into swollen limbs even if veins appear 
to be distended.
Q Safely dispose of all used injecting equipment.
Q Do not take more than one drug.
Q Don’t mix drugs including prescribed medication, 
alcohol, herbal preparation, naturopathic or 
homoeopathic preparations, caffeine and 
antidepressants.
Q Trying to counterbalance one drug with another does 
not work and taking more drugs, to do this is likely to 
place the person at greater risk of toxic overdose and 
intensify the ‘come-down’ period.
Q Avoid using caffeine, such as guarana and other 
caffeine-based drinks due to risk of dehydration.
Q Avoid using alcohol with GHB due to the potentiation 
(increased) of depressant effect, which may lead to 
overdose.
Overdose prevention
Q Never use drugs alone.
Q Do not use opioids (e.g. heroin and morphine) with 
other drugs, especially central nervous system 
depressants such as benzodiazepines and/or alcohol.
Q Buy heroin from a regular, trusted dealer in order to 
be more certain of its strength—try a small “test” 
dose before using.
Q If using after a break from heroin/opioid use, 
tolerance will be low—use less than you used to in 
order to test tolerance and reduce the risk of 
overdose.
Illicit drugs
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Cocaine
What cocaine does to you depends on…
…how much you take; the type of cocaine you take; your 
height and weight; your general health; your mood; your 
past experience with cocaine; whether you use cocaine 
on its own or with other drugs; whether you use alone or 
with others, at home or at a party, etc.
Immediate
When you have a small amount of cocaine, the effects 
can last from a few minutes to a few hours. You may:  
feel good and confident; be excited or upset; take more 
risks than usual; be less hungry; feel alert and energetic; 
feel aggressive; want to have sex.
Effects on your body may include that your heart beats 
faster; your body temperature rises; the pupils in your 
eyes become bigger; you move more quickly than usual.
Large amounts
If you take a large amount of cocaine you might: get 
headaches; feel dizzy; feel restless; become violent or 
aggressive; find it hard to concentrate; lose interest in sex; 
not feel like doing anything; have chest pain; have a heart 
attack; have convulsions (fits); overdose; have psychosis—
a serious psychological problem when you hear voices, 
imagine things, get frightened that others want to hurt you.
Long term 
If you use cocaine often and for a long time you may:
become dependent/addicted to it; become aggressive, 
violent or have more arguments than usual; have 
relationship, work, money, legal or housing problems.
The way a person takes cocaine over a long 
time can also cause some problems
Q Snorting cocaine can lead to nosebleeds, sinus 
problems and damage inside the nose
Q Injecting cocaine with used or dirty needles or other 
equipment makes you more likely to get infected with 
hepatitis C, hepatitis B and/or HIV, get blood poison-
ing (septicaemia) and skin abscesses (sores with pus).
Q Injecting cocaine over a long time can result in:
– Blocked blood vessels (caused by the things some-
times mixed with cocaine) leading to serious damage 
to the body’s organs such as the liver, heart, etc.
– Inflamed blood vessels and abscesses (sores with pus)
– A person picking at their own skin, sometimes 
resulting in serious damage that needs skin grafts 
(operations) to heal.
Q Smoking freebase cocaine (crack) can cause breathing 
difficulties, a long-term cough, chest pain and lung 
damage.
Overdose
Overdose of cocaine can happen to anyone. Even small 
amounts may cause overdose with some people who 
have an especially strong reaction to it.
When a person overdoses, it may cause faster, irregular 
or weak heartbeat; breathing problems; heart failure; 
bleeding blood vessels in the brain; death.
Mixing cocaine with other drugs
People who use cocaine sometimes take other drugs at 
the same time to try to cope with some of the things 
cocaine does to the body. Some people take drugs such as 
minor tranquillisers (pills like Valium), alcohol, marijuana 
or heroin to help them sleep.
This can make you dependent on several drugs at once. 
For example, some people need cocaine each day to get 
them going and minor tranquillisers each night to get to 
sleep. This type of dependence can lead to many serious 
physical and psychological problems.
Mixing different drugs can also make you more likely to 
overdose.
Cocaine and pregnancy
Using cocaine when you are pregnant may increase the 
chance of losing your baby before it is born, having your 
baby too early and other problems. Babies of cocaine-
using mothers tend to weigh less (small babies can be 
sicker babies) and may get withdrawal symptoms from 
their mother’s cocaine use. Your baby may also have a 
heart attack or a stroke in the womb. Little is known 
about the long-term effects on the child as it grows.
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Cocaine and driving
Cocaine can make you feel more confident when you 
drive. This can make you take dangerous risks and have 
accidents. It is illegal to drive under the influence of 
drugs, including cocaine. Penalties include losing your 
licence, a fine and/or jail.
Tolerance and dependence
Anyone can develop a “tolerance” to cocaine. Tolerance 
means that you must take more of the drug to feel the 
same effects you had previously with lower amounts.
“Dependence” on cocaine means that it takes up a lot of 
your thoughts, emotions and activities. Dependence on 
cocaine can lead to a variety of health, money, legal, 
work and relationship problems.
Withdrawal
People who are dependent on cocaine may find it very 
hard to stop using or cut down because of withdrawal 
symptoms. These can include the following—please tick 
the box if you have any of these signs:
 Wanting cocaine very badly (cravings) 
 Shaking
 Tiredness and weakness
 Long but disturbed sleep
 Muscle pain
 Wanting to kill yourself
 Deep depression (feeling very down or sad)
 Hunger
 Feeling angry or upset  
 Vomiting
 Feeling sick
These symptoms are usually fairly short-lived and most 
withdrawing people don’t need medication. However, if 
you are worried about withdrawal, contact your doctor 
or Drug and Alcohol Service. If you are in hospital let the 
nurse know about these symptoms.
Source:  NSW Department of Health
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Heroin
What heroin does to you depends on… 
… how much you take; how pure the heroin is; your 
height and weight; your general health; your past 
experience with heroin; whether you use heroin on its 
own or with other drugs; whether you use alone or with 
others, at home or at a party etc.
Immediate effects
Makes you feel really good; makes physical pain 
disappear; makes you feel nauseous or wanting to vomit; 
makes the pupils in your eyes get smaller (“pinpoint 
pupils”); makes your breathing become slow and shallow; 
causes constipation; makes you feel sleepy (“on the nod”).
Longer term effects
You may overdose (have too much heroin— the longer 
you use heroin, the more likely you are to overdose); you 
may get constipated; get damaged veins from injecting a 
lot in the same site; get skin abscesses (sores with pus); 
you may lose your appetite or get sick from the lack of 
healthy food; have your menstrual period at the wrong 
time or not at all (women); find it difficult to get pregnant 
(women); find it difficult to get an erection (men); get 
pneumonia—a serious lung disease; have heart and lung 
problems; get tetanus—a disease caused by infection 
through the places on your body where you inject.
The way a person uses heroin can also cause 
some problems
Street heroin is usually mixed with other things. 
Therefore, it is hard to know how strong the heroin is 
and this can lead to accidental overdose or death.
Injecting heroin with used or dirty injecting equipment 
makes you more likely to get infected with HIV, hepatitis 
B or C, get blood poisoning (septicaemia) and skin 
abscesses (sores with pus). So that you don’t get these 
problems, DO NOT SHARE fits (needles and syringes), 
spoons, water, filters, alcohol swabs or tourniquets.
Overdose
Overdose of heroin (“dropping”) is very common and can 
happen to anyone. Even small amounts of heroin may 
cause some people to overdose, for example, new users 
or those who started using again. This can happen after 
even a short time of not using.
Heroin and pregnancy
Using heroin during pregnancy can affect both the 
mother and her unborn child. Heroin-dependent women 
are more likely than other women to: lose their baby 
during pregnancy; have their baby too early; have their 
baby born dead; pass on infections such as hepatitis B or 
C or HIV/AIDS; have health and social problems during 
pregnancy and childbirth. It can be medically dangerous 
for a heroin dependent pregnant woman to stop or 
reduce using heroin. It is much safer to stabilise on a 
methadone program.
Mixing heroin with other drugs
You are more likely to overdose if you use heroin at the 
same time as other drugs, especially alcohol or minor 
tranquillisers (pills like valium). Mixing other drugs with 
heroin can also cause other physical and mental problems.
Heroin and driving
Heroin slows down the workings of your brain and your 
body, so it may make you drive dangerously. It is illegal to 
drive under the influence of drugs. Penalties include 
losing your licence, a fine and/or jail.
Tolerance and dependence
Anyone can develop a “tolerance” to heroin or other 
drugs. Tolerance means that you must take more of the 
drug to feel the same effects you used to have with 
smaller amounts.
“Dependence”on heroin means that it takes up a lot of 
your thoughts, emotions and activities. You spend a lot 
of time thinking about using heroin, looking for heroin, 
using it and getting over the effects of using it. You also 
find it difficult to stop using or control how much you 
use. Dependence can lead to a variety of health, money, 
legal, work and relationship problems.
Withdrawal
People who are dependent on heroin may find it very 
hard to stop using or cut down because of withdrawal 
symptoms. These can begin to occur only a few hours 
after last using heroin. Symptoms include the following.  
Please tick the box if you have any of these signs:
 Feeling restless 
 Low blood pressure
 Yawning 
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 Goosebumps
 A runny nose 
 Stomach and leg cramps
 Crying 
 Diarrhoea
 Wanting heroin very badly (cravings)
If you are worried about withdrawal, contact your doctor 
or Drug and Alcohol Service. If you are in hospital let the 
nurse know about these symptoms.
Source:  NSW Department of Health
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Cannabis (Marijuana)
The effects of marijuana will depend on how much you 
take; how strong the marijuana is; how the marijuana is 
taken (joint, one/bong, food); your size, weight, health; 
your mood; your experience with marijuana; whether 
marijuana is taken with other drugs; whether you are 
alone or with other people, at home or at a party.
If you take a large amount of marijuana, you may: feel 
confused; be restless; feel excited; see or hear things 
which are not there; feel anxious or panicky; feel distant 
or separate from reality.
Marijuana can also cause problems with…
…remembering things, thinking clearly, ability to do 
things like drive or operate machines.  These symptoms 
usually disappear when the effects of marijuana wear off.
Long-term effects
An increase in the risk of getting bronchitis, lung cancer 
and other diseases of the respiratory system; a decrease 
in motivation; a decrease in concentration, memory and 
ability to learn new things; a decrease in sex drive; a decrease 
in sperm able to work in men; irregular menstrual cycles 
in women; some people may have psychological effects 
and these are more likely if the person already has a 
schizophrenic condition.
Mixing marijuana with other drugs
It can be dangerous to mix marijuana with alcohol or 
other drugs (prescribed or non prescribed). This is 
because the effects of marijuana can become stronger.
Marijuana and pregnancy
It is not wise to use any drugs during pregnancy. 
Marijuana passes from the mother to her baby through 
the placenta. There is some evidence that women who 
smoke marijuana may give birth to smaller babies. 
Smaller babies can be sicker babies.  Other studies show 
that newborn babies of women who smoke marijuana 
may have trouble sleeping.
Marijuana and driving
Marijuana makes it more difficult to drive safely. If a 
police officer suspects marijuana or other drugs, then you 
can be arrested and taken to a hospital for a blood and 
urine test. This will show whether there is marijuana or 
any other drug in your body. 
Dependence
Physical dependency on marijuana can develop. This means 
that you may experience withdrawal symptoms if you stop 
or suddenly cut down. Marijuana withdrawal symptoms 
usually consist of the following. Please tick the box if you 
have any of these signs:
 Headaches
 Depression
 Anxiety/restlessness 
 Loss of appetite
 Difficulties in sleeping  
 Irritability/anger
 Nausea
If you are worried about withdrawal, contact your doctor 
or Drug and Alcohol Service. If you are in hospital let the 
nurse know about these symptoms.
Source:  NSW Department of Health
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Amphetamines (speed)
Effects
What speed does to you depends on how much you take 
and how pure it is; your height and weight; your general 
health; your mood; your past experience with speed; whether 
you use speed on its own or with other drugs; whether 
you use alone or with others, at home or at a party, etc.
Immediate
When you take a small amount of speed, the effects can 
last from a few hours to a few days. You may: feel very 
good and confident; feel alert and energetic; be excited 
or agitated; talk a lot; feel aggressive; feel anxious or 
panicky; take more risks than usual.
Effects on your body may include that your heart beats 
faster; you breathe faster; you feel less hungry; your 
blood pressure rises; the pupils in your eyes get bigger; 
you move more quickly; it is hard to sleep
If you take a large amount of speed you might get 
headaches; feel dizzy; feel restless; shake; have irregular 
breathing; have a very fast or irregular heartbeat; become 
pale; feel very powerful or better than others; become 
hostile or aggressive; have psychosis—a serious 
psychological problem where you hear voices, imagine 
things, fear that others want to hurt you.
Long term
Often become violent for no reason; get sick more often 
because your body can’t resist disease properly; be upset 
or depressed; have periods of psychosis; have 
relationship, work, money, legal or housing problems.
The way a person takes speed over a long 
time can also cause some problems
Q Snorting speed can lead to nosebleeds, sinus 
problems and damage inside the nose.
Q Injecting speed with used or dirty needles or other 
equipment makes you more likely to get infected with 
hepatitis C, hepatitis B and/or HIV, get blood poison-
ing (septicaemia) and skin abscesses (sores with pus).
Q Injecting speed over a long time can result in:
– Blocked blood vessels (caused by the things some-
times mixed with speed) leading to serious damage 
to the body’s organs such as the liver, heart etc.
– Inflamed blood vessels and abscesses (sores with pus)
Q Injecting speed also increases the risk of becoming 
dependent on the drug and of getting other health 
problems.
Overdose
Overdose of speed can happen to anyone. Even small 
amounts may cause overdose with some people who 
have an especially strong reaction to it.
Mixing speed with other drugs
People who use speed sometimes take other drugs at the 
same time to cope with some of the things speed does to 
the body. Some people take drugs such as minor 
tranquillisers (pills like valium), alcohol, marijuana or 
heroin to help them sleep.
This can make you dependent on several drugs at once. 
For example, some people need speed each day to get 
them going and minor tranquillisers each night to get 
them to sleep. This type of dependence can lead to many 
serious physical and psychological problems.
Mixing different drugs can also make you more likely to 
overdose.
Tolerance and dependence
Anyone can develop “tolerance” to speed. Tolerance 
means that you must take more of the drug to feel the 
same effects you used to have with lower amounts.
“Dependence” on speed means that it takes up a lot of 
your thoughts, emotions and activities.
Dependence on speed can lead to a variety of health, 
money, legal, work and relationship problems.
Withdrawal
People who are dependent on speed may find it very hard 
to stop using or cut down because of withdrawal symptoms.
These can include:
 Tiredness    
 Being ‘nervy’ or restless
 Hunger    
 Feeling angry or upset
 Feeling anxious   
 Long but disturbed sleep
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 Feeling irritable   
 Deep depression (feeling very down or sad)
 Wanting speed very badly (cravings)
These symptoms are usually fairly short-lived and most 
withdrawing people don’t need medication. However, if 
you are worried about withdrawal, contact your doctor 
or Drug and Alcohol Service. If you are in hospital let the 
nurse know about these symptoms.
Source:  NSW Department of Health
Amphetamines and pregnancy
The health risks of amphetamine use during pregnancy 
have not been clearly established. However, a history of 
use (especially IV use) should be considered as a high-risk 
pregnancy. Use during pregnancy is associated with 
higher rates of obstetric complications (spontaneous 
abortion, miscarriage and placental abruption). If 
amphetamines are used close to the birth, the baby may 
be born affected and have agitation and be overactive. 
There are only limited reports of neonatal abstinence 
syndrome, however, the need for medication for 
withdrawal has not been reported.
A mother who wishes to breastfeed should be supported 
unless she is using regularly and is unstable. Women who 
rarely use or binge use should be informed of the risks 
and provided with information on minimising harm to 
their baby, for example:
Q Express and discard milk after psychostimulant use.
Q Do not breastfeed for 24 hours after amphetamine or 
cocaine use.
Q Do not breastfeed for 24-48 hours after using ecstasy.
For further information, refer to the National clinical 
guidelines for the management of drug use during 
pregnancy, birth and the early development years of the 
newborn. (March 2006) http://www.health.nsw.gov.au/
pubs/2006/ncg_druguse.html
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AA. (Alcoholics Anonymous) A self-help group, based 
on a 12-step philosophy in which participants support 
each other in recovering or maintaining recovery from 
alcohol dependence.
Abstinence. Refraining from drug use at all times.
Alcoholic Hallucinosis. Perceptual disturbances occur in 
up to a quarter of patients with acute alcohol withdrawal, 
and include vivid dreams, nightmares, illusions, and, less 
frequently, hallucinations. Hallucinations can be auditory, 
visual, tactile, olfactory, or a combination (alcoholic 
hallucinosis). Visual hallucinations are most common, 
with imagery of insects, animals, people, or disembodied 
heads. Sometimes occurring with eye closure or in a 
darkened room, they are mostly fragmentary and tend to 
last minutes at a time over several days. Insight varies, 
and there may be paranoid delusions. Brust, JCM. (1993.)
Alcohol related brain injury (ARBI). A generic term 
that encompasses chronic impairment of memory and 
higher mental functions associated with the frontal lobe 
and limbic system. 
Amphetamine. The group of drugs commonly known as 
“speed”. Sold as white or yellow powder, they can also 
be sold as tablets or as a liquid in capsules. 
Amphetamines can be swallowed, inhaled (“snorted”) or 
injected. One form (ice) can be smoked. When bought 
illegally, they are often mixed with other substances. 
Amphetamine is a stimulant.
Anti-depressant. One of a group of psychoactive drugs 
prescribed for the treatment of depressive disorders. Also 
used for other conditions such as panic disorder.
“Bad trip”. Substance users’ jargon for an adverse effect 
of drug use, consisting of any mixture of the following 
feelings: losing control, distortions of body image, bizarre 
and frightening hallucinations, fears of insanity or death, 
despair, suicidal thoughts and strong negative mood. 
Physical symptoms may include sweating, palpitations, 
nausea and paraesthesia. A “bad trip” usually refers to the 
effect of a hallucinogen, but can also refer to 
amphetamines and other stimulants, antihistamines and 
sedatives/hypnotics.
Barbiturate. One of the sedative-hypnotic group of 
drugs that were previously prescribed but are now rarely 
seen in Australia. With increasing dosage they produce 
progressive CNS depression, ranging from mild sedation 
to anaesthesia. Very dangerous in overdose.
Benzodiazepine. One of the sedative-hypnotic group of 
drugs. Introduced as safer alternatives to barbiturates, they 
have a general depressant effect on the central nervous 
system that increases with the dose, from sedation to 
hypnosis to stupor. Benzodiazepines have significant 
potential for dependence.
Blood level alcohol. The concentration of alcohol 
(ethanol) present in blood. The legal blood alcohol limit 
for driving in NSW is .05.
“Blowing out”. Giving somebody heroin for free.
“Bodgie”. A half-weight or cap that looks like heroin but 
is mainly rock or chalk, sold as heroin. Also know as a fake.
Brief intervention. A treatment strategy in which a 
short structured therapy is offered (between five minutes 
and two hours), on one occasion or spread over several 
visits. Aimed at helping a person to reduce or stop 
substance use.
Cannabis. The generic name given to the psychoactive 
substances found in the marijuana plant Cannabis sativa.
The main active constituent is Delta 9-tetra-
hydrocannabinol (THC).
Cap. A small amount of heroin, slightly bigger than a 
match-head, wrapped in foil. 
Cocaine. A powerful CNS stimulant derived from the 
coca plant, used non-medically to produce euphoria or 
wakefulness. Often sold as white, translucent, crystalline 
flakes or powder.
Controlled drinking. Drinking that is moderated to 
avoid intoxication or hazardous use of alcohol. 
Craving. Very strong desire for a substance or for the 
intoxicating effects of that substance.
Glossary
(Adapted from Lexicon of Alcohol and Drug Terms, World Health Organisation, Geneva, 1994 and Ordinary People, Western Sydney 
Area Health Service, 1997).
Note: “Inverted commas” around a word means that the expression is slang or jargon.
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Delirium tremens (DTs). An acute confusional state 
occurring during withdrawal from alcohol, characterised 
by rapid pulse, clouding of consciousness, dehydration, 
delirium, elevated body temperature, sweating, extreme 
fear, hypertension, tachycardia, tremor and hallucinations.
Dependence. A preoccupation with obtaining and using 
a drug for its psychic effects; the need to keep taking a 
drug to feel okay. Physical dependence is referred to as 
neuroadaptation, and means that a person’s body has 
become adjusted to the substance so that the body 
needs it to function as normal.
Depressant. Any substance that suppresses, inhibits or 
decreases some aspects of CNS activity. The main classes 
of CNS depressants are sedatives/hypnotics, opioids and 
neuroleptics.
Detoxification. The process by which a person is 
withdrawn from a psychoactive substance on which they 
are dependent. Usually detoxification refers to supervised 
withdrawal, which may or may not involve the 
administration of medication.
Disinhibition. A state of mind where the person feels 
free from internal constraints on their own behaviour—a 
loss of inhibitions.
“Drop”. To overdose.
Drug. Any chemical substance used for its effects on 
bodily processes.
Dual diagnosis. Where a person has a substance use 
problem(s) and a mental health problem(s) at the same 
time.
“E”. Ecstasy.
Fit. A needle and syringe, used for injecting any drugs, 
including opioids and/or amphetamines.
Flashbacks. A perception disorder that can follow 
hallucinogen use. Flashbacks are a spontaneous 
recurrence of the feelings that occurred when the person 
was intoxicated with hallucinogens. These feelings 
include visual distortions, physical symptoms, loss of ego 
boundaries, or intense emotions, and the flashbacks can 
last from a few seconds to a few hours.
Foetal alcohol spectrum disorder. The full range of 
possible effects of foetal exposure to alcohol, from a small 
decrease in cognitive functioning to poor coordination 
and motor skills, brain damage, facial deformities, and 
growth deficits before and after the birth. The term 
Foetal Alcohol Syndrome (FAS) is used to indicate the 
severe end of the range.
“Gear”. Heroin.
Glue sniffing / petrol sniffing. Inhaling fumes from 
glue, petrol or other volatile substances (also called 
inhalants, solvents) for their psychic effect.
“Half-weight”. Half a street gram of heroin (the 
percentage of pure heroin is variable).
Hallucinogen. A substance that alters perception, 
typically by inducing illusions or even hallucinations. 
Hallucinogens can include naturally occurring compounds 
(e.g. magic mushrooms) and are usually taken orally.
“Hanging out”. Withdrawing from opioids.
Hangover. A state that follows excessive consumption of 
alcohol. Physical features may include fatigue, headache, 
thirst, vertigo, gastric disorder, nausea, vomiting, insomnia, 
fine tremors of the hands, and raised or lowered blood 
pressure. Psychological symptoms include anxiety, guilt, 
depression, irritability and extreme sensitivity. Usually lasts 
not more than 36 hours after all traces of alcohol have 
left the system.
Harm minimisation / harm reduction. The concept of 
reducing harm associated with substance use without 
necessarily stopping use. Harm minimisation is the key 
philosophy for people working with alcohol and other 
drug issues in NSW. While abstinence is a part of harm 
minimisation, it is not the only goal.
Harmful use. A pattern of substance use that is likely to 
cause damage to health—either physical (e.g. hepatitis 
following injecting of drugs) or mental (e.g. depressive 
episodes after heavy alcohol intake). Harmful use also 
commonly has adverse social consequences.
Hashish. A form of cannabis.
Hazardous use. A pattern of substance use that 
increases the risk of harmful consequences for the user.
Illicit drug. An illegal substance.
Inhalant. Any of a group of gases and highly volatile 
compounds or mixtures of compounds that are inhaled 
for their intoxicating effects. Inhalants are also called 
solvents or volatile substances.
Intoxication. The condition—resulting from use of a 
psychoactive substance—that produces behavioural 
and/or physical changes.
“Junkie half”. A half-weight, which is actually only 
about 0.3 of a gram.
LSD. A type of hallucinogenic substance.
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Maintenance therapy. A form of treatment of 
substance dependence that involves prescribing a 
substitute drug, e.g. methadone for the treatment of 
heroin dependence and nicotine replacement therapy for 
the treatment of tobacco dependence.
Marijuana. Cannabis
Mescaline. A type of hallucinogenic substance, found in 
the peyote cactus in the south-western United States and 
northern Mexico.
Methadone. A synthetic opioid drug used in 
maintenance therapy for those dependent on opioids. 
Naloxone. An opioid receptor blocker that reverses the 
features of opioid intoxication. It is sometimes prescribed 
for the treatment of opioid overdose.
Narcotic. A chemical agent that induces stupor, coma, or 
insensibility to pain. The term usually refers to opioids, 
which are called narcotic analgesics. In general use the term 
is often used incorrectly to refer generally to illicit drugs.
Narcotics Anonymous (NA). A self-help group based on 
the 12-step philosophy of Alcoholics Anonymous, in 
which participants support each other in recovering or 
maintaining recovery from opioid dependence.
Narrowing of repertoire. The tendency of substance 
use to become progressively stereotyped around a self-
imposed routine of custom and ritual. Characterised by 
reduced variation of dose and type of substance taken, 
and of time, place and manner of self-administration.
Neuroadaptation. Physical dependence on a psychoactive 
substance. This means that a person’s body has become 
adjusted to the substance so that if its use is reduced or 
ceased, the body experiences withdrawal symptoms.
Neuroleptic. One of a class of drugs used for treating 
acute and chronic psychoses. Also known as major 
tranquillisers and antipsychotics.
Nicotine. The major psychoactive substance in tobacco, 
which has both stimulant and relaxing effects Considerable 
tolerance and dependence develop to nicotine.
“Nodding”, “on the nod”. The semi-stuporous state 
experienced by heroin and high-dose methadone users 
after the euphoric effects accompanying use have 
subsided; characterised by head bobbing, bowed head 
and drooping eyelids.
Opiate. One of a group of substances derived from the 
opium poppy (opiates), with the ability to induce analgesia, 
euphoria and, in higher doses, stupor, coma, and respiratory 
depression. This term excludes synthetic opioids.
Opioids. The generic term applied to alkaloids from the 
opium poppy, their synthetic analogues, and compounds 
synthesised within the body.
Overdose. The use of any drug in such an amount that 
acute adverse physical or mental effects are produced; a 
dose that exceeds the individual’s tolerance. Overdose 
may produce transient or lasting effects, or death.
Passive smoking. The involuntary inhalation of smoke, 
usually tobacco smoke, from another person’s smoking. 
Also generally referred to as environmental tobacco smoke. 
Pharmaceutical drugs. Substances available from 
pharmaceutical sources, i.e. manufactured by the 
pharmaceutical industry or dispensed by a pharmacist.
Polydrug use. Where a person uses more than one drug, 
often at the same time or following one another, and 
usually with the intention of enhancing, potentiating, or 
counteracting the effects of another substance.
Psychoactive substance. A substance that, when ingested, 
affects mental processes, emotions and behaviour.
Psychotropic. In its most general sense, a term with the 
same meaning as “psychoactive” i.e. affecting the mind 
or mental processes.
“Rave”. A dance party, often involving the use of 
psychoactive substances—especially amphetamines and 
hallucinogens—by participants.
Recreational use. Use of a drug, usually an illicit 
substance, in social or relaxing circumstances. This term 
implies that the user is not dependent on the substance; 
it has the same connotations as “social drinking’”. 
Rehabilitation. The process by which a person with a 
substance use disorder achieves an optimal state of 
health, psychological functioning, and well-being.
Reinstatement. Returning to substance use following a 
period of abstinence.
Relapse. A return to substance use after a period of 
abstinence.
“Rush”. An immediate, intense, pleasurable effect that 
follows injection of certain substances (e.g. heroin, 
amphetamine, cocaine).
Salience. A preoccupation with substance use, or 
seeking the substance, in the user’s thoughts or actions.
Sedative/hypnotic. Any of a group of central nervous 
system depressants that can relieve anxiety and induce 
calmness and sleep.
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“Snowcone”. Cannabis sprinkled with heroin.
Solvent. See inhalant.
Somnolence. Sleepiness, the state of feeling drowsy, 
ready to fall asleep.
“Speed”. See amphetamine.
“Speedball”. A combination of a stimulant and an opioid, 
e.g. cocaine and heroin, amphetamine and heroin.
Steroid. One of a group of naturally occurring or 
synthetic hormones that affect chemical processes in the 
body, growth, and sexual and other physiological 
functions. Steroids can be taken orally or injected.
Stimulant. Any agent that activates, enhances, or increases 
neural activity of the central nervous system. Stimulants 
include the amphetamines, cocaine, caffeine, nicotine.
THC. Tetrahydrocannabinol, the main active constituent 
in cannabis.
Therapeutic community. A structured environment in 
which people with substance use problems live in order 
to achieve rehabilitation. Such communities are often 
specifically designed for drug-dependent people.
Tolerance. A decrease in response to a drug dose that 
occurs with continued use. Increased doses of the 
substances are required to achieve the effect originally 
produced by lower doses.
Tranquilliser. General term for several classes of drugs 
employed to manage symptoms of various mental disorders. 
The tranquillisers have a quieting or dampening effect on 
psychomotor processes without—except at high doses—
interfering with consciousness and thinking. In this way 
they differ from the sedatives/hypnotics, which are used 
to, among other things, induce sleep. The term tranquilliser 
is often used to refer to any drug that is used for treating 
anxiety disorders.
Volatile substance. See inhalant.
Wernicke’s Encephalopathy. An acute, life-threatening, 
neurological syndrome consisting of confusion, palsies of 
the ocular muscles and of gaze (nystagmus), peripheral 
neuropathy and ataxia. Its most common cause is 
thiamine deficiency, often associated with long-term 
excessive use of alcohol. If not treated immediately with 
thiamine, the patient is likely to progress to a permanent 
amnesic syndrome (Korsakoff’s psychosis). In some cases 
fatality can occur. NB: Always ensure thiamine is given 
before glucose if there is any suspicion of Wernicke’s.
Withdrawal syndrome. A series of symptoms that occur 
when a person stops or substantially reduces substance 
use, if they have been using for a long period and/or at 
high doses.
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Area Health Service Central Intake Number
Greater Southern Area Health Service
Greater Murray 1800 800 944  /  02 9425 3923
Southern 1800 809 423
Greater Western Area Health Service
Far West 1800 665 066  /  08 8080 1556  
Macquarie 1800 092 881  /  02 6841 2360
Mid Western 1300 887 000
Hunter / New England Area Health Service
Hunter 02 4923 2060
New England 1300 660 059
North Coast Area Health Service 1300 662 263
Mid North Coast 1300 662 263
Northern Rivers 02 6620 7612
Northern Sydney / Central Coast Area Health Service
North Sydney 1300 889 788
Central Coast 4394 4880
South Eastern Sydney / Illawarra Area Health Service
South East Sydney 02 9113 4444
Illawarra 1300 652 226
Sydney South West Area Health Service
South West Sydney 02 9616 8586
Central Sydney 02 9515 6311
Sydney West Area Health Service
Wentworth 02 4734 1333
Western Sydney 02 9840 3355
Useful contacts and resources
NSW HEALTH  Clinical guidelines for nursing and midwifery practice in NSW PAGE 105
The Alcohol and other Drugs Council of Australia 
(ADCA)
PO Box 269
WODEN ACT 2606
Telephone: 02 6281 0686
Email: adca@adca.org.au 
Alcohol and Drug Information Service (ADIS) 
24hr hotline
Telephone: 02 9361 8000 
Toll free number: 1800 422 599 
Australian Drug Foundation/Australian Drug 
Information Network (ADIN)
PO Box 818
North Melbourne, VIC 3051
Telephone: 03 9278 8100
Email: adin@adf.org.au
The Australasian Professional Society on Alcohol & 
Other Drugs (APSAD) 
PO Box 73
Surry Hills NSW 2010
Telephone: 02 9331 7747
www.apsad.org.au
Drug and Alcohol Nurses of Australasia (DANA)
The Secretary
PO Box 5095 
Warrnambool VIC 3280 
Telephone: 1300 557 594
www.danaonline.org
Drug & Alcohol Services South Australia
161 Greenhill Road
Parkside SA  5063
Telephone: 08 8274 3333
www.dassa.sa.gov.au
The Drug and Alcohol Specialist Advisory Service 
(DASAS)
Country: 1800 023 687
Sydney 9361 8006
Family Drug Support Head Office
PO Box 7363 
Leura NSW 2789 
Telephone: 1300 368 186
www.fds.org.au
National Centre for Education and Training on 
Addiction (NCETA)
Flinders University
GPO Box 2100
Adelaide SA 5001
Telephone: 08 8201 7535
www.nceta.flinders.edu.au
National Drug and Alcohol Research Centre (NDARC)
University of New South Wales
Sydney NSW 2052, Australia
Telephone: (02) 9385 0333
http://ndarc.med.unsw.edu.au/
The National Drug Research Institute (NDRI)
GPO Box U1987
Perth WA 6845
Telephone: 08 9266 1600
www.ndri.curtin.edu.au
NSW Department of Health 
73 Miller Street
North Sydney NSW 2060
Telephone: 02 9391 9000
www.health.nsw.gov.au
The Hepatitis C Council of NSW
Telephone: 02 9332 1599
Freecall: 1800 803 990 (country)
Email: hccnsw@hepatitisc.org.au 
The Network of Alcohol and Drug Agencies Inc 
(NADA)
PO Box 2345
Strawberry Hills NSW 2012
Telephone: 02 9698 8669 
www.nada.org.au 
The Quitline Service 
(A telephone-based service designed to help smokers quit 
smoking)
Telephone: 13 7848 (13 QUIT)
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